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1    Introduction 
1.1.   Metabolomics 
Metabolomics is defined as the study of the metabolite composition of a living cell, a 
biological fluid or a tissue by the means of mass spectrometry. Metabolome, the analysis 
of the complete set of metabolites, is one of the fastest developing disciplines of current 
life sciences. To date, metabolomics is considered as a major tool in addressing 
challenging research objectives including precision and personalized medicine. 
Metabolomics constitutes the downstream products of genomic, epigenomic, 
transcriptomic, and proteomic processes as shown in Figure 1. 
 
 
Figure 1: Central dogma of the “omics” studies (adapted from Gorrochategui et al., 2016). 
 
The end products of enzymatic reactions or their intermediates are defined as metabolites. 
They represent the most informative snapshot of the biochemical activity of an organism 
[1]. The present technologies in metabolomics are allowing the studies of complex 
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biological samples and the detection of thousands of metabolites [2]. Application of 
metabolomics is broad and it covers research areas like nutrition [3], drug discovery [4], 
plant biology [5] and a wide range of the studies of human diseases [6]. One of the most 
active areas of development in metabolomics is the biomedical field. The use of 
metabolomics is supporting development of prognostic and diagnostic biomarkers that 
aid medical practitioners to achieve a level of information about biological systems in 
humans required for safe diagnosis. Consequently, this experimental approach opens up 
new perspectives in many fields of medicine [7]. To date, metabolomics data is generated 
mostly by two techniques: nuclear magnetic resonance (NMR) and mass spectrometry 
(MS) [8]. However, MS is by far the dominating technology in metabolomics studies. It 
is described as an analytical technique that is recording spectral data in the form of relative 
intensity and mass-to-charge ratio (m/z) for compounds of interest. First, metabolites of 
interest need to be extracted from the investigated cells or tissues. Second, biological 
extracts need to be ionized for the mass spectrometer to generate signals for the analyzed 
metabolites. A wide range of ionization techniques for mass spectrometry are currently 
available. Prior to ionization of the biological samples usually there is a separation step 
in metabolomics. Fractionation of the biological samples reduces its complexity. Most 
commonly used techniques for this purpose are liquid and gas chromatography columns 
(LC and GC), respectively [9].  
Chromatography is a separation technique in which a mobile phase contains compounds 
to be separated is moved over chemically defined stationary phase. Separation is based 
on the differential interaction between the stationary phase and the different metabolites 
in the mobile phase. In liquid chromatography (LC) mobile phase is a liquid, in gas 
chromatography (GC) is gaseous. Differences in rates of movement along the stationary 
phase are caused by the different chemical properties of the metabolites. Retention time 
represents the time needed for each metabolite to pass along the stationary phase, and 
deduced m/z MS values are used to generate the two axes of the GC-MS and LC-MS 
spectral data [10].  
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1.2.   Untargeted versus targeted metabolomics 
Metabolomics analysis can be divided into untargeted and targeted approaches, 
depending on the design of the experiments [11].  Untargeted metabolomics focuses on 
the analysis of all the detectable metabolites in a sample. A flow chart of a typical LC-
MS metabolomics experiment is shown in Figure 2. Untargeted and targeted approaches 
are visualized. 
 
Figure 2: Analysis workflow in untargeted metabolomic studies. This figure shows the 
different steps of the metabolomic analysis pipeline (adapted from Patt et al., 2012). 
 
The workflow consists of the experimental design, the extraction protocol, data 
acquisition, processing and analysis, and metabolite identification to finally allow 
biological interpretation. The aim of the investigation determines the experimental design 
and data acquisition methods [12]. These studies are characterized by generating large 
amounts of data of high complexity which require high performance bioinformatics tools 
to process the data  [13, 14]. Data processing was improved enormously over the years 
due to the development of automated procedures such as MetAlign 
(http://www.metalign.wur.nl), MZmine (http://mzmine.sourceforge.net/) and XCMS 
(http://metlin.scripps.edu/download/). These programs are designed to extract relevant 
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information automatically from batches of crude chromatographic data. They allow for 
the rapid processing of thousands of data points, background noise subtraction, signal 
recognition and alignment. This processing is needed for the transformation of the 
untargeted metabolomics data into straightforward metabolite identifications. Output of 
these tools is usually a data table listing the amount of each signal in all samples [15].  
Due to its comprehensive nature, untargeted metabolomics must be connected to 
advanced chemometric techniques in order to reduce extensive datasets into a smaller set 
of manageable signals, such as multivariate analysis. These signals then require 
annotation using either in silico libraries or experimental investigation with identification 
step by means of analytical chemistry. Untargeted analysis offers the opportunity for 
novel target discovery including the discovery of unknown chemical compounds, as 
coverage of the metabolome is only restricted by the methodologies of sample preparation 
and the sensitivity and specificity of analytical instrumentation [16-18]. By contrast, 
targeted metabolomics is the measurement of defined groups of metabolites. Targeted 
metabolomics is of high importance, particularly in systems medicine, systems biology 
and biomarker validation where metabolite quantification is of importance. These 
methods target a limited number of known metabolites, often relying on triple quadrupole 
mass spectrometry. Data processing for targeted analysis is moreover simplified as the 
user already knows which metabolite is to be expected. In addition, it is possible to set up 
a specific processing method for the assay identifying metabolites according to retention 
time and/or fragmentation pattern. Such approaches have been developed for instance to 
rapidly quantify eleven key gut microbiota-host co-metabolites within only 10 minutes 
[19]. Similarly, the development and validation of an assay for the quantification of ten 
metabolites associated with the Krebs cycle, purine degradation, and oxidative stress in 
human urine was achieved [20]. Chromatography can be used to ensure the separation of 
isobaric species (for example, the metabolites citrate and isocitrate) or species that 
fragment in such a way that they resemble other species (for example ATP may fragment 
under certain conditions to resemble ADP or AMP in terms of the ions produced) to 
further enhance the robustness and reliability of the method [21].  
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1.3.   Limitations and challenges of the metabolomics approach 
The first major challenge in metabolomics is the identification of the measured 
metabolites. In mass spectrometry-based studies metabolite spectral databases are 
essential for metabolite identification. The most common metabolite identification 
approach is done by querying metabolomics databases for the neutral or ionized 
molecular mass values of the identified peaks using a tolerance window [22]. The quality 
of the stored data in these databases is critical for the performance of identification 
algorithms [23]. Assuming no prior knowledge of the measured metabolites as in 
untargeted analysis, each peak m/z value can lead to multiple plausible neutral molecular 
masses that can represent different ionization adducts (H+, Na+, K+...). This multiplicity 
often results in a high number of false positive identifications [24, 25].  Second major 
challenge in metabolomics studies is the ion suppression. Ion suppression appears as one 
particular manifestation of matrix effects, which are influencing the extent of analyte 
ionization. This change often is observed as a loss in response, thus, the term ionization 
suppression. However, it also can be observed as an increase in the response of the desired 
analyte depending upon the type of sample [26]. Furthermore, subtle variations between 
tested individuals in biomedical studies can result in large variations of the observed 
metabolite concentrations. The corresponding flux of the metabolites is influenced by 
genetic and environmental conditions. Some of the environmental factors include diet, 
stress, xenobiotic use, lifestyle, and disease. Genetic variation can result from differences 
in gender, epigenetics, and gene polymorphisms. All this has to be taken into 
consideration when designing a metabolomics experiment [27].  
The third major challenge lies in the decision which instrumentation is employed to 
analyze the samples. It is known that no single technical approach is able to reveal the 
entire metabolome. This is due to the heterogeneity of the chemical constitution of the 
metabolites and the specific limitations of each instrument [28, 29].  
By far the most challenging part of a metabolomic study is the confirmation of discovered 
potential biomarkers. This is essential towards the understanding of biological changes 
occurring within the system and is until now considered a major bottleneck in 
metabolomics investigations.  Technological advances with better databases could help 
solve this problem. In fact, metabolite identification from LC-MS data is more 
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problematic as the databases are much less developed than those for GC-MS analysis. 
These include the Human Metabolome Database (HMDB) (http://www.hmdb.ca) and the 
METLIN Metabolite Database (http://metlin.scripps.edu). It is also difficult to compare 
data sets between laboratories due to different used analytical instrumentation and 
experimental setup [30, 31]. 
 
1.4.   Microbiology and metabolomics 
Infectious diseases continue to be a major health concern worldwide: hepatitis C, AIDS, 
malaria, tuberculosis (TB) and urinary tract infections are ongoing pandemics [32]. 
However, microorganisms are also of central importance for the ecological process 
keeping our world in balance. They are also major tools of biotechnology. For all this 
processes metabolomics can provide valuable information about the molecular processes 
involved. Metabolomics alone, however, is inadequate to understand the cellular 
metabolic activity: flux measurement, genomic, proteomic and transcriptomic data must 
be added to obtain a systems biology view of the biological process of interest.  Clearly, 
biological processes require an integrated approach to study the sum of all systems [33, 
34]. The new omics technologies, computational methods and genome information are 
needed for the successful implementation of systems biology. Technologies such as the 
next-generation sequencing have opened the door to elucidate total transcriptomes, 
encompassing microRNAs, long noncoding RNAs and mRNAs [35]. Microorganisms are 
ideal for conducting systems biology studies because they are relatively easy to operate 
and manipulate. Thus, microbial metabolomics integrates biological information into 
systems microbiology to aid the understanding of microbial interactions and cellular 
functions [36]. The influence of the microbes on human health has been left unstudied 
leaving human development, physiology, immunity and nutrition almost entirely 
unknown.  
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1.5.   Identification of the microbes 
Traditionally, bacterial identification in microbiology laboratories was performed using 
phenotypic characterization, including Gram staining in combination with a variety of 
biochemical tests, taking into account culture requirements and growth characteristics.  
However, these methods of bacterial identification are known to have major limitations. 
First, often it is observed that there are organisms with biochemical characteristics that 
do not fit into the patterns of any known genus and species. Second, traditional methods 
cannot be applied to uncultivable organisms which represent over 95% of all known 
bacteria. Third, identification of anaerobes and mycobacteria require additional expertise 
and equipment, which are not available in most clinical microbiology laboratories [37]. 
However, these problems can be avoided using a technology, known as 16S rDNA 
sequencing. The microbiologist George Fox and colleagues described their technology in 
1980 that revolutionized the way prokaryotic organisms are characterized, classified, and 
identified. In their study, molecular techniques were used to determine the nucleotide 
sequence of ribosomal RNA from various prokaryotic organisms in order to assess their 
relative position in the evolutionary tree [38].  
Since that time, such analyses have become commonplace in microbiology research 
laboratories as a tool for classification of microbial organisms. According to 16S rRNA 
gene analyzes, life on earth has now been classified into three domains: Bacteria, 
Archaea, and Eucarya. Each domain has been subdivided into at least two kingdoms by 
further genotypic and/or phenotypic analyses [39, 40]. The relationship between the 
major branches of life, the Archaea, Bacteria and Eucarya, as well as the major branches 
within these domains is based on determined 16S rRNA/18S rDNA gene sequences, as 
shown in Figure 3. 
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Figure 3: Universal phylogenetic tree based on the 16S rRNA gene sequence comparisons 
(adapted from Woese et al., 1985). 
 
This approach can also be used to determine the structure of microbial communities [38, 
41]. Among the three domains of life, Bacteria, Archaea and Eucarya, the largest amount 
of rRNA gene sequencing work is related to bacteria. Using obtained 16S rRNA gene 
sequences, many bacterial genera and species had to be renamed and reclassified. Most 
importantly, this technique made it possible to classify uncultivatable bacteria [42]. Due 
to the increasing availability of PCR and DNA sequencing facilities, 16S rRNA gene 
sequencing is not only being used in research but it plays a major role in clinical 
microbiology laboratories worldwide.  
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1.6.   Urinary tract infections  
Urinary tract infections (UTIs) are considered some of the most common bacterial 
infections, affecting 150 million people each year worldwide [43]. UTIs are clinically 
classified as uncomplicated and complicated. Uncomplicated UTIs are characterized by 
no structural or neurological urinary tract abnormalities and they affect individuals that 
are otherwise healthy [44]. The UTIs are described as complicated if they are associated 
with factors that compromise the urinary tract or host defense such as urinary obstruction, 
urinary retention caused by neurological disease, immunosuppression, renal failure or 
transplantation and the presence of foreign devices as calculi, indwelling catheters or 
materials used for  drainage [45, 46]. Bacteria in UTIs are both Gram-negative and Gram-
positive bacteria and certain fungi, as shown in Figure 4. Uropathogenic Escherichia 
coli (UPEC) is found to be most common causative agent for both uncomplicated and 
complicated UTIs. Other agents associated with UTIs are Klebsiella pneumoniae, 
Staphylococcus aprophyticus, Enterococcus faecalis, Streptococcus spp, Proteus 
mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and Candida spp [47, 48]. 
The challenge in diagnosis and treatment of UTI lies in the inconsistent nature and 
vagueness of the presenting illness. UTIs are commonly treated with broad-spectrum 
antibiotics which can lead to long-term alteration of the normal microbiota of the vaginal 
and gastrointestinal tract and in the development of multidrug-resistant microorganisms.  
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Figure 4: Epidemiology of urinary tract infections (adapted from Ana L. Flores-Mireles et 
al, 2015). 
 
Moreover, high rates of recurrent UTIs suggested that antibiotics are not an effective 
therapy for all UTIs [49]. Certain clinical practice guidelines define that UTI as the 
presence of  >50,000 colony forming units/mL of a single uropathogen when analyzed by 
culturing the corresponding urine [50]. Knowing that identification is often not possible 
by phenotypic methods. It is more precise by 16S rRNA gene sequencing. 16S rRNA 
gene sequencing has become the reference method for bacterial taxonomy and 
identification and clinicians need the bacteria identity in order for accurate  diagnosis and 
optimal antibiotic therapy [51].  However, these methods are time-consuming and 
expensive. A test that could aid clinicians in fast accurate and inexpensive microbial 
determination of the diagnosis to judge the severity of UTIs would be of great benefit. 
Metabolomics can be used to quantify specific chemical constituents within a body fluid 
[52]. Metabolomics is an attractive technology because of its ability to non-invasively 
provide both qualitative and quantitative measurements, while simultaneously studying 
thousands of compounds in the same biologic fluid. Urine is an excellent biological fluid 
for various medical studies because of its easy availability and rich chemical composition 
with hundreds of metabolites already identified and quantified by LC-MS [53, 54]. Some 
of the metabolites that are indicative of UTIs that were reported in recent metabolomics 
studies are acetic acid/creatinine, 6-hydroxynicotinic acid, acetate, lactate, succinate, 
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formate, glucose, fructose and alanine levels. Those levels were measured in cohort 
studies and the infected urine samples were usually infected by a single pathogen [55-
58]. However, the levels of these general and often found metabolites are of subject to 
other environmental factors which questions their efficient utilization as specific 
biomarkers for UTIs. Therefore, we aimed at the development of a metabolomics 
approach for the identification of highly specific biomarkers safely indicating UTIs. 
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1.7.   Aim of the study 
This thesis aimed at employing metabolomics approaches at three research topics: 
 
i. The identification of highly specific biomarkers in human urine which safely 
indicate urinary tract infections (UTIs). For this purpose, a metabolomics 
approach was planned where the metabolome of the urine of UTI patients was 
compared with those of healthy persons. For the safe and efficient identification 
of urine metabolites indicating UTI the mathematics of the bioinformatics-based 
identification strategy using the obtained LC-MS data had to be systematically 
optimized. Obtained potential biomarkers were to be discussed in the context of 
the current knowledge. 
 
ii. Performance evaluation of four publicly available in silico fragmentation tools 
that aid structure elucidation in metabolomics and that participated in the 2016 
Critical Assessment of Small Molecule Identification (CASMI) challenge. 
Furthermore, development of voting/consensus model to improve the outcomes 
of each of the existing tools (MetFragCL, CFM-ID, MAGMa+ and MS-Finder). 
 
iii. Metabolite profiling of 12 healthy individuals exposed to endotoxin LPS over the 
period of 8 hours. In addition, metabolomic profiling of 12 healthy individuals 
that underwent “iceman training” and were exposed to endotoxin LPS. Metabolic 
response was investigated between the two groups. 
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2.1.   Abstract – Part I 
The current methodology for urinary tract infection (UTI) diagnosis includes cost-
intensive patient symptomology, anamnesis and classical culture-based microbiological 
analysis. Clinical parameters that lead to uncertainty are asymptomatic bacteriuria, 
sample contamination and non-infectious inflammatory conditions. In order to develop 
simple, direct and reliable diagnostic tools, a metabolomics approach using urine samples 
from 92 patients was carried out. Single Strand Conformation Polymorphism (SSCP) 
analyses were performed to identify the organisms causing the UTI. Data obtained from 
comprehensive LC-MS analyses of the training set (28 healthy and 28 infected 
individuals) were used to establish a reliable prognostic model. Using metabolomics data 
from 20 healthy and 16 infected individuals as validation set, three putative biomarkers, 
thieno-(2, 3-c) pyridine, heneicosanoyl-glycero-3-phospho-(1’-glycerol) and metabolite 
with molecular formula C9H17NO of the training set were identified as statistically 
significant to represent the specific host response to the infection. No obvious relation of 
these metabolites to the identity of the infection-causing bacteria was discovered. 
Obtained results were confirmed in the validation set showing not only the reproducibility 
of the analytical platform but also the biological significance of the detected metabolites. 
The potential benefit of these metabolites as putative diagnostic biomarkers was validated 
through additional analysis, combinatorial receiver operating characteristic (ROC) curve 
and could be useful in novel diagnostic strategies. 
 
Keywords 
Urinary tract infection, metabolomics, in silico fragmentation, mass spectrometry, 
prognostic model, linear regression, putative biomarker 
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2.2.   Introduction – Part I 
Urinary tract infections (UTIs) are among the most common diseases worldwide. An 
estimated 150 million cases of UTIs occur globally and account for medical expenditures 
of approximately 1000 €/patient making it one of the biggest health concerns of today 
[59]. For women, the lifetime risk of developing a UTI is greater than 50%, while only 
20% of all men are affected [60]. Additionally, UTIs are generally self-limiting, but have 
a propensity to recur in individuals without anatomical or functional abnormalities [61, 
62]. UTIs are generally treated with antibiotics and are consequently prone to the 
selection for antibiotic resistant uropathogens and commensal bacteria.  
Moreover, antibiotic treatment adversely affects the gut and vaginal microbiota [63]. 
Uropathogens produce adhesins, siderophores and toxins which enable them to invade 
and colonize the urinary tract [64, 65]. Escherichia coli still remains the most common 
infecting organism in patients with uncomplicated UTI [66] although other pathogens are 
present including Aerococci [67], Proteus, Staphylococci, Pseudomonas, Enterococci 
and Klebsiella [68]. Cultivation of bacteria from urine samples combined with 
appropriate observation of patients’ symptoms are currently the gold standard for 
diagnosis. However, it is not uncommon to treat UTI solely based on the observed 
symptoms with broad spectrum antibiotics [69]. Non-cultivable bacteria, contamination 
of collected urine samples and misinterpretation of asymptomatic UTI remain the major 
drawbacks in current clinical diagnosis [70]. This often results in patients’ unnecessary 
antibiotic exposure and overtreatment. Consequently, novel methods and approaches for 
fast, reliable and inexpensive UTI diagnosis are much needed [71, 72]. The interplay 
between uropathogens and their hosts has been studied for decades using many different 
experimental approaches [73-75]. Although much has been learned from such studies, 
most have focused on the global effects of infection, often strain specific ones and not on 
the discovery of potentially reliable biomarkers which are validated in another sample 
set. A recent study described an NMR-based urinalysis using a quantitative metabolomics 
approach to evaluate the microbial-human co-metabolite trimethylamine for its function 
as a diagnostic biomarker for the detection of UTI’s in patients [76]. 
The application of mass spectrometry in clinical environments becomes more common 
due to its high resolution analytical power. However, efficient and reliable utilization of 
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mass spectrometry in clinical routine application requires sophisticated data interpretation 
[77, 78]. Current methods include support vector machines [79], genetic algorithms [80] 
and other machine learning algorithms [81, 82]. Predictive modelling for an outcome with 
multiple variables are usually employed to automate the covariate selections from high 
dimensional mass spectrometry data (HDOD) [83, 84].  
Therefore, hybrid approaches that integrate data pattern discovery and regression analysis 
in order to retain desired features of both analytical approaches are utilized. The 
development of a prognostic model usually involves two major steps: model building and 
validation. The first goal is to identify a group of “exemplars” representative of the data’s 
subjects’ pattern. These are typically gained through clustering analysis via unsupervised 
learning [85, 86]. The obtained clustering pattern identifies informative exemplars which 
provide valuable associations for an outcome using a subsequent “supervised learning” 
analysis. In this study, the prognostic model is built via linear regression with the method 
of least squares based on a training set. For every metabolite in this set a p-value is 
computed, which indicates the significance of difference between infected and non-
infected individual metabolites. After model building the significant metabolites are 
validated using a validation set.  
The quality of a prognostic model is evaluated through its performance, i.e. the ability of 
the model to correctly predict the prognosis of a patient based on the observed predictors. 
A few examples of prognostic models include: The Nottingham Prognostic Index, which 
is used to determine prognosis following breast cancer surgery [87] and validated 
biomarkers used for the prediction of future cardiovascular events [88]. Receiver 
operating characteristic (ROC) curve analysis is a standard method for assessing the 
performance of the prognostic models. It is widely accepted as a statistically valid and 
objective means for determining the clinical utility of a biomarker in metabolomics 
studies. The area under the curve (AUC) of the ROC curve facilitates the identification 
of sensitive and specific biological markers [89].   
The aim of this study was to identify potential biomarkers in urine samples of UTI 
patient’s indicative of an infection event by using metabolomics as a platform regardless 
of the pathogen type. For this purpose, we created a prognostic model with urine samples 
from healthy and UTI patients. Data from the urine samples were used in a training set 
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and another unlabeled, randomized set of samples was used for validation purposes. The 
randomized validation set was utilized to avoid batch effects, model overfitting and to 
examine the significance of the results, as reproducibility still remains a bottleneck. 
Metabolomics research struggles with low identification rates compared to proteomics 
[90]. One of the reasons is that in many cases reference tandem mass spectra are not 
available. This fact opened the window for a very vibrant development of in silico 
fragmentation algorithms that aid structure elucidation [91, 92].  
In this paper we describe how in silico fragmentation tool, Molecular Structure Correlator 
(MSC) (Agilent, USA), aids annotation of MS/MS spectra of the three statistically 
significant compounds when the reference spectra is missing, by predicting the 
fragmentation pattern of the molecule, comparing it with the experimental MS/MS 
spectra and querying the publicly available databases. General workflow of this study is 
described in the Figure 5. 
 
Figure 5: General workflow 
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2.3.   Materials and Methods – Part I 
2.3.1.   Human urine samples 
Urine samples were collected from February to May 2015 in a Urology clinic in 
Braunschweig, Germany. In total 92 clean mid-stream catch urine samples from patients 
were collected for pathogenic bacteria identification. Two mL per patients urine sample 
were stored at 4 °C for direct culture-independent bacteria identification and cultivation 
purposes. The rest of the urine samples were stored at - 80 °C after less than one hour 
after sample collection for subsequent metabolomics analysis. Samples were identified as 
infected UTI samples if the colony forming unit (CFU) number was >10 4 per mL of urine 
from patients showing typical UTI symptoms. Other standard methods for UTI diagnosis 
that were used are described in detail elsewhere [93]. These samples were additionally 
subjected to metabolomics analyses. The results for the urine of 28 healthy and 28 
infected individuals served as training set for prognostic model development. After the 
complete analysis of these training set data, another 36 urine samples, 16 from UTI 
patients and 20 from healthy persons, were collected and obtained metabolomics data was 
used for validation purposes. They were unlabeled and randomized during the analyses 
and the obtained results were later evaluated in the context with the information from the 
clinical and SSCP analyses. The study reported in this manuscript was approved by the 
Institutional Review Boards of the Technical University and the involved clinic. All 
patients provided written informed consent for the collection of samples and subsequent 
analysis. 
2.3.2.  16S rRNA sequence analysis for identification of the 
uropathogens using single strand conformation polymorphism (SSCP) 
analysis  
The total DNA from the urine samples was extracted using the BIO 101 Fast DNA Spin 
Kit for the preparation of DNA from soil (MP Biomedical, Strasbourg, France). Lysis of 
the bacterial cells was achieved by using a FastPrep24 instrument (MP Biomedical, 
Strasbourg, France) for 45 s at a speed of 5.5 m/s at 4 °C. For the amplification of a 400 
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bp fragment of the 16S rRNA gene, which included its highly variable regions V4 
(positions 519 - 536 of Escherichia coli 16S rRNA gene) and V5 (907 - 926 of E.coli 16S 
rRNA gene), the primers Com1 (5’ – CAG CAG CCG CGG TAA TAC -3’) and Com2-
PH (5’-CCG TCA ATT CCT TTG AGT TT – 3’) were used [94]. Prior to the  single 
strand digestion primer Com2-PH was phosphorylated [95]. Polymerase chain reaction 
(PCR) reaction mixtures contained 20 µM desoxynucleoside triphosphates, 0.5 µM of 
each primer, 2.5 U/100 µL of DNA polymerase (Thermo Taq Polymerase, NEB, Ipswich, 
USA) and up to 100 ng DNA in 1x ThermoPol buffer. Reaction conditions for the PCR 
cycles were composed of an initial denaturation step at 95 °C for 3 min, 30 cycles of 94 
°C for 50 s and 72 °C for 50 s with a final extension at 72 °C for 10 min. PCR products 
were purified using a Qiaquick PCR purification Kit (Qiagen, Hilden, Germany). The 
amplified DNA quality was checked by gel electrophoresis on a 1.5% agarose gel. SSCP 
profiles were generated and visualized as described elsewhere.43 The SSCP gels were 
bordered by DNA molecular weight marker (Roche, Mannheim, Germany). Selected 
bands of the SSCP profiles were excised with a sterile razor blade. The single-stranded 
DNA of each band was eluted for 10 min at 95 °C in 50 µL buffer containing 500 mM 
ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA (pH 8.0) and 0.1% sodium 
dodecyl sulfate. Each DNA-fragment was amplified by PCR with the corresponding 
Com-primers and the resulting PCR products were purified as described above. The re-
amplified DNA molecules recovered from bands of the community profile were used for 
DNA sequence determination [96].  Bioinformatic interpretation of obtained DNA 
sequences was carried out using the corresponding tools at NCBI [97]. Alignments used 
had a minimal sequence identity of ≥ 95%. 
2.3.3.   Sample preparation for LC-MS analysis 
Urine samples were thawed and mixed by shaking. Creatinine concentrations in all 
samples were determined using Creatinine Urinary Colorimetric Assay Kit (Cayman 
Chemical Company, Ann Arbor, USA). Urine samples were then diluted with HPLC-
grade water (Sigma Aldrich, USA) to a creatinine concentration of 500 mg/L. After all 
the samples were normalized based on the creatinine concentration, 300 µL of the 
acidified urine samples were incubated at 37 °C with shaking at 1000 rpm for 10 min. 
Subsequently, 100 µL of urine were then added to 300 µL LC-MS grade methanol (Sigma 
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Aldrich, USA) containing internal standards. Samples were further incubated at 37 °C 
under aeration with shaking at 1000 rpm for 15 min followed by centrifugation at 13500 
rpm for 15 min. For the LC-MS analyses, 200 µL were taken, otherwise the samples were 
stored at - 80 °C. 
2.3.4.   Metabolomics measurements 
The metabolite compositions of the obtained extracts were analyzed on Agilent 1290 
UPLC- system (Agilent, Santa Clara, USA) in the positive and negative electrospray 
ionization mode. Chromatographic separation of the dissolved metabolites was performed 
using a ZIC®-pHILIC column 3.5 µM of particle size, 200 Å pore size, 100 x 2.1 mm 
(Merck Sequant, Germany), coupled to a high-resolution 6540 QTOF/MS detector 
(Agilent, Santa Clara, USA) in detection range of 50 to 1700 m/z at 2 GHz in extended 
dynamic range. The LC mobile phase was: A) 20 mM ammonium formate (Sigma-
Aldrich, USA) in water (Thermo, USA) with 5% acetonitrile (Thermo, USA) (pH 9) and 
B) 5% acetonitrile with 20 mM ammonium formate in water with a gradient from 5% A 
to 35% in 0.5 min, further to 75% in 1 min, to 85% in 1.3 min, to 95% in 2 min and run 
until 2.3 min before shifting back to 5% at 3 min until 4 min. The flow rate was 300 
μL/min with an injection volume of 1 μL.  
Mass spectrometry was performed using a high-resolution 6540 QTOF/MS detector 
(Agilent, Santa Clara, USA) with a mass accuracy of < 2 ppm. Spectra were recorded in 
a mass range from 50 m/z to 1700 m/z at 2 GHz in extended dynamic range. The LC-MS 
data files were analyzed using the untargeted approach described elsewhere [98]. Briefly, 
raw data processing was done by the Molecular Feature Extraction (MFE) tool in the 
MassHunter Qualitative Analysis B.05.00 software (Agilent Technologies) which 
included background noise removal. Ions were grouped by charge state relation, isotopic 
distribution and the presence of adducts by using the accuracy of the mass measurements. 
Samples were then aligned using MassProfiler Professional (B.12.01, Agilent 
Technologies) using the following settings: abundance filter = 5000, minimum number 
of ions = 2, compound alignment parameter: RT Window = 5%, RT Window (min) = 
0.25, Mass Window (ppm) = 15, Mass Window (mDa) = 2, frequency filter = remain 
entities that appear in at least 10% of all samples.  
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After the MFE list was created, recursion was the next step. The Find Compounds 
function of the Formula tool by MassHunter Qualitative Analysis was importing the most 
significant features back into MassHunter Qualitative Analysis as targeted features to 
improve the detection of the specific features of the samples. This feature finding 
improved the reliability of the procedure and lead to an improvement of the accuracy of 
the analysis. The generated data matrix was then normalized to internal standards using 
the R software package (R, Auckland, New Zealand).  
Statistically significant candidate compounds were further analyzed in a targeted manner 
by performing MS/MS analyses on the UPLC-QTOF/MS using identical conditions. 
Candidate compounds were used for fragmentation with the collision energies of 0 V, 10 
V, 20 V and 40 V respectively. Spectra were recorded at a rate of 3 spectra/s.  The peak 
picking and raw data processing was performed with Mass Hunter software package 
(Agilent, USA). Annotation of compounds detected by LC−MS was performed by 
searching accurate masses of features against the data available in METLIN 
(www.metlin. scripps.edu), KEGG (www.genome.jp/kegg), and LIPIDMAPS 
(www.lipidmaps.org/) and Metabolomic Discoveries’ database entries of authentic 
standards and IDEOM database entries through peak mass within 5 ppm mass accuracy.  
Retention time prediction was applied to aid metabolite annotation [99].  The annotation 
of the three potential biomarkers was done by additional MS/MS analysis and these 
spectra were used as an input for in silico fragmentation software Molecular Structure 
Correlator (MSC) (Agilent, USA). The MSC program correlates accurate mass MS/MS 
fragment ions for a compound of interest with one or more proposed molecular structures 
for that compound. First, Molecular Formula Generator (MFG) computes all possible 
molecular formulas based on the MS1 information of the compounds. In addition to MFG 
tool of Agilent’s MassHunter package, IDEOM was used for formula generation as well. 
Then, MSC software tries to map each observed fragment ion to the proposed structures 
giving each proposed structure a score. Then, MS2 spectra of the significant compounds 
was compared against the proposed structures and they were annotated in this manuscript 
based on the highest score given by the in silico fragmentation tool. Potential biomarkers 
possessed a proposed structure with a score of  ≥ 95 and the candidate structures were 
obtained by querying a PubChem database [100]. 
Results and Discussion – Part I 
 
- 30 - 
 
2.4.   Results and Discussion – Part I 
2.4.1.   Identification of the bacteria in urine samples 
In this study, overall 92 urine samples were analyzed for the presence of bacteria in this 
study, 44 from patients with diagnosed UTI and 48 from healthy subjects. For the 
identification of the bacteria DNA prepared from the urine samples was subjected to 
SSCP analysis in combination to 16S rRNA gene sequencing. The results are summarized 
in Table 1.  
Table 1: Overview of all identified bacterial genera found in the investigated urine samples 
when analyzed with PCR-SSCP method and in vitro cultivation. In 21 urine samples more 
than one bacterial species was found. 
Uropathogen Healthy samples 
n=40 
Infected samples 
n=52 
Escherichia 0 14 
Staphylococcus 1 9 
Aerococcus 0 3 
Proteus 0 4 
Lactobacillus 2 8 
Thiobacillus 0 1 
Enterococcus 2 13 
Citrobacter 0 2 
Prevotella 1 8 
Pseudomonas 0 2 
Finegoldia 0 1 
Enterobacter 0 1 
Veillonellaceae 0 1 
Porphyromonas 0 1 
Morganella 0 1 
Fusobacterium 0 1 
 
In 14 samples Escherichia coli, in 13 Enterococcus, in 9 Staphylococcus and in 8 
Lactobacillus and Prevotella were discovered. Other genera including Aerococcus, 
Proteus, Pseudomonas, Morganella and Citrobacter were found in 1 to 4 urine samples. 
In a few samples of healthy persons typical commensals like Staphylococcus or 
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Lactobacillus were detected. Overall, analytical urine samples from UTI patients 
contained typical known urinary tract infectious bacteria. The SSCP analysis 
demonstrated in 21 out of 44 urine samples from UTI cases the presence of more than 
one pathogen bacterium.  
 
2.4.2.   Urinary metabolomics 
Next, the metabolites from the urine samples were extracted and subjected to an 
untargeted UPLC/MS-based metabolome analysis as outlined in the experimental section. 
The data matrix was constructed with samples as observations and peak intensity as 
response variables for further analysis, accounting for 2027 peaks in total. The training 
data set consisted of the metabolites from the urine samples of 28 healthy and 28 infected 
persons and was used to develop a prognostic model.  Our task was to uncover the effect 
of an infected status in general and the influence of certain bacteria in detail on the 
metabolite composition. Levels of 1783 putatively annotated metabolites in positive and 
993 metabolites in negative mode were measured. Each collected sample was labelled as 
infected, healthy or as blank Consideration of the “blank” (extraction solvent, methanol 
containing internal standards) identified the confounder. Boolean infected status of a 
sample was used by a linear regression as an independent predictor  [101]. 
Boolean data indicate two values, in this case the two values were “infected” and “non-
infected”. In order to determine which metabolites were indicative of the infection status, 
the relation between the metabolite level and the infection status was calculated by 
multiple linear regression analysis with the least squares method separately for each 
metabolite. The method of least squares fits a linear function to a dataset by minimizing 
the sum of the squares of the residuals (𝑟𝑖). The residuals are errors, which occur in the 
difference between the calculated function (𝑓(𝑥𝑖, 𝛽)) and every point (𝑥𝑖, 𝑦𝑖) given in the 
dataset,  
𝑟𝑖 = 𝑦𝑖 − 𝑓(𝑥𝑖, 𝛽). 
The least squares minimize the sum of all residuals 𝑟𝑖, 
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min 𝑆 =  𝑚𝑖𝑛 ∑ 𝑟𝑖
2
𝑛
𝑖=1
=  𝑚𝑖𝑛 ∑(𝑦𝑖 − 𝑓(𝑥𝑖, 𝛽))
2.
𝑛
𝑖=1
 
The regression computed the gradient between the amount of the metabolite of the 
infected and the healthy patient. The associated p-value indicates how significant the 
gradient differs to zero, so how significant the amounts of the various metabolites of the 
infected and non-infected differed.  Since tested for multiple outcomes (each metabolite 
representing a single outcome), it was necessary to prevent the accumulation of false 
positives with each test. Multiple test corrections had to be performed controlling the 
family-wise error rate. For this purpose, the Holm-Bonferroni correction procedure was 
employed [102].  A new significance level 𝐹𝑊𝐸𝑅, Family wise error rate, was defined 
with the given significance level ∝= 0.05 and 𝐹𝑊𝐸𝑅 ≤∝.  
The metabolites 𝑚𝑘 and the corresponding p-values 𝑝𝑘 for the gradient were sorted in 
ascending order with 𝑘 ∈ (1, … , 𝑁), with 𝑁 the number of all metabolites. For the given 
significance level ∝ , let 𝑘 be the minimal index such that 𝑝𝑘 >
∝
𝑁+1−𝑘
.  
If such 𝑘 exist, all metabolites 𝑚𝑘∗ with 𝑘
∗ ∈ (1, … , 𝑘 − 1) are defined as significant, all 
metabolites 𝑚𝑘∗ with 𝑘
∗ ∈ (𝑘, … , 𝑁) are not significant.  Using this approach, we 
established that the association between the infected status of the samples, regardless of 
the causing pathogen, and the putatively annotated metabolites heneicosanoyl-glycero-3-
phospho-(1’-glycerol), thieno-(2, 3-c) pyridine and a metabolite with molecular formula 
C9H17NO were statistically significant.  Out of 1034 metabolites in the positive mode 
only 3 of them had p < 0.05 after the correction being the criterion for metabolites to be 
considered as potential biomarkers.  
Metabolites measured in the negative ionization mode failed to reveal significance 
according to described criterion. The significant metabolites were used in a principal 
component analysis (PCA) with the training data set in order to decipher whether an 
unsupervised method of multivariate statistical analysis could discriminate different 
groups, shown in Figure 6. 
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Figure 6: Scores plot of the Principal Component Analysis (PCA) prognostic regression 
model built with a mass spectral data derived from the from urine training set, A, and the 
validation set, B. colored by infectious status. Red dots indicate samples from infected 
patients and green dot samples from the healthy subjects. The first principal component of 
the training set, A, accounted for 43% while the second principal component accounted for 
31% overall variability. 
 
This PCA model yields a graphical display and offers an interpretation tool that enables 
investigation of the key metabolites of UTI. The scores plot of the first two components 
PCA model showed that the UTI group can clearly be separated from the healthy group. 
Finally, no obvious relation of the discovered metabolites to the identity of the infectious 
bacteria in the analyzed samples was observed. In agreement, all suggested potential 
biomarkers are most likely host-derived. Data for healthy group tended to cluster to the 
right part of the figure, whereas that for UTI group clustered to the left. This model 
provided good group separation, with first principal component accounting for 43% of 
overall variability while the second principal component explains 31% of overall 
variability. 
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2.4.3.   Validation of putative biomarkers 
For the validation of the obtained results, a second PCA model with the results from the 
initial training set and a novel validation set, consisting of metabolomics data for the urine 
of 20 healthy and 16 UTI affected persons was applied. Again, a trend separating infected 
samples from the non-infected samples became obvious with the first two principal 
components, as shown in Figure 7, indicating that combination of the new datasets with 
the observed data of the 3 statistically significant compounds was driving the analysis and 
contributed to the clustering.  
 
Figure 7: The first two principal components of the validation set, B, explain 76% of overall 
variability. 
 
This dataset confirmed the results from the training set with two distinct visible clusters. 
The applied statistical model predicted 76% of the first two principal components, 
putatively annotated thieno-(2,3-c) pyridine, heneicosanoyl-glycero-3-phospho-(1’-
glycerol), and C9H17NO. The concentration of putatively annotated compound, thieno-(2, 
3-c) pyridine (Figure 8A) was found increased by more than 2 fold in the urine of the 
infected patients. This metabolite was described as a cell adhesion-inhibiting anti-
inflammatory compound [103]. Thus, elevated levels in patients with UTIs are to be 
expected. Second putatively annotated biomarker for this syndrome is the metabolite 
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heneicosanoyl-glycero-3-phospho-(1’-glycerol) that was found significantly increased in 
the samples from the UTI patients as shown in Figure 8B. 
Human urine usually contains only very small amounts of lipids. However, under certain 
nephrotic syndrome conditions the urinary excretion of cholesterol, cholesterol esters, 
triglycerides, free fatty acids and phospholipids is considerably increased [104].  
Previous studies also showed that increased urinary phospholipids may indicate early 
aminoglycoside toxicity in patients [105]. 
The third statistically significant compound, C9H17NO (Figure 8C), that was found 
increased in UTI patients and their experimental MS/MS spectra resulted with multiple 
possible isomers with an in silico fragmentation score of < 85. This indicated the in silico 
fragmentation software failed to narrow down the possible structure for the given 
experimental MS/MS spectra.  
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Figure 8: Box plots of the normalized peak intensities of representative putative biomarkers. 
(A) Thieno-(2,3-c) pyridine, (B) Heneicosanoyl-glycero-3-phospho-(1’-glycerol), (C) 
C9H17NO. 
 
However, the metabolite with the same molecular formula was found in urine samples of 
patients suffering from diabetic nephropathy [106]. In silico fragmentation algorithms, 
even though they are used widely in the community and represent reliable tools for 
structure elucidation, may also have a false discovery rate [107]. Therefore, our next step 
will be the synthesis of all putatively annotated biomarkers and the comparison of their 
fragmentation pattern to the ones of our analyses in order to confirm the structure of these 
evidently important compounds.  
Previously reported studies have focused on the discovery but rarely on the validation of 
metabolomic biomarkers. For this purpose each statistically significant metabolite of the 
test and validation sets, a binary logistic regression model was established to obtain the 
receiver operating characteristic (ROC) curve of the combinatorial biomarkers [108]. 
First, univariate ROC curve analyses were applied to quantify the predictive performance 
of each potential biomarker. The specificity and sensitivity trade-offs were calculated for 
each significant metabolite using the area under the ROC curve (AUC).  
To further evaluate the usefulness of the putatively annotated metabolites combinations 
for the diagnosis of UTI, multivariate exploratory ROC analysis was performed. The 
AUC for thieno-(2,3-c) pyridine was 0.82 in the training set and 0.88 in the validation set, 
as shown in Figure 9A and B, respectively.   
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Figure 9: Receiver operating characteristic (ROC) curves of the putative biomarkers for 
Thieno-(2,3-c) pyridine (A) in the training set and (B) in the validation set, for 
Heneicosanoyl-glycero-3-phospho-(1’-glycerol) (C) in the training set and (D) in the 
validation set and for C9H17NO (E) in training set and (F) in the validation set 
 
The AUC for heneicosanoyl-glycero-3-phospho-(1’-glycerol) in the training set was 0.82 
and 0.92 in the training set (Figure 9C and D).  
 
 
The AUC for metabolite C9H17NO went from 0.80 in the training to 0.62 in the validation 
data set, as shown in the Figure 9E and F, indicating that further validation of this 
metabolite is needed.  
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As it is known that a single biomarker is not considered adequately sensitive and specific 
for clinical screenings, results of multiple markers could be combined in order to 
accurately classify patients’ diagnosis [109]. For this purpose, combinatorial ROC curve 
analyses of the all three putative biomarkers were performed. The AUC in the training set 
was 0.97 and 0.99 in the validation set (Figure 10A and B).  
 
Figure 10: Receiver operating characteristic (ROC) curves of the combinatorial putative 
biomarkers (A) in the training set and (B) in the validation set 
 
Metabolomics community seems to have dynamic similar approaches when discovering 
metabolite signatures when the reference material is missing [110]. While this 
information can be of great value further analysis with synthesized standards needs to 
follow this experimental set up in order for real life applications.  
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Taken together, these results indicate that the putative biomarkers, alone or in 
combination, can discriminate the infected samples from the controls with high accuracy 
and should be discussed as a powerful tool in UTI diagnostics. Characteristics of the 
putative biomarkers are listed in Table 2. 
Table 2: Characteristics of the putative biomarkers for urinary tract infection detected in LC-
MS chromatograms with the developed prognostic model 
Annotation Molecular 
formula 
Experimental 
parent ion 
Ionization Mass error 
(ppm) 
InChIKey FC 
Thieno-(2,3-
c)pyridine 
C7H5NS 136.0215 positive 0.675 GDQBPBM
IAFIRIU-
UHFFFAO
YSA-N 
2.3 
unknown C9H17NO 156.1378 positive 1.265 BTQGBUA
SSGEZMW
-
UHFFFAO
YSA-N 
2.21 
Heneicosano
yl-glycero-
3-phospho-
(1’-glycerol) 
C27H55O9P 555.3653 positive 0.279 XEIBLFIFG
ABXTL-
IZZNHLLZ
SA-N 
4.89 
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2.5.   Conclusion – Part I 
State of the art metabolomics was performed on urine samples from patients suffering 
from urinary tract infections in comparison to healthy subjects. The combination of 
different statistical approaches identified three host-derived compounds indicative of a 
urinary tract infection: 1. thieno-(2,3-c) pyridine, 2. heneicosanoyl-glycero-3-phospho-
(1’-glycerol), and 3. a metabolite with the molecular formula of C9H17NO.  
Importantly, the additional confirmation via receiver operating characteristics (ROC) 
curve analysis validated these findings. Found metabolites are independent of the nature 
of the infecting agent. Here we present a novel approach for the reliable identification of 
putative biomarkers in urinary tract infections which could serve for the development of 
inexpensive and dependable diagnostic tools.
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3.1.   Abstract – Part II 
In mass spectrometry-based untargeted metabolomics, rarely more than 30% of the 
compounds are identified. Without the true identity of these molecules it is impossible to 
draw conclusions about the biological mechanisms, pathway relationships and 
provenance of compounds. Public libraries of tandem mass spectra are still very small in 
comparison to the wealth of natural products with hundreds of thousands known 
compounds today. The only way to address this discrepancy is to use in silico 
fragmentation software to identify unknown compounds by comparing and ranking 
theoretical MS/MS fragmentations from target structures to experimental tandem mass 
spectra (MS/MS). 
We compared the performance of four publicly available in silico fragmentation 
algorithms that participated in the 2016 CASMI challenge. We used all 312 MS/MS 
training spectra and the 208 challenge MS/MS spectra to improve the outcomes of each 
of the existing tools (MetFragCL, CFM-ID, MAGMa+ and MS-Finder). For the category 
2 CASMI contest, pure in silico methods were compared solely based on information 
provided by the CASMI organizers. First, parameters were optimized by changing mass 
resolution to 5 ppm search windows, yielding only for MetFragCL a significant 
improvement from 12% to 25% correct top hits. Next, we combined the results of the four 
tools into consensus models by testing different combinations of tools and voting models 
yielding 27% correct top hits as the optimal outcome. However, metabolomics 
researchers would always try to rank hits by using other metadata, resources, databases 
and weighing factors. This approach was defined as challenge in the category 3 of the 
CASMI contest. We found that optimizing the use of metadata or weighing factors 
eventually defined the ultimate outcomes of each method. The voting/consensus method 
improved the original CASMI outcomes to up to 87% correct hits. In the last boost, we 
performed a comprehensive analysis how outcomes of the different tools could be 
combined and reached a final success rate of 92% for the training data and 87% for the 
challenge data, using a combination of MAGMa+ and CFM-ID along with MS/MS 
matching. Boosting without using any in silico tool yielded 62% correct hits showing that 
the use of in silico methods is still important.
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3.2.   Introduction – Part II 
Many fields of research, from environmental analysis to forensics and biology, move 
towards hypothesis-generating screening approaches using liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) [111, 112]. Such approach yields 
hundreds to thousands of signals per study, most of them of unidentified structures even 
after comprehensive searches of existing mass spectral libraries such as NIST, MassBank, 
Metlin or MassBank of North America (MoNA). Overall, tandem mass spectral databases 
cover less than one percent of the compound space that is covered in ChemSpider or 
PubChem with 50 to 90 million compounds.  
As an alternative strategy for compound annotation in silico fragmentation software tools 
have been developed and are used to identify MS/MS spectra when the reference MS/MS 
spectrum is not available.  
Such software tools include MetFragCL [92], MIDAS [76], MAGMa [113, 114], 
MAGMa+ [115], MOLGEN-MS/MS [116], CSI:FingerID [117], CFM-ID [118], 
FingerID [119], Input output kernel regression (IOKR) [120] and the MS-Finder software 
[121]. A number of commercial software solutions such as MassFrontier (HighChem), 
MS-Fragmenter (ACDLabs) or Molecular Structure Correlator (Agilent) are also 
available, but lack open access code or algorithm transparency.  
The data for our investigation was obtained from the CASMI website (http://www.casmi-
contest.org/2016/). The Critical Assessment of Small Molecule Identification (CASMI) 
contest was founded in 2012 to help scientists with their compound identification methods 
by providing community challenges and competitions [122]. For practical reasons, 
including the source code and model availability, error handling, batch processing 
capabilities and the ability to perform local database queries we only covered in silico 
fragmentation software that were used for results submitted by the CASMI 2016 deadline. 
We surveyed four different tools that all use different algorithms for in silico 
fragmentation, MetFragCL, CFM-ID, MAGMa+ and MS-Finder. MetFragCL retrieves 
candidate structures and fragments them using a bond dissociation approach and those 
fragments are then compared to the product ions in a measured spectrum to determine 
which candidate best explains the measured compound by assigning it a score that is a 
function of the mass to charge ratio (m/z),  intensity and bond dissociation energy (BDE) 
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of the matched peaks, while 5 of neutral loss rules account for rearrangements [92]. CFM-
ID (competitive fragment modelling) employs a method for learning a generative model 
of collision induced dissociation fragmentation [118]. CFM-ID can be used to assign 
fragments to spectra to rank the candidates, but also to predict MS/MS spectra from 
structures alone. MAGMa+ is a parameter optimized version of the original MAGMa 
software [113]. MAGMa analyses substructures and utilizes different bond dissociations. 
It furthermore calculates a penalty score for all the bonds that are disconnected and form 
a specific substructure [123]. The improved MAGMa+ version utilized a parameter 
optimization approach to find optimal processing parameters [115]. The MS-Finder 
algorithm simulates the alpha-cleavage of linear chains up to three chemical bonds and 
considers also bond-dissociation energies. Multiple bonds (double-, triple-, or cycles) are 
modelled as penalized single bonds in which hydrogens are lost (hydrogen rearrangement 
rules). The total score also includes mass accuracy, isotopic ratio, product ion assignment, 
neutral loss assignment and existence of the compound in an internal structure database 
[121]. First-principle quantum chemical models for spectrum prediction [124] have only 
been developed for electron ionization but not for electrospray collision induces 
dissociation tandem mass spectrometry (ESI-CID-MS/MS). The CASMI 2016 contest 
consisted of three categories. Category 1: “Best Structure identification on Natural 
Products”, with 19 natural product dereplication challenges. The data for Categories 2 
and 3 consist of training sets and challenge sets of 312 and 208 compounds respectively. 
For Category 2: “Best Automatic Structural Identification - In Silico Fragmentation” no 
other information than the in silico fragmentation was allowed. Category 3: “Best 
Automatic Structural Identification - Full Information” allowed for any type of additional 
information to be used, including mixed models, structure rankings and MS/MS search. 
In order to obtain the ground truth of performance of in silico fragmentation software it 
is important to exclude all pre-knowledge or any bias such as molecular formula lookup, 
database ranking, or any other means that would influence the score. Furthermore, it is 
important to include a large number of unknown compounds in order to improve the 
statistical power of the investigation. We therefore chose the 312 training and the 208 
challenge MS/MS spectra for investigating the capabilities of current software to perform 
unbiased batch-processing of hundreds of test and validation cases. Additionally, we 
compare the tools’ performances when more information is allowed to be used and how 
consensus modelling can improve results.  
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3.3.   Materials and Methods – Part II 
3.3.1.   Tandem mass spectral input data 
The CASMI 2016 website (http://www.casmi-contest.org/2016/) provided 312 training 
and 208 validation files contained MS/MS information as *.MGF file. The MS/MS 
spectra were acquired on a Q Exactive Plus hybrid quadrupole Orbitrap mass 
spectrometer (Thermo Fisher), with <5 ppm mass accuracy and MS/MS resolution of 
35,000 using ESI ionization. Spectra were collected in stepped 20, 35 and 50 eV in mode. 
Only [M+H]+ (positive) and [M-H]- ion species were available. Spectral meta-data 
included the ChemSpider ID, compound name, the monoisotopic mass, molecular 
formula, SMILES, InChI and InChIKey. Some of the candidate structures were erroneous 
and did not match the provided formula, SMILES or InChIKey. After contest deadline, 
the CASMI organizers provided all correct results for the 312 training and 208 challenge 
cases that were used in our evaluation. 
3.3.2.   Query compounds from ChemSpider 
The CASMI team provided for each of the training and validation cases possible 
candidate lists. These compounds were obtained from ChemSpider with a ±5ppm search 
window and the structure files contained the ChemSpider ID, compound name, 
monoisotopic mass, molecular formula, SMILES, InChI and InChIKey. Because 
compound masses are unevenly distributed, some mass spectra yielded up to 8000 
possible structure candidates within the 5 ppm mass window, whereas one mass spectrum 
was only associated with a single possible candidate structure, pentabromophenol. A total 
of 432,511 candidates were available for the training set and 258,808 candidates were 
obtained for the validation set (challenge set). 
Each of the four software tools used different structure handling libraries or routines, 
hence structure conversion issues occurred. Such errors can be attributed to salt forms, 
isotopic elements, radical compounds and conversion issues.  Each of the four tested 
software tools required different input formats and output formats. For that purpose, an 
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application was written in Java to pre- and post-processes all files. Source and result files 
can be found under (https://sourceforge.net/projects/in-silico-fragmentation/). 
3.3.3.   Software settings 
3.3.3.1.   MS-Finder 
The MS-Finder software (version 1.70) was downloaded from the Riken institute website 
(http://prime.psc.riken.jp/Metabolomics_Software/MS-FINDER/index.html) and was 
used on a standard personal computer with a 2.50 GHz Intel Core-i7 CPU and 16 GBytes 
of RAM under the Windows 10 operating system. MS-Finder requires specially formatted 
MS1 and MS2 files as input. The settings are listed in Supplemental Table 1. The MS-
Finder program has a resource folder where two databases are located that the software 
uses to rank the candidate structures. The file ExistStructureDB_vs8.esd is an internal 
structure lookup database and the file ExistFormulaDB_vs8.efd (comprising formula 
from 13 metabolomics databases) is used to prioritize generate molecular formulas. These 
databases were emptied in order to evaluate the pure in silico fragmentation performances 
for challenge 2 and a new database was created, analogous to the one of MS-Finder, from 
provided CASMI candidate files.  
Both databases were opened in Notepad++ and all data except the header row was deleted 
and saved in the same format. Settings were adjusted to ±5 ppm mass accuracy and all 
compounds were processed in batch mode. Detailed information about the process can be 
obtained from the supplement section Supplemental document 1. 
3.3.3.2.   CFM-ID 
The CFM-ID software (version 2.2, revision 26) was downloaded from 
https://sourceforge.net/projects/cfm-id/  and was used on a server with 48-core AMD 
Opteron 6344 processor (2.6 GHz) running CentOS Linux 7. Out of several available 
command line utilities, the cfm-id executable was used for this project. Given an input 
spectrum and a list of candidate SMILES (or InChI) as provided by CASMI, cfm-id 
computes a predicted spectrum for each candidate and compares it to the input spectrum. 
It returns a ranking of the candidates according to how closely they match. The original 
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CFM positive and negative models were used for the spectrum prediction, which were 
originally trained on data from the Metlin database. Mass tolerances of ±5 ppm were used 
and the Jaccard score and dot product score were applied for spectral comparisons. The 
better rankings produced by this comparative method were used for final evaluation. The 
input spectrum was repeated for the low, medium and high energies, which originally 
emulate 10, 20 and 40 eV CID MS/MS spectra. Additional information is contained in 
Supplemental document 1. 
3.3.3.3.   MetFragCL 
The command line version of MetFragCL software (version 2.2-CL) was downloaded 
from https://github.com/c-ruttkies/MetFrag and was used on MacBook Pro with 2.7 GHz 
Intel Core i5 and 16 GB DDR3. MetFragCL needs a parameter file of specific layout as 
input and it contains all necessary information for the processing of a given MS/MS peak 
list. Parameters for fragmentation are shown in Supplemental Table 2. Candidate files 
were prepared with the same application used for the analysis of the results, as mentioned 
previously. Finally, the in silico fragments are matched against the query peaklist 
provided by CASMI. The measured peaks correspond to the charged fragments, so the 
matching function adds (positive mode) or removes (negative mode) a proton (1.007 Da) 
to the fragment mass. Additional settings are described in Supplemental document 1. 
3.3.3.4.   MAGMa+ 
The MAGMa+ software was downloaded from https://github.com/savantas/MAGMA-
plus and was used on a cluster node with a 48-core AMD Opteron 6344 processor running 
CentOS Linux 7. MAGMa+ is an optimized version of the software MAGMa and is 
written as a Python wrapper script with identical command line arguments as the original 
MAGMa program with few changed parameters. Each candidate molecule was used to 
annotate the corresponding spectral tree with in silico generated substructures according 
to the algorithm published previously [123]. A Python script (process_hmdb.py) is 
provided that generates an SQLite .db database file from the public HMDB .sdf structures 
file, which is then used when running MAGMa.  This script was modified to produce an 
analogous database file from the provided InChIs for each set of CASMI candidates. An 
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additional Python script was written to generate spectral-tree files required by MAGMa 
from the CASMI peak lists and metadata. Additional information can be found in 
Supplemental document 1.
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3.4.   Results – Part II 
3.4.1.   CASMI Category 2 (Best Automatic Structural Identification - 
In Silico Fragmentation Only): parameter optimization and 
development of voting/consensus model 
Four tools that were tested in this analysis also participated in the CASMI challenge. First, 
parameter optimization of all tools already resulted in improved results in comparison to 
ones submitted to CASMI. Such parameter optimization includes using a 5 ppm window 
for spectral comparison. Detailed parameter setting for each tool are listed in 
Supplemental document. Secondly, each tool provided a ranked list of all MS/MS spectra 
(training and challenge) which was then used as an input for voting/consensus model 
resulting in new improved rankings, as described below. 
 
3.4.1.1.   In silico performance using the training set 
Following the guidelines of the Category 2 challenge by the 2016 CASMI organizers, we 
evaluated each in silico software individually by using the best recommended settings 
and without secondary database rankings or use of other metadata. We utilized the 312 
MS/MS spectra from the CASMI training set for parameter optimization of each tool and 
development of voting/consensus model. The number of compounds to be queried for 
each individual case ranged from less than 20 to over 8,000 compounds. The individual 
software tools were able identify between 10-17% of the training set as top hits (see Table 
3). CFM-ID ranked the correct metabolite first in with 15% of the cases and 40% as top 
5 candidates. MS-Finder ranked the correct metabolite first in 10% of cases and 27% in 
the top 5. MAGMa+ ranked 16% of the compounds correctly. MetFragCL was the best 
performing tool in our comparison placing 17% cases correctly in the top rank and 43% 
in the top 5 hits (Figure 11). 
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Figure 11: Comparison of all in silico fragmentation tools and a voting consensus model on 
a training data set consisted of 312 MS/MS spectra obtained in both positive and negative 
ionization mode 
 
3.4.1.2.   Voting/consensus model 
Each software provided candidate ranking for each MS/MS spectrum from the training 
and challenge data set. For ranking of the structures we considered only the first block of 
an InChiKeys to discard enantiomeric or diastereomeric isomers. The voting/consensus 
model combines the ranking results of all tools and creates a new ranking system based 
on two criteria. The primary score of the voting/consensus model is calculated as the sum 
of the number of tools that successfully ranked a candidate compound. In case all four 
tools found the candidate structure, this primary score was four. If none of tools ranked a 
candidate, the score was zero. The secondary score was calculated for each candidate 
structure by: 
𝑆𝑒𝑐𝑜𝑛𝑑𝑎𝑟𝑦 𝑠𝑐𝑜𝑟𝑒 = 𝑅𝑎𝑛𝑘𝑖𝑛𝑔  (𝑠𝑜𝑓𝑡𝑤𝑎𝑟𝑒 𝐴) ∗  𝜔 (𝑡𝑜𝑝 10 𝑠𝑜𝑓𝑡𝑤𝑎𝑟𝑒 𝐴) 
where ω represents the calculated the sensitivity. Sensitivity for each software was 
calculated using a training data set as follows: 
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𝜔 =
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑠
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑙𝑦 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑠 + 𝑓𝑎𝑙𝑠𝑒𝑙𝑦 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑠
 
 
Correctly assigned structures were tested with different thresholds: top rank (correct 
structure had to be ranked #1 by a software), top 5 (correct structure had to be within top 
5 structures), top 10 and top 20. Best results were obtained with the sensitivity calculated 
for top 10 correctly assigned structures as shown in Table 3, and these were used for the 
validation set later on. By sorting the results in two levels with primary scores in 
descending and secondary scores in ascending order, new rankings are obtained for each 
candidate structure. The best voting consensus model was chosen for each experiment. 
The voting/consensus model was written in R script and Java. The code is freely available 
(https://sourceforge.net/projects/in-silico-fragmentation/).  
Application of voting/consensus model to both categories is shown in the Figure 12. 
 
Figure 12: In silico fragmentation can be used to identify unknown MS/MS spectra by 
matching theoretical fragments to experimental MS/MS spectra and score all fragmented 
compounds. 
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3.4.1.3.   Voting/consensus model applied to in silico results 
Subsequently we improved overall rankings by applying the voting/consensus model as 
detailed in the method section. In comparison to each individual tools’ results the 
voting/consensus model built by combination of MetFragCL and CFM-ID improved the 
overall results by 5%, ranking 22% cases in the top rank, 49% in the top 5 and 63% of 
the compounds in the top 10, as shown in Figure 11, respectively. 
 
3.4.2.  CASMI Category 3 (Best Automatic Structural Identification - 
Full Information): application of voting/consensus model 
This category uses the same data files and candidate lists as for Category 2, but in 
Category 3 any form of additional information could be used (retention time information, 
mass spectral libraries, patents, reference count etc.). This category allows to demonstrate 
whether or how much additional information and meta – data can improve the results of 
the unknown annotation. For this category we have used database and MS/MS boosting 
systems for each of the tools as well as the voting/consensus model in order to further 
improve the rankings. 
 
3.4.2.1.   Compound database search and importance ranking 
In all published research, in silico fragmentation tools are rarely used as stand-alone tools 
without searching structure databases. Nevertheless, querying public databases is 
important to rank in silico results according the occurrence or importance of compounds. 
For example, if a candidate result structure is contained in multiple databases, it is most 
likely an often observed or important molecule. Similar methods could be used for 
literature citation ranking or presence in target databases according to the purpose of a 
study (e.g. metabolomics). Two approaches were used here. First, we have combined the 
results of each in silico fragmentation tool with its membership in the local database of 
MS-Finder. Then we created a new ranked list for each tool and for the voting consensus 
model. Second, we created another voting/consensus model based on the occurrence 
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count in this database. The MS-Finder query structure database contains 220,213 entries 
sorted according to InChIKey, PubChem, exact mass, formula and SMILES. This local 
compound database covers structures from the most important databases including the 
BMDB, CheBI, DrugBank, ECMDB, FoodDB, HMDB, KNApSack, PlantCyc, SMPDB, 
T3DB, UNPD, YMDB and STOFF-IDENT [125]. 
 
3.4.2.2.   MS/MS search settings 
In addition to structure database search we have also searched MS/MS libraries as 
described elsewhere [126]. The NIST MS PepSearch program is a batch command-line 
version that is related to the NIST MS Search GUI program. Originally aimed at peptide 
scoring it can also be used for small molecule scoring.  
Using .msp as input files, the NIST [127] and MassBank [119] MS/MS libraries were 
searched with a 5 ppm precursor window. Detailed parameters are listed in Supplemental 
Table 3. Out of 312 MS/MS spectra in the training set 276 (88,4%) had a hit in the MS/MS 
database with dot product score ranging from 183 (for Training-109) up to dot product 
score 999 (Training-029). In the challenge data set out of 208 MS/MS spectra 125 (60%) 
had a library coverage with dot product score ranging from 441 (Challenge-182) up to 
dot product score of 999 (Challenge-049). Using a training data set different cut offs of 
dot product scores were tested in order to determine which one results with most correctly 
identified MS/MS spectra. A dot product score of 400 is experimentally determined to be 
the best one to use on a training data set and the same cut off was then applied on a 
validation data set. 
 
3.4.2.3.   Sorting according to importance using ChemSpider ID 
ChemSpider is a database of over 50 million chemicals from many different sources and 
is now maintained by the Royal Society of Chemistry [128]. The CASMI contest provided 
ChemSpider structures as SMILES and InChI codes together with their ChemSpider ID.  
ChemSpider entries are numbered by increasing numbers according to date of entry.   
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In general, more information is known for lower-entry number ChemSpider hits, and such 
compounds can be deemed more important.  
High entry number ChemSpider IDs often refer to new synthetic compounds, but 
infrequently also to completely novel natural products. Nevertheless, low ChemSpider 
IDs can be given a higher relevance score during structure candidate rankings.  
Ordering the candidate structures according to their ChemSpider ID alone provided 
correct results in many cases.  
Randomization and ordering of the candidate structures allowed for another comparison 
of results when in silico fragmentation tools are not used.  
 
3.4.2.4.   Final scoring model for the validation set 
For CASMI challenge 3, any combination of tools was allowed to yield rankings. 
Accordingly, we optimized combining in silico tool outcomes with presence of structure 
hits in compound databases and MS/MS matching into a modified voting/consensus 
model (see Figure 11). Finally, the optimized scoring system for the Challenge 3 was 
created as follows: 
𝐹𝑖𝑛𝑎𝑙 𝑠𝑐𝑜𝑟𝑒 = 𝑝𝑟𝑖𝑚𝑎𝑟𝑦 𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑜𝑛 + 𝐷𝐵 𝑚𝑒𝑚𝑏𝑒𝑟𝑠ℎ𝑖𝑝 + 2 ∗ 𝑆𝑇𝑂𝐹𝐹 𝐼𝐷 𝑚𝑒𝑚𝑏𝑒𝑟𝑠ℎ𝑖𝑝 
+ 
4 ∗ 𝑀𝑆/𝑀𝑆 𝑁𝐼𝑆𝑇𝑚𝑒𝑚𝑏𝑒𝑟𝑠ℎ𝑖𝑝 
Only in case of ties was the in silico ranking used as secondary score. Each candidate 
structure found in the compound databases (DB membership) was boosted once, 
regardless of its occurrence in the database 
The STOFF-IDENT compound database  [125] was used in addition and the compound 
occurrence in this database was boosted twice. This database was chosen for this case 
specifically because most of the CASMI compounds were environmentally relevant. 
When for example investigating metabolites the database has to be a metabolite library 
such as KEGG or HMDB. For each MS/MS spectrum that was found in NIST and 
MassBank libraries we have boosted four times to the results list of every tool. Then final 
rankings were obtained by sorting the sum of the scores in descending order. The higher 
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the final score the higher the new ranking. Overall approach boosted the overall result of 
each individual tool. A total of 49 different combinations were tested and the related data 
can be found in Table 3. The best voting/consensus model, built on CFM-ID and 
MetFragCL and it placed ~93 % correctly in the top rank and ~98 % in the top 10.  
 
Table 3: Results of the in silico fragmentation performance for four publicly available 
software tools: MetFragCL, CFM-ID, MAGMa+ and MS-Finder. DB designates priority 
ranking by structure importance and MS/MS designates MS/MS library search. The 312 
MS/MS spectra were the CASMI 2016 training data and the performance of each tool was 
compared to the voting/consensus model.  
# Tools Top 
hits 
Top 
5 
Top 
10 
Top 
20 
1 MetFragCL+CFM-ID+DB+MS/MS Voting/consensus 290 304 305 306 
2 MetFragCL+DB+MS/MS 288 305 305 307 
3 MetFragCL+CFM-ID+MAGMa(+)+DB+MS/MS 
Voting/consensus 288 304 305 307 
4 MetFragCL+MAGMa(+)+DB+MS/MS Voting/consensus 287 304 305 307 
5 CFM-ID+DB+MS/MS 287 304 304 306 
6 CFM-ID+MAGMa(+)+DB+MS/MS Voting/consensus 287 303 306 307 
7 ID-sorted+DB+MS/MS 286 306 306 308 
8 MetFragCL+MS-Finder+CFM-ID+DB+MS/MS 
Voting/consensus 286 303 305 307 
9 MAGMa(+)+DB+MS/MS 286 301 302 303 
10 MetFragCL+MS-Finder+MAGMa(+)+DB+MS/MS 
Voting/consensus 285 302 306 307 
11 MS-Finder+DB+MS/MS 285 300 302 303 
12 MetFragCL+MS-Finder+CFM-
ID+MAGMa(+)+DB+MS/MS Voting/consensus 284 302 305 307 
13 MS-Finder+CFM-ID+MAGMa(+)+DB+MS/MS 
Voting/consensus 284 302 305 306 
14 MetFragCL+MS-Finder+DB+MS/MS Voting/consensus 283 303 305 307 
15 MS-Finder+MAGMa(+)+DB+MS/MS Voting/consensus 283 302 305 306 
16 MS-Finder+CFM-ID+DB+MS/MS Voting/consensus 283 302 304 305 
17 MetFragCL+CFM-ID+DB Voting/consensus 243 291 296 304 
18 MetFragCL+MS-Finder+CFM-ID+DB Voting/consensus 241 290 297 301 
19 MS-Finder+DB 239 284 294 296 
20 MetFragCL+MAGMa(+)+DB Voting/consensus 238 290 298 301 
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21 MetFragCL+DB 238 290 296 301 
22 MetFragCL+CFM-ID+MAGMa(+)+DB Voting/consensus 238 289 297 305 
23 CFM-ID+MAGMa(+)+DB Voting/consensus 238 288 298 303 
24 MS-Finder+CFM-ID+MAGMa(+)+DB Voting/consensus 237 287 298 301 
25 MS-Finder+CFM-ID+DB Voting/consensus 237 286 297 300 
26 MS-Finder+MAGMa(+)+DB Voting/consensus 236 288 298 299 
27 MetFragCL+MS-Finder+MAGMa(+)+DB 
Voting/consensus 236 287 298 301 
28 MAGMa(+)+DB 236 287 294 299 
29 CFM-ID+DB 236 286 295 302 
30 MetFragCL+MS-Finder+DB Voting/consensus 235 290 296 300 
31 Randomize+DB+MS/MS 195 273 289 305 
32 Randomize+DB 193 268 283 298 
33 ID-sorted 143 249 267 270 
34 MetFragCL+CFM-ID in silico Voting/consensus 69 154 194 230 
35 MetFragCL+MS-Finder+CFM-ID+MAGMa(+) in silico 
Voting/consensus 67 149 185 232 
36 MetFragCL+MS-Finder+CFM-ID in silico 
Voting/consensus 63 148 184 230 
37 MetFragCL+CFM-ID+MAGMa(+) in silico 
Voting/consensus 60 151 189 228 
38 CFM-ID+MAGMa(+) in silico Voting/consensus 59 137 185 222 
39 MS-Finder+CFM-ID+MAGMa(+) in 
silicoVoting/consensus 56 135 175 218 
40 MetFragCL+MAGMa(+) in silico Voting/consensus 54 131 168 211 
41 MetFragCL+MS-Finder+MAGMa(+) in silico 
Voting/consensus 54 130 165 212 
42 MS-Finder+CFM-ID in silicoVoting/consensus 54 114 150 201 
43 MetFragCL in silico only 52 134 171 210 
44 MAGMa+ in silico only 50 121 151 189 
45 CFM-ID in silico only 48 124 170 209 
46 MetFragCL+MS-Finder in silico Voting/consensus 47 121 146 190 
47 MS-Finder+MAGMa(+) in silico Voting/consensus 45 110 137 194 
48 MS-Finder in silico only 30 83 114 142 
49 Randomize 4 13 27 46 
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3.4.2.5.   Validation set performance for Categories 2 and 3 
Finally, we chose the best performing methods and evaluated the 208 unknown MS/MS 
spectra from the validation set. This validation result mimics the approach an experienced 
investigator would take when identifying unknown compounds, by developing and tuning 
and cross-validating the algorithm on the training set and then applying the optimized 
parameters on the validation set. Again, each tool was used individually without any 
additional information and the voting/consensus model was applied using the weights 
calculated from the training set, as described previously (see Table 3). Here for pure in 
silico fragmentation alone MetFragCL performed best by identifying 25% of the 
compounds as correctly found. CFM-ID followed with 18% correctly identified 
compounds and MAGMa+ and MS-Finder identified less than 14% correct. When 
boosting the results with structure database lookup and MS/MS search the results 
improved tremendously to over 83% for MetFragCL and MS-Finder. The best results 
were obtained with 87% correct annotations for the CFM-ID and MAGMa+ 
voting/consensus model, as shown in Table 4. 
 
Table 4: Results of in silico performance of MetFragCL, MS-Finder, CFM-ID and 
MAGMa+ using 208 MS/MS spectra from the 2016 CASMI contest (validation/challenge 
set). DB designates structure ranking importance and MS/MS library search. 
# Tools Top hit Top 5 Top 10 Top 20 
1 CFM-ID + MAGMa + DB + MS/MS 
Voting/consensus 181 188 194 200 
2 CFM-ID + DB + MS/MS 180 191 196 199 
3 MAGMa + DB + MS/MS 180 188 192 198 
4 MS-Finder + DB + MS/MS 174 184 185 191 
5 MetFragCL + DB + MS/MS 174 189 192 197 
6 MetFragCL in silico 53 92 111 137 
8 CFM-ID in silico 37 96 112 137 
9 MAGMa+ in silico 28 71 97 116 
7 MS-Finder in silico 22 56 78 92 
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3.4.8.   Calculation times 
We investigated a total of 520 compounds. However, each individual in silico tool had to 
process 691,319 compounds from the query database. This large number of database 
compounds made it challenging for a number of tools. Performance-wise MetFragCL was 
the fastest with only 12 hours’ calculation time for the 312 training compounds, 
MAGMa+ needed 18 hours, whereas MS-Finder needed one day, using a regular personal 
computer as given in the method section. CFM-ID needed two days on a 48 CPU cluster 
to finish the calculation of the training set. Here additional time-out parameters can be set 
in the future to avoid very long computational times for individual compounds. 
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3.5.   Discussion – Part II 
3.5.1.   Training set performance 
Results uploaded to the CASMI contest website as well as our post-hoc tool comparison 
clearly shows that in silico algorithms alone are still far away from practical use, with 
only 17% of the answers correctly annotated in the training data set. Even when 
combining all in silico tools in a voting/consensus model, only 22% of the compounds 
were ranked as top-candidates. Importantly, even these numbers assume that ‘unknowns’ 
detected in LC-MS/MS of metabolomic or environmental studies are present as existing 
structures in PubChem or ChemSpider.  
In fact, in actual untargeted profiling studies, many structures must be considered to be 
real unknowns, for example as chemical or biochemical derivatives of compounds listed 
in PubChem or ChemSpider databases. Few approaches exist to enumerate such database 
derivative structures, for example the ‘metabolic in silico network expansion DB’ 
(MINE)[126]. Completely de-novo spectra-to-structure calculations are yet impossible.  
At current, best results were obtained when structure database importance and MS/MS 
search were used along with in silico voting/consensus models. Interestingly, each of the 
in silico tools experienced tremendous boosts, leading to 93% correctly assigned 
structures when combining CFM-ID and MetFrag results. Indeed, combined approaches 
have been successfully used in past CASMI challenges [114, 120, 129, 130]. However 
previous challenges did not include a large enough number of compounds for full testing. 
Our step-wise combinatorial multi-model approach shows a more detailed view of overall 
performances. Once customizable tools are available, we will extend our searches to other 
in silico fragmentation algorithms and tools such as CSI:FingerID [117] (which currently 
does not allow for localized database search) or the novel Input Output Kernel Regression 
models (IOKR) [131] (which in not yet publicly available).  
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3.5.2.   Validation set performance and structure diversity 
When the four in silico tools to the validation set of 208 MS/MS spectra individually and 
in the best selected combinations, performances observed in the training set were 
corroborated. With 25% correctly assigned structures MetFragCL was the best stand-
alone in silico fragmentation tool. The voting/consensus model built on MetFragCL and 
CFM-ID improved the results in the top rank by only 2%. When boosting the pure in 
silico outputs by database presence and MS/MS scoring, the best individual tool to use 
was CFM-ID, correctly assigning 86% of the cases in the top rank. The best 
voting/consensus model was again the combination of CFM-ID and MAGMa+ which 
outperformed CFM-ID by only 1% in the top rank.  
Based on PCA analysis of the molecular descriptor space we can conclude that no 
overfitting occurs. A number of structurally different compounds were associated only to 
the validation set (see Figure 13). 
 
Figure 13: Principal component analysis of the molecular descriptor space from the training 
and validation set. Individual outliers show compounds only found in a specific data set. 
Overlapping dots show very similar compounds. 
Lower performances of in silico models in the validation set compared to the training set 
can be explained by differences in the structural scaffolds of both sets that can be observed 
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when visualizing structure fingerprints by Principal Component Analysis (PCA). Indeed, 
structural differences between training tools (by MS/MS databases) and real world 
applications (in actual LC-MS/MS profiling studies) are very likely to be expected. PCA 
also readily separated each tool according to their ranking positions of each 208 
candidates from the validation data set, accounting for 74% overall variances (see 
Supplemental Figure 1). 
 
3.5.3.   Voting/consensus model performance 
The voting/consensus model we proposed and its secondary criterion is calculated by 
using the weight of each software for top 10 rankings, assuming that experts will usually 
rely and use the top 10 candidates proposed by a software. However, the weights could 
be calculated differently and it might have a better impact on the candidate ranking than 
the calculations we propose. The best voting/consensus model uses the results of CFM-
ID and MetFragCL when only in silico performance is evaluated. When structural 
database importance and MS/MS search is added to boost the results, the best 
voting/consensus model is obtained from CFM-ID and MAGMa+ (see Table 3 and Table 
4).   
 
3.5.4.   MS/MS data quality 
The CASMI 2016 contest provided compounds were environmental xenobiotics and 
drugs, all covered in structure databases. About 70 MS/MS spectra had not yet been 
deposited in commercial or publicly available MS/MS databases. Therefore, these 
MS/MS spectra were not available for any software to be used as training set, rendering 
these spectra an excellent test for the CASMI 2016 contest to test in silico fragmentation 
algorithms. Moreover, many compounds contained fluorine atoms in their structure for 
which fragmentation patterns are harder to interpret. Similar to real LC-MS/MS runs, a 
range of challenge MS/MS spectra were sparse in the number of product ion peaks, 
causing in silico tools to fail for lack of data (Supplemental Table 4). While often 
hundreds of isomers are retrieved per chemical formula, annotation tools must fail if too 
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few MS/MS product ions are generated [132]. We recommend acquiring and combining 
MS/MS data under multiple collision energies, or even with different mass spectrometers, 
for important unknowns that are detected as statistically significant in metabolomics 
studies.   
 
3.5.5.   Software use and performance 
Offering a command-line version for in silico fragmentation software that is capable to 
run batches of test is required to process potentially thousands of unknown tandem mass 
spectra from profiling studies. Multi-threading and use of all CPU cores is required. 
However, the true challenge lies in providing tools that can be used in batch mode but are 
still user-friendly enough for untrained investigators. Many of these software tools 
operate across Windows, Linux and MacOS and require different libraries and 
dependencies, demanding a team environment that is skilled in cheminformatics 
techniques. Structure clean-up steps from the provided structure databases proved to be 
time demanding, involving tasks such as removing counter ions, adduct salts, or isotopes. 
Offering web-based research tool is recommended. However, data transfer over the web 
is often forbidden in industrial environments and is also prone to network errors and 
server outages. Because almost all mass spectrometry vendors use Windows platforms 
we further recommend providing Windows-based tools for in silico fragmentations.  
For individual performance checking it is also useful to investigate each individual result 
with graphical user interfaces. Here MS-Finder provides a convenient desktop solution 
for Windows.  
 
3.5.6.   Continuous integration and design of experiment 
Continuous integration refers to a concept in software technologies where multiple 
software tools are continuously compiled to improve results and to fix errors. This 
strategy includes test-driven developments were the software has to pass specific test 
units, in order to catch implementation errors. The Design of Experiment (DOE) is a long 
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standing concepts were the whole parameter space is scanned to find the best input 
parameters. Our voting/consensus software uses output results of all integrated in silico 
tools. It would be prudent to test formats as well as output accuracies whenever new 
software versions are released.  
Specifically, it should be tested whether overall voting/consensus results are actually 
improved or getting worse by new software releases. 
Our newly developed voting/consensus model software can automatically evaluate 
hundreds of optimization models and to report overall outcomes or top hits, top ten hits 
and the specificity of the model. Our software is suited to be extended to include more in 
silico software tools, with output statistics to be modified to calculate additional statistical 
figures of merit. Such extensions require that in silico software tools are publicly available 
in a useable form so the results can be independently validated.  
One could imagine that future CASMI contests are completely run automatically by 
software, preventing errors and individual interventions. 
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3.6.   Conclusion – Part II 
In silico algorithms for structural fragmentation of compounds are still in early 
development. In many cases, existing tools only cover simple fragmentations, but not the 
more complex rearrangement reactions [132]. Once more and more MS/MS spectra are 
becoming available and corresponding structural diversity increases, these can be used to 
train and optimize in silico algorithms which will lead to better performance.    
 
Pure in silico algorithms only identified 17% of the compounds correctly. The 
voting/consensus model slightly improved the results to 22%. Once the database and 
MS/MS search was added the algorithm was able to correctly identify 87-93% of the 
unknown compounds as the first hit, showing the importance of ranking and database 
queries. These results confirm that voting/consensus models can be used for real-world 
applications. Our software will also allow for automatic testing and performance tuning 
without user interaction.  
 
The true challenge is presented by the identification of  “unknown unknown” compounds 
that are not yet covered in compounds databases or that are computationally derived as 
chemical or enzymatic derivatives.  Here classical experimental ways of structure 
elucidation including compound purification and subsequent NMR, UV and MS will play 
a role to elucidate the correct isomer structure. 
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3.8.1.   Methods 
The CASMI 2016 website (http://www.casmi-contest.org/2016/) provided files contained 
MS/MS information as *.MGF file as well as structures for each of the challenge and 
validation sets. That included the ChemSpider ID, compound name, the monoisotopic 
mass, the molecular formula, SMILES, InChI and InChIKey. 
Tools that were used for this research, information how to install and use them are 
presented below. 
 
3.8.2.   Software settings 
 3.8.2.1.   MS-Finder 
MS-Finder software and its documentation was taken from its website 
http://prime.psc.riken.jp/Metabolomics_Software/MS-FINDER/index.html. 
MS-Finder program has a resources folder where two databases are located and that the 
software uses to rank the candidate structures (ExistStructureDB_vs8.esd) and to generate 
molecular formulas (ExistFormulaDB_vs8.efd). These databases have to be emptied in 
order to evaluate the pure in silico fragmentation performances. Under normal 
circumstances this is not required. Both databases were opened in Notepad++ and 
everything except the header row was deleted and saved in the same format. Unknown 
structures were imported as user-defined db by merging all candidates .csv files provided 
by CASMI using the following steps: a) Windows Start Button. b) Type cmd and hit enter 
("Command Prompt" in Windows 10). c) Go to the folder with the CSV files (for help 
how to do that enter "help cd").  d) Type copy *.csv all.txt and hit enter to copy all data 
in the files into all.txt. e) Type exit and hit enter to close the DOS window.  f) Open Excel. 
g) Click File Open to open all.txt file that was saved in the same folder where the 
candidate .csv files are. h) Choose Delimited. i) Next.  j) Check Comma.  k) Finish. l) 
Remove all the headers from newly created file and change the structure of the table 
according to the file located in the MS-Finder Local DB example folder. m) Save as .txt 
file. Now, user-defined database is ready to use. Once all the settings were applied, 
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databases and MS/MS data have been prepared, in the Analysis tab Compound annotation 
(batch job) was selected followed by Batch job settings set to both processes (formula 
finder and then structure finder) and top N hits was set to 12176 for the training and to 
8555 for the challenge set (this corresponds to the candidate files with the highest number 
of possible structures provided by CASMI, to ensure that all given structures are 
considered and ranked by the software). Detailed settings are provided in the 
Supplemental Table 1. 
 
Supplemental Table 1: Settings used for open source in silico fragmentation tool MS-Finder 
# Settings YES/NO or other information 
1 Formula finder: Lewis and Senior check yes 
2 Isotopic ratio tolerance 20% 
3 Element ratio check Common range (99.7%) covering 
4 Element probability check yes 
5 Mass tolerance type ppm 
6 Mass tolerance (MS1) 5 ppm 
7 Mass tolerance (MS2): 10 ppm 
8 Element section (O, N, P, S, F, Cl, Br, I, Si): yes 
9 Result cut off 12176 for training and 8555 for challenge data set. 
10 Structure finder: In silico MS/MS 
fragmenter setting: Tree depth 
2 
11 Relative abundance cut off 1% 
12 Result cut off 12176 for training and 8555 for challenge data set. 
13 Local Databases User-defined db 
14 MINE database Never use it 
15 PubChem online setting Never use it 
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3.8.2.2.   MetFragCL 
Command line version of the tool and its documentation was downloaded from its website 
and used on a Mackintosh http://c-ruttkies.github.io/MetFrag/projects/metfragcl/. The 
settings that were used to run the analysis for both sets, training and validation, are listed 
in the Supplemental Table 2. 
 
Supplemental Table 2: Setting used for open source in silico fragmentation tool MetFragCL 
# Settings Information 
1 PrecursorIonMode 1 (1 for positive and -1 for negative 
ionization mode) 
2 IsPositiveIonMode True (False for negative ionization mode) 
3 FragmentPeakMatchAbsoluteMassDeviation 0.001 
4 FragmentPeakMatchRelativeMassDeviation 5 
5 MaximumTreeDepth 2 
6 MetFragPostProcessingCandidateFilter InChIKeyFilter 
7 Adduct type of the precursor [M+H ]+ for positive and [M-H]- for 
negative ionization mode 
 
3.8.2.3.   MAGMa+:  
A Python script (process_hmdb.py) is provided that generates an SQLite .db database file 
from the public HMDB .sdf structures file, which is then used when running MAGMa.  
This script was modified to produce an analogous database file from the provided InChIs 
for each set of CASMI candidates. An additional Python script was written to generate 
spectral-tree files required by MAGMa from the CASMI peaklists and metadata. The 
docker images and associated docker files  that were used with detailed settings can be 
found here https://hub.docker.com/r/ssmehta/magma-plus/. Command line to start the run 
is: docker run -it -v /path/to/magma-plus/supplement:/data ssmehta/magma-plus:v1.0.0.  
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Once the 4 .sdf files were generated, one for positive and negative mode as well as for 
training and challenge data sets, they were now ready to be converted into MAGMa+ 
structure database file. MAGMa+ parameters that we used include -i (ionization mode: -
1 for negative and 1 for positive mode), -p (maximum relative ppm error), -q (maximum 
absolute m/z error in Da), -c (minimum intensity of MS1 precursor ion peaks to be 
annotated), -d (minimum intensity of fragment peaks to be annotated, as percentage of 
base peak) and. The following settings were applied: read_ms_data -i  -1 /1, -p 10 , -q  
0.01, -c 0, -d 0 and -s hmdb. 
 
3.8.2.4.   CFM-ID 
The original CFM positive and negative models were used for the spectrum prediction, 
which were trained on data from the Metlin database. Mass tolerances of 5 ppm were used 
and the Jaccard score and DotProduct score were applied for spectral comparisons, the 
better rankings produced by this comparative method were used for final evaluation. The 
input spectrum was repeated for the low, medium and high energies, which originally 
emulates 10, 20, 40 V CID, however this information was not available. The docker 
images and associated docker files that were used and the detailed settings can be found 
here https://hub.docker.com/r/ssmehta/cfmid/ and the command line to run the tool and 
reproduce all the results is: docker run -it -v /path/to/cfmid/supplement:/data 
ssmehta/cfmid:r25. 
 
3.8.2.5.   MS/MS database search 
The NIST MS PepSearch program is a batch command-line version that is related to the 
NIST MS Search GUI program. The input files were .msp files and the NIST and 
MassBank MS/MS libraries were searched with a 5 ppm precursor window. Detailed 
parameters are listed in Supplemental Table 3. 
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Supplemental Table 3: Detailed parameters used for MS/MS search using the NIST MS 
PepSearch program 
# Settings Information 
1 Presearch mode standard 
2 m/z limits Min. = 0 and Max. = 2000 
3 Search tolerance settings Precursor ion tolerance, m/z units 0.005 
4 Ignore peaks around precursor yes 
5 Fragment peak m/z tolerance 0.5 
6 Min. match factor (MF) to output (0-999) 1 
7 Min. peak intensity (1-999) 1 
8 Max. number of output hits 1 
9 Show spectra without matches yes 
10 Include Hit-Unknown precursor m/z difference yes 
11 Include m/z in the output yes 
12 Output the input spectrum number yes 
13 Set program priority above normal yes 
14 Use number of replicates no 
15 Calculate rev-dot yes 
16 Q-TOF no 
17 Load libraries in memory no 
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3.8.2.6.   CSI: FingerID  
CSI: FingerID combines computation and comparison of fragmentation trees with kernel 
methods. Kernel denotes a similarity coefficient for either MS/MS spectra or 
fragmentation trees and is used for the prediction of molecular properties of the unknown 
compound. Currently it is not possible to modify the candidate database locally thus we 
did not compare CSI: FingerID with the other tools in the main manuscript. However, it 
is of interest to see how it performs on the same data set we have incorporated the results 
in the supplement. CSI: FingerID was downloaded as a 64 bit GUI version from 
https://bio.informatik.uni-jena.de/software/sirius/ and was used on Windows. Settings are 
listed in the Supplemental Table 4. With these settings CSI:Finger ID was able to 
correctly annotate 140 MS/MS spectra of the validation set or 67,30%. However, since it 
was not possible to customize the local database in order to test the in silico fragmentation 
possibilities we did not compare these results to other tools. 
 
Supplemental Table 4: Parameter setting for in silico fragmentation tool CSI:FingerID 
# Settings Information 
1 File type .mgf 
2 Elements beside CHNOPS Br, Cl, F, I 
3 Search tolerance settings Precursor ion tolerance, m/z units 0.005 
4 Ionization [M-H]- and [M+H]+ 
5 Instrument Q-TOF 
6 ppm 5 
7 Consider PubChem formulas 
8 Search with CSI:FingerID PubChem  
9 Export CSI:FingerID results  
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Supplemental Table 5 lists all the compounds that every tool we tested had problems with. 
 
Supplemental Table 5: List of the compounds where every tool performed poorly. Ranking 
position calculated by each tool per correct solution is shown. 
Correct solution Ranking position of the correct compound given by in silico 
fragmentation tool 
InChIKey (1st block) MetFragCL MS-Finder CFM-ID MAGMa+ 
ZZORFUFYDOWNEF 137 541 75 308 
YHQDZJICGQWFHK 98 184 205 119 
BWHOZHOGCMHOBV 119 182 125 156 
SYELZBGXAIXKHU 234 105 85 144 
IRCMYGHHKLLGHV 151 1161 181 460 
LCGTWRLJTMHIQZ 123 111 124 129 
RJGDLRCDCYRQOQ 169 186 57 210 
AFYCEAFSNDLKSX 123 366 142 227 
VHBFFQKBGNRLFZ 213 118 53 212 
CWJSHJJYOPWUGX 576 24 125 341 
WWYNJERNGUHSAO 113 71 73 193 
VVBLNCFGVYUYGU 1031 5460 644 1825 
FRQMUZJSZHZSGN 177 116 51 271 
MMBILEWCGWTAOV 361 253 45 281 
CHIFOSRWCNZCFN 79 675 1160 1238 
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Supplemental Figure 1 shows PCA also readily separated each tool according to their 
ranking positions of each 208 candidates from the validation data set, accounting for 74% 
overall variance. 
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4. 1.   Introduction – Part III 
Activation of the sympathetic nervous system has profound effects on metabolism, 
predominantly mediated through release of catecholamines such as epinephrine [133]. 
Likewise, there exists extensive interplay between inflammation and metabolism, and 
increasing interest in the use of metabolic fingerprints as prognostic tools in inflammatory 
or infectious diseases [134]. Recent advancement of metabolomic profiling, such as 
reversed phase chromatography coupled to electrospray mass spectrometry (ESI–MS), 
allow the detection of highly polar compounds that also occur in blood plasma[135]. 
When applied to biofluids in the field of medicine [136], the profiling of metabolites has 
enabled investigation of the full array of metabolites in the plasma, yielding an 
instantaneous and comprehensive snapshot of the “metabolic status” of a subject or 
patient. 
We have recently showed that the sympathetic nervous system can be voluntarily 
activated through a training program consisting of meditation, exposure to cold, and 
breathing exercises, which resulted in attenuation of the innate immune response [137]. 
Trained healthy volunteers were able to profoundly increase their enogenous adrenaline 
levels, which resulted in suppression of the immune response during experimental human 
endotoxemia (a well-characterized, standardized and reproducible model of systemic 
inflammation elicited by administration of lipopolysaccharide [LPS]) [137]. However, it 
is unknown to what extent the studied intervention affects metabolic processes and if 
these play a role in the observed effects. 
 
Herein, we have used an established metabolomics profiling platform [99] to investigate 
the metabolic response in subjects that were trained in the behavioral intervention and 
underwent experimental human endotoxemia. 
Materials and Methods – Part III 
 
- 78 - 
 
4.2.   Materials and Methods – Part III 
4.2.1.   Subjects and experimental design 
Metabolomic profiling was performed on plasma samples obtained in a previously 
published parallel randomized controlled study registered at ClinicalTrials.gov as 
NCT01835457 [137]. The study protocol is described in detail elsewhere [137]. 
 Briefly, after approval from the local ethics committee of the Radboud university medical 
center (CMO 2012/455), 24 healthy nonsmoking male volunteers with a median age of 
22 years (range 19-27) provided written informed consent and were included in the study. 
All study procedures were in accordance with the Declaration of Helsinki, including 
current revisions, and Good Clinical Practice guidelines. Subjects were screened before 
the study and had a normal physical examination, electrocardiography, and routine 
laboratory values. The subjects were randomly allocated to the trained group (n=12) or 
the control group (n=12) by the opening of sealed envelopes prepared by unblinded staff 
not involved in the study, shown in Table 5. 
 
Table 5: Subject demographic characteristics. Parameters were measured during screening 
visit. BMI, body mass index; HR, heart rate; MAP, mean arterial blood pressure. Data are 
presented as median (range) 
  Parameter Control group, 
n= 12 
Age, y 22 (19–27) 
Height, cm 185 (179–189) 
Weight, kg 78 (65–91) 
BMI, kg/m2 23 (20–27) 
HR, beats/min 61 (40–75) 
MAP, mmHg 94 (78–105) 
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The trained group underwent a 10-day training program provided by Dutch individual 
Wim Hof, which consisted of three main elements: meditation, exposure to cold, and 
breathing techniques (see [137] for a detailed description). After completion of the 
training, subjects underwent experimental human endotoxemia at our intensive care 
research unit, consisting of administration of an intravenous bolus of 2 ng/kg of US 
Standard Reference Escherichia coli endooxin (E. coli O:113 [LPS], Clinical Center 
Reference Endotoxin; National Institutes of Health, Bethesda, MD, USA). The 
experimental human endotoxemia protocol is provided in detail elsewhere [137]. The 
control group did not undergo any training procedures and also underwent experimental 
human endotoxemia. Subjects in the trained group started practicing the learned breathing 
techniques half an hour before LPS administration until two-and-a-half hours afterwards. 
The control group did not practice any techniques throughout the endotoxemia 
experiment. 
 
4.2.2.   Sample preparation for LC-MS analysis 
Ethylenediaminetetraacetic acid (EDTA) anti-coagulated blood was obtained one hour 
before LPS administration (T= minus 1 h), and at T= 0, T= 1, T= 2, T= 4 and T= 8 h. 
Blood was immediately centrifuged at 2000 g for 10 minutes at 4 °C after which plasma 
was stored at –80 °C until analysis. Sample extraction was described previously [99] with 
some modification. Briefly, 50 µL of plasma was mixed with 450 µL of 90% (v/v) 
methanol containing internal standards and incubated for 15 min at 37 °C with 1150 rpm. 
Precipitated proteins were separated from the extract by centrifugation for 12 min at 15 
000 rpm. Supernatant was transferred into micronical vials and was stored at -80 °C until 
further analysis. 
 
4.2.3.   LC-MS analysis 
Modified reversed-phase chromatography in combination with high resolution mass 
spectrometry (HRMS) was employed in this study. Samples were analyzed on an Agilent 
1290 UPLC system (Agilent, Santa Clara, USA) with a Discovery HS F5-3 column (15cm 
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x 2.1mm, 3µm, Supelco, Sigma Aldrich) coupled to a high-resolution 6540 QTOF/MS 
Detector (Agilent, Santa Clara, USA) operated in both positive and negative ESI mode in 
a detection range of 50 to1700 m/z at 2 GHz in extended dynamic range. The LC solvent 
consisted of 95% 10 mM ammonium formate with 0.1% formic acid and 5% acetonitrile 
(A) and 95% acetonitrile with 5% 10 mM ammonium formate with 0.1% formic acid (B) 
with a multi-step gradient with 5% B from 0-0.1 min, then to 35% B at 1.5 min, to 95% 
B at 2.05 min kept constant until 3.2 min, to 5% B at 3.21 min and washing until 4.3 min 
with 5% B. The flow rate was kept constant at 700 µL/min from 0 min to 2.2 min, 
increased from 2.2 min to 2.5 min up to 900 µL/min until 3.2 min. The flow rate was 
decreased from 900 µL/min to 800 µL/min from 3.2 min to 3.1 min and constant until 3.7 
min were the flow rate was changed to 700 µL/min.  
The run time was 4.3 min, 1 µl of sample was injected and the column heated to 40 °C. 
The DualAJS ESI source was set to the following parameters: gas temperature 200 °C, 
drying gas 8 L/min, nebulizer 35 psig, sheath gas temp: 350 °C, sheath gas flow 11 L/min, 
VCAp 3500 V and nozzle voltage of 0 V. Online calibration of the instrument was 
performed throughout the data acquisition using Agilent ES-TOF Reference Mass 
Solution Kit. 
 
4.2.4.   Cytokine and catecholamine determination  
Plasma concentrations of the cytokines TNFα, IL-6, IL-8, and IL-10, and catecholamines 
norepinephrine, epinephrine, and dopamine concentrations were determined as described 
previously [137]. 
 
4.2.5.   Raw data processing and data analysis 
Chromatograms were generated by the LC-MS instrument in .d format. Raw data was 
converted to mzXML and chromatogram peaks extracted XCMS [138] (v1.42.0) which 
was optimized by using the IPO R package [139], as shown in Table 6 with following 
settings: 
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Table 6: Parameter settings used for raw data processing 
Parameter Value 
peakwidth c(10, 70) 
ppm 20 
sntresh 10 
mzdiff 0.0034 
prefilter c(3, 100) 
noise 100 
gapInit 0.8448 
gapExtend 2.0544 
bw 5 
mzwid 0.015 
minfrac 0.5 
max 50 
  
All further analysis was done in R programming language [140]. IDEOM software 
((http:// mzmatch.sourceforge.net/ideom.php) [141] was used to eliminate noise and for 
putative peak annotation by exact mass within ±10 ppm against Metabolomic Discoveries 
in house metabolite library [98] in negative and positive ESI mode, respectively. 
Retention time prediction was applied to aid metabolite annotation.  
For biological interpretation and visualization of the annotated metabolites iPath2.0, a 
web-based tool (http://pathways.embl.de), was utilized [142]. It provides an overview of 
important regulatory pathways directly connected to the annotated metabolites with 
identifiers obtained from publicly available databases such as KEGG [143] and HMDB 
[144] allowing a more general overview and hypothesis generation.  
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4.3.   Results – Part III 
In this study we aimed to further investigate our previous reporting by using the 
metabolomics platform and to identify metabolomics response in human plasma obtained 
from subjects that were trained in the behavioral intervention and underwent experimental 
endotoxemia. Snap-shot of global metabolomics profiles was obtained through untargeted 
analysis by UPLC-MS platform resulting in 973 detected features in both positive and 
negative ionization mode. As unknown metabolites are a major bottleneck in 
metabolomics [145] we were able to annotate 228 detected features including lipids, 
amino acids, alkyl-amines,  carbohydrates, flavonoids and xenobiotics. Complete list of 
the global metabolomics profiling is provided in the appendix.  
Principal component analysis (PCA) was calculated to illustrate the variances between 
the different sample groups. The colored ellipses describe the 50% confidence interval of 
the normal distribution for each group in the two-dimensional space of the PCA. For 
graphical representation in a heat map, the data is arranged in a matrix, in which each 
metabolite is depicted in one row, each sample or group is depicted in one column, and 
(mean) metabolite abundances in a specific sample / group are illustrated by color. Each 
metabolite’s abundances are centered and scaled. Firstly, centering is done by subtracting 
the total metabolite’s mean. Consequently, samples/groups with an average abundance of 
this metabolite get the value zero and appear white, an abundance below average get 
negative values and appear blue, an abundance above average get positive values and 
appear red. Secondly, scaling is done by dividing the centered metabolite by its standard 
deviation. The resulting values are in a similar range for all metabolites. Thus, the 
variance within a metabolite becomes comparable with other ones.  
Finally, the rows and columns are rearranged in such way that rows or columns with 
similar profiles are grouped. To do so, similarity is determined by a hierarchical 
clustering, as shown in Figure 14. 
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Figure 14: Heat map describing the highest differences between the trained individuals and 
control group from T= - 1 hour up to T= 8 hours, during experimental endotoxemia. 
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Differential analysis, which covers one-way ANOVA, t test and the related plots has been 
developed internally, code is available in supplementary material. A p-value of < 0.05 
was considered statistically significant after correction [146]. 
Overall, 174 metabolites were significantly changed between the two groups according 
to the described method. PCA was utilized to identify the clusters of these significantly 
changed compounds, as shown in the supplementary material. Described statistical 
approach identified metabolites that were significantly changed between the control 
group and the group that was trained in the behavioral intervention.  At the baseline of 
this study, at time point T= minus 1 hour, 19 annotated metabolites were found to be 
statistically significant. All 19 were decreased in the intervention group when compared 
to the controls. Table 7 lists significantly changed metabolites and metabolic pathways 
associated with them.  
 
Table 7: Significantly changed metabolites between intervention and control group at 
experimental baseline, T= minus 1 hour before LPS administration. P values between groups 
were calculated for each metabolite using t test. 
Annotation Intervention/Con
trol p value 
Intervention/Con
trol log2 ratio 
           Class 
L-Carnitine 0.0001 -0.3686 Alkylamines 
Succinic acid semialdehyde 0.0029 -0.4872 Fatty Acids and 
Conjugates 
PC(14:1(9Z)/22:4(7Z,10Z,13
Z,16Z)) 
0.0031 -0.7081 Glycerophospholipids 
PS(41:4) 0.0063 -0.5367 Glycerophospholipids 
Stenopalustroside A 0.0071 -1.8404 Flavonoids 
Glycerophosphoserine (55:0) 0.0087 -0.4692 Glycerophospholipids 
Gly-Ser-His 0.0098 0.4250 Peptide 
PC(18:2(9Z,12Z)/18:2(9Z,12
Z)) 
0.0166 -0.4393 Glycerophospholipids 
Cys-Cys-Gly-Tyr 0.0209 -1.3794 Peptide 
PC(20:3(8Z,11Z,14Z)/18:2(9
Z,12Z)) 
0.0259 -0.4077 Glycerophospholipids 
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1-18:2-2-18:3-
monogalactosyldiacylglycerol 
0.0271 -0.7988 
 
 
3S-hydroxyhexacosanoyl-
CoA 
0.0293 -0.3437 Fatty Acyls [FA] 
Glycerophosphocholine 
(38:6) 
0.0310 -0.4260 Lipids 
Xanthine-8-carboxylate 0.0328 -0.5598 Purine Nucleobase 
L-Acetylcarnitine 0.0348 -0.5574 Acylated Ester of 
Carnitine 
PC(P-
18:1(11Z)/22:6(4Z,7Z,10Z,13
Z,16Z,19Z)) 
0.0352 
 
-0.3669 
 
Glycerophospholipids 
SM(d18:0/16:1(9Z)) 
 
0.0388 
 
-0.2667 
 
Sphingolipids 
PC(18:2(9Z,12Z)/20:2(11Z,1
4Z)) 
0.0453 -0.3977 Glycerophospholipids 
[FA amino(8:0)] 3-amino-
octanoic acid 
0.0473 -0.4346 Amino Fatty Acids 
PC(16:0/16:0) 0.0489 -0.4399 Glycerophospholipids 
 
At T= 1 hour, when the intervention group was practicing their learned breathing 
techniques for 90 minutes already and one hour after LPS administration to both groups, 
differential analysis found 23 metabolites to be statistically important.  
One of the metabolites was lactic acid which was measured and absolutely quantified in 
our previous reporting [137] and showed the same trend in metabolomics measurement.  
 
This reproducibility indicates that the samples were not affected by storage at -80 °C for 
3 years (Figure 15). 
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Figure 15: Absolute quantified curve of lactic acid resulting from Kox et al. 2013. (on the 
left) compared to relative intensities curves of lactic acid (median) resulting from global 
profiling analysis (on the right). 
 
Two hours after the LPS administration to both groups, at the time point T= 2 hours, 32 
metabolites significantly changed, Table 8 lists annotated metabolites.   
 
Table 8: Significantly changed metabolites between intervention and control group at T= 1 
hour, 1 hour after LPS administration. P values between groups were calculated for each 
metabolite using t test 
Annotation Intervention/Control p 
value 
Intervention/Con
trol log2 ratio 
L-Carnitine 3.21547E-05 -0.631637312 
L-Histidine 0.000456607 -1.595711952 
Arginine 0.001848177 -0.718394548 
Glutamine 0.002752166 -0.657182892 
Succinic acid semialdehyde 0.006775379 -0.742579455 
1,6-Naphthalenedisulfonic acid 0.007209301 1.111041353 
Deoxyuridine triphosphate 0.007312922 2.351714715 
6-Phosphonoglucono-D-lactone 0.008142158 1.511555956 
Pyruvic acid 0.012352668 1.482658261 
Piperidine 0.013569688 -0.39067304 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.014302873 1.690514439 
hydroxymethyl-dCDP 0.016124487 -0.557976741 
Pyrrolidine 0.021054846 -0.337365318 
3-Deoxy-D-glycero-D-galacto-2-
nonulosonic acid 0.023427577 1.114202881 
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N3-fumaramoyl-L-2,3-diaminopropanoate 0.023985261 2.149570973 
Lactic acid 0.025882427 1.623274519 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 0.026178041 1.505049739 
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0.035474078 -0.602270254 
3'-O-Methyladenosine 0.036879331 -0.312817564 
Cer(d18:0/20:0) 0.037376408 -1.032399698 
[FA amino(8:0)] 3-amino-octanoic acid 0.039280006 -0.463100982 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.043106053 -0.585611723 
Deoxycytidine 0.04833029 2.736706038 
 
Changes in metabolite fingerprints of the intervention group were noticeable at every 
further time point (Tables 9-11).   
 
Table 9: Significantly changed metabolites between intervention and control group at T= 2 
hours, 2 hours after LPS administration. P values between groups were calculated for each 
metabolite using t test 
Annotation Intervention/Control p 
value 
Intervention/Control 
log2 ratio 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.000453154 0.633052106 
Imidazoleacetic acid riboside 0.00049886 0.503853852 
Glucose 0.001778245 0.506498004 
Acetic acid 0.003266229 0.581486106 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-ynylidene)-
1,6-dioxaspiro[4.4]non-3-ene 
0.004792354 0.643716391 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid 0.00517793 1.093635637 
5'-Dehydroadenosine 0.006256427 0.527173281 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-dimethyl-
quinazolin-2-yl)- guanidine 
0.006877273 0.805137545 
SM(d18:0/16:0) 0.007075819 -1.424118576 
L-Acetylcarnitine 0.007959175 -0.838860409 
3-O-Caffeoyl-4-O-methylquinic acid 0.00802707 0.762762642 
Pyruvic acid 0.008775753 1.001101019 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.009249669 0.351702995 
cis-(homo)2aconitate 0.010613247 0.317167047 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) 0.011135255 -1.499581685 
Pipecolic acid 0.018714721 1.660902676 
Prolyl-Gamma-glutamate 0.021398618 0.520703039 
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PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.021674782 -0.378903957 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.021986358 -0.428642284 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.023161953 -0.12122738 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.02391054 -0.40226308 
2,3-Dimethylbenzofuran 0.024579573 1.191079228 
Erucicoyl-EA 0.026110355 -1.856514729 
Artonin K 0.026813143 0.458822728 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.028668246 0.244989077 
Glyceric acid 0.029843722 0.828594932 
Probenecid 0.031060035 0.688706121 
6-Phosphonoglucono-D-lactone 0.035558039 0.660784473 
2-Hydroxyundecanoate 0.038276913 1.727739069 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.038858826 -0.395289175 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.042226454 0.748984021 
Dimethylarginine 0.043996958 0.226609983 
1,6-Naphthalenedisulfonic acid 0.044510103 0.511170137 
PE(P-18:1(9Z)/14:0) 0.045007043 0.295286158 
[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-eicosatetraenoate) 
0.046548262 -0.304351104 
Proline betaine 0.049002205 1.498820108 
SM(d18:0/16:1(9Z)) 0.050031937 -0.268109447 
 
Table 10: Significantly changed metabolites between intervention and control group at T= 4 
hours, 4 hours after LPS administration. P values between groups were calculated for each 
metabolite using t test. 
Annotation Intervention/Control 
p value 
Intervention/Control 
log2 ratio 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.000453154 0.633052106 
Imidazoleacetic acid riboside 0.00049886 0.503853852 
Glucose 0.001778245 0.506498004 
Acetic acid 0.003266229 0.581486106 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-ynylidene)-
1,6-dioxaspiro[4.4]non-3-ene 
0.004792354 0.643716391 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid 0.00517793 1.093635637 
5'-Dehydroadenosine 0.006256427 0.527173281 
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N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-dimethyl-
quinazolin-2-yl)- guanidine 
0.006877273 0.805137545 
SM(d18:0/16:0) 0.007075819 -1.424118576 
L-Acetylcarnitine 0.007959175 -0.838860409 
3-O-Caffeoyl-4-O-methylquinic acid 0.00802707 0.762762642 
Pyruvic acid 0.008775753 1.001101019 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.009249669 0.351702995 
cis-(homo)2aconitate 0.010613247 0.317167047 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) 0.011135255 -1.499581685 
Pipecolic acid 0.018714721 1.660902676 
Prolyl-Gamma-glutamate 0.021398618 0.520703039 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.021674782 -0.378903957 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.021986358 -0.428642284 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.023161953 -0.12122738 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.02391054 -0.40226308 
2,3-Dimethylbenzofuran 0.024579573 1.191079228 
Erucicoyl-EA 0.026110355 -1.856514729 
Artonin K 0.026813143 0.458822728 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1->3)-
(4'''-p-coumaroylrhamnosyl)-(1->6)-galactoside] 
0.028668246 0.244989077 
Glyceric acid 0.029843722 0.828594932 
Probenecid 0.031060035 0.688706121 
6-Phosphonoglucono-D-lactone 0.035558039 0.660784473 
2-Hydroxyundecanoate 0.038276913 1.727739069 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.038858826 -0.395289175 
N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoate 0.042226454 0.748984021 
Dimethylarginine 0.043996958 0.226609983 
1,6-Naphthalenedisulfonic acid 0.044510103 0.511170137 
PE(P-18:1(9Z)/14:0) 0.045007043 0.295286158 
[ST (20:4)] cholest-5-en-3beta-yl (15S-hydroperoxy-
5Z,8Z,12E,14Z-eicosatetraenoate) 
0.046548262 -0.304351104 
Proline betaine 0.049002205 1.498820108 
SM(d18:0/16:1(9Z)) 0.050031937 -0.268109447 
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Table 11: Significantly changed metabolites between intervention and control group at T= 8 
hours, 8 hours after LPS administration. P values between groups were calculated for each 
metabolite using t test. 
Annotation Intervention/Control 
p value 
Intervention/Control 
log2 ratio 
LysoPC(18:2(9Z,12Z)) 0.00156078 0.695969939 
cis-(homo)2aconitate 0.005863374 -0.225869858 
N(6)-Trimethyl-L-lysine 0.006496653 0.457005453 
Isocitric acid 0.011816495 0.705278276 
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.012130867 -0.827580957 
[ST (20:4)] cholest-5-en-3beta-yl (15S-hydroperoxy-
5Z,8Z,12E,14Z-eicosatetraenoate) 
0.012247553 -0.431581308 
7-methylthioheptanaldoxime 0.014039927 -3.627904943 
Ranunculin 0.026072558 0.934292231 
Galactaric acid 0.031745087 1.37301928 
N-(tetracosanoyl)-sphinganine-1-O-[myo-inositol-1-
phosphoryl-6-D-mannopyranosyl-alpha1-2-myo-
inositol-1-phosphate] 
0.031994853 -0.312246552 
Cer(d18:1/24:1(15Z)) 0.032272052 -2.164909433 
Glycerophosphocholine 0.033417648 0.510012714 
SM(d18:0/16:1(9Z)) 0.034190487 -0.297114732 
148.0117@0.9983 0.03442392 -1.830026736 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.035216806 -0.149472955 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.036427559 -0.358672396 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.038555695 -0.148511072 
Gnidicin 0.038827746 -1.422500552 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.040539259 -0.396508141 
SM(d18:1/18:1(11Z)) 0.042167473 -0.599451656 
Artonin K 0.044067613 -0.327621346 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-ynylidene)-
1,6-dioxaspiro[4.4]non-3-ene 
0.046945216 -0.399323188 
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4.4.   Discussion and Conclusion – Part III 
In this study two objectives were monitored: metabolite changes in the two groups of 
healthy individuals induced by breathing techniques and the changes in metabolome in 
two groups of subjects during experimental endotoxemia. As demonstrated here and fully 
described in recent review articles and our own reporting, human endotoxemia 
experiment is providing an insight and understanding of the inflammatory pathways [137, 
147]. Subjects that took part in training consisted of meditation, exposure to cold and 
breathing exercises for 10 days prior to endotoxemia experiment. Baseline of this study 
showed significant changes in their metabolome when compared to the control group 
(Table 2), T= minus 1 hour. Metabolite with the highest significance is L-carnitine. It is 
significantly decreased in the intervention group. About 75% of carnitine is obtained 
through nutrition in humans [148]. If not obtained from food it is synthesized 
endogenously from two essential amino acids, lysine and methionine in brain, kidney and 
liver [149]. Decreased levels of members of the urea cycle (carnitine and acetylcarnitine) 
as well as amino acids (glutamine, histidine and arginine) indicates that are being utilized 
as the substrates for energy production.  
Furthermore, carnitine levels were decreased in the intervention group through 
endotoxemia experiment as well. Carnitine levels are reduced in patients suffering Gram-
negative sepsis [150] and that prophylactic use of carnitine has been shown to reduce the 
endothelial damage caused by lipopolysaccharide (LPS) and TNF-α. [151]. Other 
metabolites that were decreased in the trained group one hour after LPS administration 
were L-acetylcarnitine, succinic acid semialdehyde, arginine, histidine and glutamine as 
well as fatty acids and lipids. Furthermore, pyruvic acid and lactic acid were significantly 
elevated in the trained group. Gene transcription data reported findings of significant 
increase of lactate production and NAD+ concentration when cells were stimulated with 
LPS or C. albicans [152]. Taken together these findings show that an important 
mechanism of host defense is the shift from oxidative phosphorylation to aerobic 
glycolysis, known as the Warburg effect [153]. Inflammation is characterized with 
metabolic changes in essential amino acids, arginine. Protein breakdown is increased in 
order to increase arginine availability and via de novo synthesis of arginine is increased 
in moderate inflammation, while in severe inflammation arginine levels are reduced [154, 
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155]. Interestingly, levels of essential amino acid arginine were found decreased in the 
intervention group during the endotoxemia experiment. Furthermore, four hours after the 
LPS administration to both groups, at T= 4 hours, levels of dimethylarginine were 
significantly increased in the trained group.  Similar results were observed in another 
study where ratios of arginine, dimethylarginine, citrullin and ornithine were analyzed in 
septic shock patients. In this study it was observed that the arginine/ornithine ratio was 
decreased in sepsis, indicating increased arginase activity (an alternative pathway for 
arginine metabolism) [156]. In addition to decreased arginine levels, histidine is found to 
be significantly decreased in the trained group as well. These findings are in line with 
report by Kamisoglu et al., plasma profiling in humans during the endotoxemia 
experiment. Second cluster of that study displayed significantly increased levels of 
several amino acids, including proteinogenic amino acids such as histidine and a core 
member of urea cycle, citrullin, which is known to be an effective arginine precursor 
[157].These findings were described as a strong indication of the involvement of amino 
acids in the immediate response to inflammatory insult [158]. Our analysis discovered 
several metabolites of energy metabolism to be significantly increased in the trained 
group during the endotoxemia experiment (glucose, isocitric acid, acetic acid, lactic acid, 
pyruvic acid, glyceric acid and 6-phosphoglucono-D-lactone). Study by Agwunobi et al. 
reported in their investigation on the the effects of LPS on healthy volunteers. In their 
reporting LPS induced a fever, tachycardia, and mild arterial hypotension while glucose 
utilization was increased significantly 120 min after LPS administration but then declined 
progressively. The reduction in glucose utilization was related to impaired nonoxidative 
glucose disposal [159]. Also in line with our findings is the study by Wellhoener et al, 
where intravenous endotoxemia was given to heathy volunteers and it significant increase 
in levels of lactate, glycerol and pyruvate 60 to 90 minutes after the LPS was administered 
[160]. In agreement with our data, in studies of human diseases energy-related changes 
are commonly seen in metabolomics which provide an indicator of disease severity [161]. 
Interestingly, glucose levels were increased in the trained group when compared to the 
control group. Additionally, several research groups reported significant increases in 
concentration of organ failure-related compounds: lactate, 2-hydroxyisovalerate, 
isobutyrate, creatinine, trimethylamine N-oxide, and urea [162, 163].  
All together, these data confirm direct implication of LPS to altered energy, lipid and 
protein metabolism, supporting our findings.
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5   Patent for diagnosis of urogenital tract 
infections: Part IV 
Inventors: Dieter Jahn, Nicolas Schauer, Ivana Blaženović 
Ref: 856-3 EP 
 
5.1.   Summary of the invention 
In a first aspect, the present invention relates to a method of diagnosing a urinary tract 
infection (UTI) in a patient comprising the step of: 
determining the level of one or more metabolites in a biological sample from a patient, 
wherein said one or more metabolites are selected from the group consisting of: 
heneicosanoyl-glycero-phospho-(glycerol), thienopyridine, and a metabolite with the 
sum formula C9H17NO, wherein the O is present in a hydroxy group, the N is present in 
a tertiary amine group, and the metabolite comprises a -C≡C-H group. 
In a second aspect, the present invention relates to a method of determining whether a 
patient responds to a therapeutic treatment of a urinary tract infection comprising the step 
of: determining the level of one or more metabolites in a biological sample from a patient, 
wherein said one or more metabolites are selected from the group consisting of: 
heneicosanoyl-glycero-phospho-(glycerol), thienopyridine, and a metabolite with the 
sum formula C9H17NO, wherein the O is present in a hydroxy group, the N is present in 
a tertiary amine group, and the metabolite comprises a -C≡C-H group. 
In a third aspect, the present invention relates to the use of one or more metabolites for 
diagnosing a urinary tract infection in a patient or for determining whether a patient 
responds to a therapeutic treatment of a urinary tract infection, wherein said one or more 
metabolites are selected from the group consisting of: heneicosanoyl-glycero-phospho-
(glycerol), thienopyridine, and a metabolite with the sum formula C9H17NO, wherein the 
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O is present in a hydroxy group, the N is present in a tertiary amine group, and the 
metabolite comprises a -C≡C-H group. 
In a fourth aspect, the present invention relates to a kit comprising means for determining 
the level of one or more metabolites in a biological sample from a patient, wherein said 
one or more metabolites are selected from the group consisting of: 
heneicosanoyl-glycero-phospho-(glycerol), thienopyridine, and a metabolite with the 
sum formula C9H17NO, wherein the O is present in a hydroxy group, the N is present in 
a tertiary amine group, and the metabolite comprises a -C≡C-H group. 
This summary of the invention does not necessarily describe all features of the present 
invention. Other embodiments will become apparent from a review of the ensuing 
detailed description. 
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6   Summary 
In the first part of the thesis a metabolomics approach was undertaken for the 
identification of biomarkers in human urine indicating a urinary tract infection (UTI). For 
this purpose, the urine of 44 patients suffering from UTI and 48 healthy persons was 
analyzed for their metabolite composition using LC-MS analysis. For the accurate 
identification of metabolites indicative of UTI the statistical approach for LC-MS data 
interpretation had to be optimized. For this purpose, a prognostic model was developed 
and the relation between the metabolite level and the infection status was calculated by 
multiple linear regression analysis with the least squares method separately for each 
metabolite. Utilization of this novel data interpretation approach led to identification of 
thieno-(2,3-c) pyridine and heneicosanoyl-glycero-3-phospho-(1’-glycerol) as 
metabolites safely indicating UTIs. 
In a second project, software used for putative biomarker annotation, four in silico 
fragmentation tools (MetFragCL, CFM-ID, MAGMa+ and MS-Finder) and their 
performance was addressed on a Critical Assessment of Small Molecule Identification 
(CASMI) 2016 dataset. Pure in silico algorithms only identified 17% of the compounds 
correctly. The voting/consensus model developed for this purpose slightly improved the 
results to 22%. Once the database and MS/MS search was added the algorithm was able 
to correctly identify 87-93% of the unknown compounds as the first hit, showing the 
importance of ranking and database queries. These results confirmed that 
voting/consensus models can be used for real-world applications. Our software will also 
allow for automatic testing and performance tuning without user interaction.  
In a third project, metabolomic profiling was performed on plasma samples obtained in a 
previously published parallel randomized controlled study by Kox et.al., 2013. Metabolic 
signatures revealed altered lipid, protein and central metabolism in both intervention and 
control group as a response to endotoximia and breathing techniques. 
Overall, obtained results underscore the increasing power and relevance of metabolomics 
in biomedical research and diagnosis. 
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7   Zusammenfassung 
Im ersten Teil der Arbeit wurde eine Metabolom Analyse zur Identifikation von 
Biomarkern in humanem Urin, welche auf eine Harnwegsinfektion (HWI) hinweisen, 
durchgeführt. Zu diesem Zweck wurden Urinproben von 44 an HWI leidenden und 48 
gesunde Personen auf die Komposition ihrer Metabolite mittels LC-MS analysiert. Um 
eine korrekte Identifikation der auf HWI hindeutenden Metabolite zu gewährleisten 
musste die statistische Herangehensweise der LC-MS Dateninterpretation optimiert 
werden. Zu diesem Zweck wurde ein prognostisches Model entwickelt, bei welchem die 
Beziehung zwischen der Metabolit Konzentration und dem Stand der Infektion mit Hilfe 
linearer Regressionsanalyse mit der Kleinstquadratmethode individuell für jedes 
Metabolit ermittelt werden konnte. Die Anwendung dieses neu entwickelten 
Datenanalysesystems  führte zur Identifikation von Thieno-(2,3-c) Pyridin und 
Heneicosanoyl-glycero-3-phosphp-(1´-glycerol) als Metabolite für die sichere 
Identifikation einer HWI. 
In einem zweiten Projekt wurde eine Software zur Annotation potentieller Biomarker und 
vier in silico Fragmentierungstools (MetFragCL, CFM-ID, MAGMa+ und MS-Finder) 
nach ihrer Performanz durch die Anwendung auf ein Critical Assessment of Small 
Molecule Identification (CASMI) 2016 Datenset beurteilt. Die in silico Algorithmen 
alleine haben 17 % der Komponenten korrekt identifiziert. Ein "voting/consensus" Model 
wurde für diesen Test entwickelt und erzielte eine Verbesserung der Ergebnisse auf 22%. 
Die zusätzliche Integration einer Datenbank und MS/MS Suche verbesserte die korrekte 
Identifikation unbekannter Komponenten mittels der Algorithmen auf 87-93% für den 
ersten Treffer. Zusammenfassend wurde gezeigt, dass das "voting/consensus" Model für 
reale Anwendungen genutzt werden kann. Zudem erlaubt unsere entwickelte Software 
sowohl automatisierte Tests als auch eine automatisierte Performanzverbesserung.  
In einem dritten Projekt wurde ein metabolisches Profiling an Plasmaprobem 
durchgeführt, welche im Rahmen einer parallel randomisierten kontrollierten Studie von 
Kox et al. 2013 gesammelt wurden. Diese Analyse des Metaboloms zeigte eine 
veränderte Komposition der Lipide, Proteine und Metabolite des zentralen Stoffwechsels 
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sowohl in der Interventions- als auch in der Kontrollgruppe als Reaktion auf Endotoxämie 
und Atemmethoden. 
Zusammenfassend verdeutlichen die gewonnenen Erkenntnisse die zunehmende 
Bedeutung und Relevanz von Metabolom  Analysen in der biomedizinischen Forschung 
und Diagnose. 
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8   Outlook 
This work investigated the metabolic profiles of patients suffering from urinary tract 
infections and healthy individuals that underwent human endotoxemia. Furthermore, it 
was investigated the performance of tools that aid structure elucidation in metabolomics 
studies. The results raise new questions in terms of data analysis, design of experiments 
and annotation of MS/MS spectra. 
 
1.  Prognostic model developed for metabolomics – based identification of urinary tract 
infections identified two host-derived compounds indicative of a urinary tract infection: 
a) Thieno - (2,3-c) pyridine and b) Heneicosanoyl-glycero-3-phospho-(1’-glycerol). 
However, in order to truly validate the importance of these compounds, a cohort study is 
needed with as many meta – data as possible. Furthermore, the indicative putative 
biomarkers need to be synthetized, fragmented and compared against experimental data 
in order to confirm the true identity of these molecules. 
 
2.  Developed voting/consensus model although it improves the results of the four tools 
tested (CMF – ID, MAGMa+, MetFragCL and MS – Finder), it depends on the results of 
the underlying tools. Once more and more MS/MS spectra are becoming available and 
corresponding structural diversity increases, these can be used to train and optimize in 
silico algorithms which will lead to better performance.    
 
3.  Metabolomics data obtained from 24 healthy individuals divided into intervention and 
control group confirm direct implication of LPS to altered energy, lipid and protein 
metabolism, supporting previous findings. However, sample size needs to be increased in 
order to avoid model overfitting. 
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Supplemental tables for Part III  
Table A1 Metabolome changes in the control group at time point 0 hours (before LPS 
administration) compared to the baseline of this study, - 50 minutes.  1-way ANOVA results in the 
global.p values, and t-tests are the local / pairwise comparisons (local p). 
Metabolite global.p global.p.adj Control   
0/Control 
-50: 
local.p 
Control   
0/Control 
-50: ratio 
Propionylcarnitine 0.12 1 0.97 0.01 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)) 0.04 1 0.08 -0.40 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.03 1 0.96 0 
Phosphocreatinine 0.45 1 0.44 0.17 
L-Histidine 0.65 1 0.05 0.77 
Hymenocardine 0.34 1 0.44 0.24 
Chinomethionat 0.49 1 0.06 -0.84 
Glycerophosphoinositol (41:6) 0.17 1 0.08 -0.85 
N(6)-Trimethyl-L-lysine 0.01 1 0.15 -0.28 
5'-Dehydroadenosine 0.02 1 0.34 -0.14 
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.36 1 0.19 -0.47 
Moracin 0.12 1 0.14 -0.54 
N-desmethylclarithromycin 0.38 1 0.57 0.06 
Glutamine 0.01 1 0.73 0.05 
CDP-Glycerophospholipid(40:6) 0.11 1 0.14 -0.31 
PC(P-18:0/15:0) 0.21 1 0.91 -0.11 
[FA amino(8:0)] 3-amino-octanoic acid 0 0.38 0.12 -0.29 
PI(O-20:0/14:1(9Z)) 0.30 1 0.72 -0.09 
Urea 0.11 1 0.39 -0.12 
Triradylglycero (60:5) 0.23 1 0.72 -0.10 
Prolyl-Gamma-glutamate 0.07 1 0.03 -0.30 
[PR trimethyl,methyl,methyl(5:0/15:0)] 2,6,14-
trimethyl-6,7-epoxy-10-methylene-9-(3-
methylpent-4-enyl)-pentadec-2-ene 
0.09 1 0.49 -0.28 
1-18:2-2-18:3-monogalactosyldiacylglycerol 0.41 1 0.09 -0.53 
N(alpha)-t-Butoxycarbonyl-L-leucine 0.24 1 0.20 -0.84 
Bruceoside A 0.01 1 0.15 -0.67 
Phosphatidyl glycerophosphate (O-42:2) 0.49 1 0.32 -0.29 
PS(41:2) 0.11 1 0.68 -0.10 
PC(O-16:0/18:2(9Z,12Z)) 0.10 1 0.31 -0.19 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.54 1 0.06 -0.29 
LysoPC(18:2(9Z,12Z)) 0 0.01 0.15 -0.37 
L-Carnitine 0.01 1 0.05 -0.18 
PC(o-18:0/20:4(8Z,11Z,14Z,17Z)) 0.35 1 0.33 -0.14 
Epimedin K 0.52 1 0.87 -0.01 
Galactaric acid 0.32 1 0.25 -1.11 
Iodipamide 0.73 1 0.66 -0.20 
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PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.27 1 0.31 -0.30 
Ranunculin 0 0.12 0.28 -0.78 
Spirolide B 0.60 1 0.13 -0.20 
CDP-Glycerophospholipid 
(18:1(9Z)/18:2(9Z,12Z)) 
0.32 1 0.73 -0.10 
PS(39:4) 0.75 1 0.76 -0.09 
3-Amino-1,2,4-triazole 0.52 1 0.93 -0.04 
Di-2-thienyl disulfide 0.19 1 0.14 -0.33 
[6]-Gingerdiol 3,5-diacetate 0.74 1 0.72 0.19 
PC(o-16:1(9Z)/18:2(9Z,12Z)) 0.24 1 0.09 -0.26 
Glycerophosphocholine (40:6) 0.15 1 0.64 -0.12 
PI(O-36:2) 0.25 1 0.50 -0.22 
CDP-Glycerophospholipid (38:4) 0.25 1 0.88 -0.04 
PC(18:1(9Z)/18:1(9Z)) 0.09 1 0.48 -0.12 
PE(24:1(15Z)/15:0) 0.17 1 0.43 -0.13 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.45 1 0.07 -0.23 
Prostaglandin F1a 0.31 1 0.02 1.23 
Succinic acid semialdehyde 0.01 1 0.12 -0.27 
3-O-Caffeoyl-4-O-methylquinic acid 0.06 1 0.73 -0.08 
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) 0.23 1 0.10 -0.23 
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) 0.57 1 0.51 -0.12 
Glucose 0 0.47 0.51 -0.08 
Oxolucidine B 0 0.02 0.07 -0.44 
Beta-1,4-D-
Mannosylchitobiosyldiphosphodolichol 
0.19 1 0.30 0.12 
PE-NMe(18:1(9Z)/18:1(9Z)) 0.36 1 0.41 -0.16 
Artonin K 0 0 0.07 -0.22 
5-Ethoxy-4,5-dihydro-2(3H)furanone 0 0.65 0 -0.39 
Didodecyl thiobispropanoate 0.38 1 0.80 -0.13 
Erucicoyl-EA 0.75 1 0.40 0.48 
PC(16:0/16:0) 0.57 1 0.36 -0.20 
Xanthine-8-carboxylate 0.10 1 0.73 0.08 
N-(tetracosanoyl)-sphinganine-1-O-[myo-
inositol-1-phosphoryl-6-D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.56 1 0.50 0.07 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.48 1 0.20 -0.19 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.25 1 0.75 0.24 
Ganglioside GM3 (d18:0/20:0) 0.50 1 0.08 -0.18 
Epoxymurin B 0.77 1 0.29 -0.58 
carboxynorspermidine 0.59 1 0.58 -0.17 
PE(15:0/22:0) 0.33 1 0.42 -0.13 
Glycerophosphoserine (55:0) 0.39 1 0.23 -0.17 
PS(37:2) 0.34 1 0.57 -0.18 
DG(43:5) 0.63 1 0.57 -0.11 
3S-hydroxyhexacosanoyl-CoA 0.56 1 0.36 -0.16 
Trihexosylceramide (d18:1/24:0) 0.84 1 0.59 0.06 
PS(21:0/0:0) 0 0.27 0.22 -0.43 
PE(P-18:1(9Z)/14:0) 0.32 1 0.94 -0.01 
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Creatine 0.72 1 0.32 -0.35 
L-Acetylcarnitine 0.01 1 0.30 -0.28 
PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.63 1 0.14 -0.24 
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)) 0.75 1 0.55 0.26 
Tartronate semialdehyde 0.37 1 0.84 -0.11 
SM(d34:2) 0.65 1 0.94 -0.01 
Sedoheptulose 0.69 1 0.21 -0.23 
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) 0.88 1 0.78 -0.13 
LysoPE(20:0/0:0) 0.04 1 0.79 -0.19 
Diphenylcarbazide 0.65 1 0.58 -0.36 
PC(P-18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.61 1 0.47 -0.15 
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z)) 0.14 1 0.28 -0.16 
PE-NMe(16:0/18:1(9Z)) 0.54 1 0.71 -0.22 
PC(14:1(9Z)/20:2(11Z,14Z)) 0.17 1 0.35 -0.19 
L-Cyclo(alanylglycyl) 0.77 1 0.77 -0.22 
PG(O-36:1) 0.26 1 0.38 -0.15 
CDP-Glycerophospholipid (38:6) 0.67 1 0.55 -0.13 
D-Sedoheptulose 7-phosphate 0.87 1 0.78 -0.07 
PS(41:4) 0.44 1 0.35 -0.20 
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)) 0.89 1 0.85 -0.03 
Dehydrotomatine 0.73 1 0.30 -0.28 
Tin chloride (SnCl4) 0.64 1 0.82 0.02 
PC(14:1(9Z)/22:2(13Z,16Z)) 0.28 1 0.31 -0.16 
PC(o-18:1(11Z)/18:2(9Z,12Z)) 0.62 1 0.70 -0.09 
Arginine 0 0.60 0.70 -0.07 
Adenosine 0.11 1 0.40 -0.30 
6-Deoxodolichosterone 0.81 1 0.33 -0.34 
Niclosamide 0.41 1 0.07 -0.52 
LysoPC(20:4(8Z,11Z,14Z,17Z)) 0.02 1 0.11 -0.55 
1,2,4,8-Tetraacetoxy-7-hydroxy-3-(4-
hydroxyphenyl) dibenzofuran 
0.66 1 0.34 -0.57 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic 
acid 
0.04 1 0.37 -0.43 
Glycerophosphocholine (38:6) 0.71 1 0.54 -0.13 
N-(2-formyl-3-chlorophenyl) anthranilic acid 0.39 1 0.66 -0.04 
5-Aminopentanoic acid 0.75 1 0.90 0.01 
Narciclasine 0 0 0.38 0.19 
Uric acid 0.93 1 0.34 -0.14 
PE-NMe2(18:1(9Z)/18:1(9Z)) 0.54 1 0.38 -0.15 
PE(22:1(13Z)/15:0) 0.45 1 0.70 -0.07 
[FA hydroxy(4:0)] 1,9S,11R,15S-tetrahydroxy-
13E-prostaene 
0.94 1 0.52 0.34 
2,3-Butanediol glucoside 0.63 1 0.57 -0.24 
Cer(d18:0/20:0) 0.84 1 0.27 0.26 
LysoPE(18:0/0:0) 0.20 1 0.15 -0.44 
Camelliagenin A 0.82 1 0.87 -0.11 
LysoPC(16:0) 0 0.38 0.13 -0.37 
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FA amino(7:0) aminoheptanoic acid 0 0.22 0.24 -0.22 
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0 1 0.99 0 
PC(18:1(9Z)/20:1(11Z)) 0.36 1 0.77 -0.05 
Propanoylagmatine 0.96 1 0.76 -0.04 
Lysyl-Tryptophan 0.85 1 0.67 -0.13 
hydroxymethyl-dCDP 0.04 1 0.62 -0.09 
Lactic acid 0.12 1 0.85 -0.07 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-
dimethyl-quinazolin-2-yl)- guanidine 
0.08 1 0.90 -0.03 
Deoxycytidine 0.26 1 0.78 -0.37 
Glycerophosphocholine 0.05 1 0.09 -0.44 
1-Octen-3-yl glucoside 0.61 1 0.90 -0.05 
Di-2-propenyl hexasulfide 0.86 1 0.47 0.06 
PC(20:3(8Z,11Z,14Z)/20:1(11Z)) 0.88 1 0.74 0.10 
PE(20:2(11Z,14Z)/15:0) 0.36 1 0.38 -0.29 
N3-fumaramoyl-L-2,3-diaminopropanoate 0.13 1 0.74 -0.27 
Leucyl-Proline 0.83 1 0.44 -0.25 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-ynylidene)-
1,6-dioxaspiro[4.4]non-3-ene 
0 0.94 0.35 -0.15 
Lenticin 1 1 0.77 -0.13 
Tetrahexosylceramide (d18:1/16:0) 0.54 1 0.47 -0.17 
N-(2-hydroxyhexacosanoyl)-eicosasphinganine-
1-O-[D-mannopyranosyl-alpha1-2-myo-inositol-
1-phosphate] 
0.58 1 0.29 -0.16 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.78 1 0.53 -0.10 
Acetic acid 0.15 1 0.39 -0.13 
[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-eicosatetraenoate) 
0.75 1 0.96 -0.01 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.01 1 0.45 -0.12 
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)) 0.70 1 0.33 -0.15 
PG(16:0/16:0) 0.93 1 0.21 0.63 
Dimethylarginine 0.18 1 0.40 -0.15 
Hordatine B glucoside 0.50 1 0.16 0.29 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.12 1 0.43 -0.27 
PS(35:0) 0.47 1 0.39 -0.30 
Glyceric acid 0.07 1 0.55 -0.57 
PE(18:3(6Z,9Z,12Z)/22:0) 0.27 1 0.52 -0.12 
PI(16:1(9Z)/18:1(11Z)) 0.40 1 0.60 0.14 
Glycerophosphocholine (52:4) 0.88 1 0.52 0.06 
Psidinin C 0.70 1 0.22 -0.76 
Methyl 3-hydroxybutyrate 0.97 1 0.62 -0.13 
Gnidicin 0.14 1 0.74 -0.30 
Isocitric acid 0.78 1 0.33 -0.28 
6-Phosphonoglucono-D-lactone 0.03 1 0.85 -0.09 
2,3-Dimethylbenzofuran 1 1 0.90 0.10 
Sorbitan stearate 0.86 1 0.38 -0.45 
cis-(homo)2aconitate 0 0.05 0.28 -0.09 
Probenecid 0.71 1 0.63 0.15 
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Deoxyuridine triphosphate 0.08 1 0.98 0.02 
SM(d18:0/16:1(9Z)) 0.70 1 0.40 -0.13 
PC(22:2(13Z,16Z)/16:1(9Z)) 0.59 1 0.73 0.08 
PE(P-18:1(9Z)/14:1(9Z)) 0.78 1 0.39 -0.08 
5-(4-Acetoxy-1-butynyl)-2,2'-bithiophene 0.52 1 0.66 0.14 
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) 0.34 1 0.86 -0.06 
Pyruvic acid 0.05 1 0.38 -0.47 
Creatinine 0.92 1 0.40 -0.12 
(2alpha,3alpha,5alpha,22R,23R)-2,3,22,23-
Tetrahydroxy-25-methylergost-24(28)en-6-one 
0.06 1 0.25 -0.43 
PE-NMe(16:0/16:0) 0.81 1 0.88 -0.05 
Pipecolic acid 0.98 1 0.87 0.09 
PG(42:6) 0.56 1 0.26 -0.21 
N-(2-hydroxytetracosanoyl)-4,8-sphingadienine 0.96 1 0.64 -0.17 
Diisopropyl sulfide 0.56 1 0.63 0.16 
Lumequoylacetone 0.82 1 0.78 -0.16 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.71 1 0.66 -0.04 
PE(18:3(6Z,9Z,12Z)/20:0) 0.30 1 0.59 -0.19 
Prenol 30,32-dihydroxy-2b-methyl-
bishomohopane 
0.71 1 0.29 -0.77 
2-Hydroxyundecanoate 0.99 1 0.94 -0.07 
PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) 0.92 1 0.53 -0.12 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.37 1 0.39 -0.12 
Pyrrolidine 0.14 1 0.60 -0.07 
Cer(d18:1/24:1(15Z)) 0.90 1 0.37 -0.51 
1,6-Naphthalenedisulfonic acid 0.09 1 0.39 -0.24 
TG(41:0) 0.86 1 0.53 -0.11 
CDP-Glycerophospholipid (38:5) 0.12 1 0.21 -0.30 
Ganglioside GM3 (d18:1/24:1(15Z)) 0.13 1 0.33 -0.24 
SM(d18:0/16:0) 0.99 1 0.88 -0.07 
Luteolin 7,4'-diglucuronide-3'-glucoside 0.37 1 0.16 -0.89 
5,8-Dihydro-6-(4-methyl-3-pentenyl)-1,2,3,4-
tetrathiocin 
0 0 0.09 -0.15 
4-Hydroxybutyric acid 0.40 1 0.77 0.23 
PS(P-39:0) 0.25 1 0.25 -0.24 
7-methylthioheptanaldoxime 0.38 1 0.24 -1.11 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.86 1 0.39 -0.15 
PI(18:2(9Z,12Z)/20:1(11Z)) 0.57 1 0.42 -0.32 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) 0.89 1 0.67 0.19 
UDP-N-acetylmuramoyl-L-Ala-D-gamma-Glu-6-
carboxy-L-Lys-D-Ala 
0.92 1 0.37 0.06 
PI (36:0) 0.74 1 0.65 -0.15 
Stenopalustroside A 0.48 1 0.70 -0.22 
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)) 0.81 1 0.35 -0.14 
6-Hydroxyluteolin 6-xyloside 0.44 1 0.87 -0.07 
Triradylglycerol (61:8) 0.90 1 0.70 0.04 
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TG(15:0/20:0/20:0) 0.70 1 0.89 -0.02 
Piperidine 0.02 1 0.54 -0.07 
Phosphocreatine 0.72 1 0.22 -0.50 
5-Hexyltetrahydro-2-furanoctanoic acid 0.94 1 0.56 -0.21 
Proline betaine 1 1 0.98 0.01 
Iodixanol 0.51 1 0.07 -0.26 
Triradylglycerol (65:6) 0.53 1 0.96 0 
3'-O-Methyladenosine 0.36 1 0.23 -0.18 
Kanzonol R 0.84 1 0.59 -0.30 
5-(3-Buten-1-ynyl)-2,2'-bithienyl 0.87 1 0.44 0.10 
1-Pyrrolinium 0.99 1 0.81 -0.11 
SM(d18:1/18:1(11Z)) 0.38 1 0.72 0.10 
SM(d33:1) 0.72 1 0.63 -0.12 
beta-D-Glucosyl-1,4-N-acetyl-D-
glucosaminyldiphosphoundecaprenol 
0.95 1 0.78 -0.02 
2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-
benzopyran-7-ol acetate 
0.84 1 0.57 0.13 
Imidazoleacetic acid riboside 0.02 1 0.73 0.04 
 
 
Table A2 Metabolome changes in the control group at time point 1 hour (after the LPS 
administration) compared to the baseline of this study, - 50 minutes.  1-way ANOVA results in the 
global.p values, and t-tests are the local / pairwise comparisons (local p). 
Metabolite global.
p 
global.p.adj Control  
60/Contro
l -50: 
local.p 
Control  
60/Contro
l -50: 
ratio 
Propionylcarnitine 0.12 1.00 0.02 -0.63 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)) 0.04 1.00 0.03 -0.67 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.03 1.00 0.03 0.34 
Phosphocreatinine 0.45 1.00 0.06 0.43 
L-Histidine 0.65 1.00 0.07 0.50 
Hymenocardine 0.34 1.00 0.08 0.47 
Chinomethionat 0.49 1.00 0.08 -0.94 
Glycerophosphoinositol (41:6) 0.17 1.00 0.09 -0.84 
N(6)-Trimethyl-L-lysine 0.01 1.00 0.09 -0.34 
5'-Dehydroadenosine 0.02 1.00 0.09 -0.18 
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.36 1.00 0.10 -0.65 
Moracin 0.12 1.00 0.10 -0.60 
N-desmethylclarithromycin 0.38 1.00 0.11 0.25 
Glutamine 0.01 1.00 0.12 0.25 
CDP-Glycerophospholipid(40:6) 0.11 1.00 0.12 -0.30 
PC(P-18:0/15:0) 0.21 1.00 0.12 1.10 
[FA amino(8:0)] 3-amino-octanoic acid 0.00 0.38 0.13 -0.29 
PI(O-20:0/14:1(9Z)) 0.30 1.00 0.13 -0.41 
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Urea 0.11 1.00 0.13 -0.20 
Triradylglycero (60:5) 0.23 1.00 0.14 -0.54 
Prolyl-Gamma-glutamate 0.07 1.00 0.14 -0.19 
[PR trimethyl,methyl,methyl(5:0/15:0)] 2,6,14-
trimethyl-6,7-epoxy-10-methylene-9-(3-
methylpent-4-enyl)-pentadec-2-ene 
0.09 1.00 0.14 0.39 
1-18:2-2-18:3-monogalactosyldiacylglycerol 0.41 1.00 0.15 -0.67 
N(alpha)-t-Butoxycarbonyl-L-leucine 0.24 1.00 0.16 -0.99 
Bruceoside A 0.01 1.00 0.17 -0.66 
Phosphatidyl glycerophosphate (O-42:2) 0.49 1.00 0.17 -0.40 
PS(41:2) 0.11 1.00 0.17 -0.32 
PC(O-16:0/18:2(9Z,12Z)) 0.10 1.00 0.18 -0.23 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.54 1.00 0.18 -0.19 
LysoPC(18:2(9Z,12Z)) 0.00 0.01 0.19 -0.34 
L-Carnitine 0.01 1.00 0.19 -0.12 
PC(o-18:0/20:4(8Z,11Z,14Z,17Z)) 0.35 1.00 0.21 -0.19 
Epimedin K 0.52 1.00 0.22 0.13 
Galactaric acid 0.32 1.00 0.22 -1.28 
Iodipamide 0.73 1.00 0.23 -0.70 
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.27 1.00 0.24 -0.36 
Ranunculin 0.00 0.12 0.24 -0.89 
Spirolide B 0.60 1.00 0.25 -0.17 
CDP-Glycerophospholipid 
(18:1(9Z)/18:2(9Z,12Z)) 
0.32 1.00 0.25 -0.37 
PS(39:4) 0.75 1.00 0.25 -0.28 
3-Amino-1,2,4-triazole 0.52 1.00 0.25 0.49 
Di-2-thienyl disulfide 0.19 1.00 0.25 -0.27 
[6]-Gingerdiol 3,5-diacetate 0.74 1.00 0.26 0.53 
PC(o-16:1(9Z)/18:2(9Z,12Z)) 0.24 1.00 0.26 -0.20 
Glycerophosphocholine (40:6) 0.15 1.00 0.27 -0.31 
PI(O-36:2) 0.25 1.00 0.27 -0.39 
CDP-Glycerophospholipid (38:4) 0.25 1.00 0.27 -0.31 
PC(18:1(9Z)/18:1(9Z)) 0.09 1.00 0.27 -0.22 
PE(24:1(15Z)/15:0) 0.17 1.00 0.29 -0.21 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.45 1.00 0.30 -0.17 
Prostaglandin F1a 0.31 1.00 0.30 0.69 
Succinic acid semialdehyde 0.01 1.00 0.31 -0.17 
3-O-Caffeoyl-4-O-methylquinic acid 0.06 1.00 0.31 -0.20 
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) 0.23 1.00 0.31 -0.19 
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) 0.57 1.00 0.31 -0.18 
Glucose 0.00 0.47 0.32 -0.11 
Oxolucidine B 0.00 0.02 0.32 -0.25 
Beta-1,4-D-
Mannosylchitobiosyldiphosphodolichol 
0.19 1.00 0.33 -0.17 
PE-NMe(18:1(9Z)/18:1(9Z)) 0.36 1.00 0.33 -0.21 
Artonin K 0.00 0.00 0.34 -0.11 
5-Ethoxy-4,5-dihydro-2(3H)furanone 0.00 0.65 0.34 -0.15 
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Didodecyl thiobispropanoate 0.38 1.00 0.35 -0.55 
Erucicoyl-EA 0.75 1.00 0.35 0.58 
PC(16:0/16:0) 0.57 1.00 0.35 -0.26 
Xanthine-8-carboxylate 0.10 1.00 0.36 -0.25 
N-(tetracosanoyl)-sphinganine-1-O-[myo-
inositol-1-phosphoryl-6-D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.56 1.00 0.37 0.14 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.48 1.00 0.37 -0.17 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.25 1.00 0.38 0.77 
Ganglioside GM3 (d18:0/20:0) 0.50 1.00 0.38 -0.10 
Epoxymurin B 0.77 1.00 0.39 -0.49 
carboxynorspermidine 0.59 1.00 0.39 0.27 
PE(15:0/22:0) 0.33 1.00 0.40 -0.16 
Glycerophosphoserine (55:0) 0.39 1.00 0.40 -0.17 
PS(37:2) 0.34 1.00 0.40 -0.28 
DG(43:5) 0.63 1.00 0.41 -0.18 
3S-hydroxyhexacosanoyl-CoA 0.56 1.00 0.41 -0.16 
Trihexosylceramide (d18:1/24:0) 0.84 1.00 0.42 0.12 
PS(21:0/0:0) 0.00 0.27 0.42 -0.27 
PE(P-18:1(9Z)/14:0) 0.32 1.00 0.44 0.11 
Creatine 0.72 1.00 0.44 -0.29 
L-Acetylcarnitine 0.01 1.00 0.44 -0.19 
PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.63 1.00 0.45 -0.14 
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)) 0.75 1.00 0.45 0.44 
Tartronate semialdehyde 0.37 1.00 0.45 0.40 
SM(d34:2) 0.65 1.00 0.45 -0.16 
Sedoheptulose 0.69 1.00 0.46 -0.16 
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) 0.88 1.00 0.46 -0.43 
LysoPE(20:0/0:0) 0.04 1.00 0.47 0.52 
Diphenylcarbazide 0.65 1.00 0.47 0.41 
PC(P-
18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
0.61 1.00 0.47 -0.18 
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z)) 0.14 1.00 0.47 -0.11 
PE-NMe(16:0/18:1(9Z)) 0.54 1.00 0.48 -0.39 
PC(14:1(9Z)/20:2(11Z,14Z)) 0.17 1.00 0.48 -0.15 
L-Cyclo(alanylglycyl) 0.77 1.00 0.49 -0.48 
PG(O-36:1) 0.26 1.00 0.49 -0.14 
CDP-Glycerophospholipid (38:6) 0.67 1.00 0.49 -0.18 
D-Sedoheptulose 7-phosphate 0.87 1.00 0.49 -0.17 
PS(41:4) 0.44 1.00 0.50 -0.16 
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)) 0.89 1.00 0.51 0.12 
Dehydrotomatine 0.73 1.00 0.51 -0.19 
Tin chloride (SnCl4) 0.64 1.00 0.52 -0.05 
PC(14:1(9Z)/22:2(13Z,16Z)) 0.28 1.00 0.52 -0.12 
PC(o-18:1(11Z)/18:2(9Z,12Z)) 0.62 1.00 0.53 -0.14 
Arginine 0.00 0.60 0.53 0.12 
Adenosine 0.11 1.00 0.54 0.20 
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6-Deoxodolichosterone 0.81 1.00 0.54 -0.22 
Niclosamide 0.41 1.00 0.55 -0.17 
LysoPC(20:4(8Z,11Z,14Z,17Z)) 0.02 1.00 0.55 -0.20 
1,2,4,8-Tetraacetoxy-7-hydroxy-3-(4-
hydroxyphenyl)dibenzofuran 
0.66 1.00 0.56 -0.36 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic 
acid 
0.04 1.00 0.56 -0.29 
Glycerophosphocholine (38:6) 0.71 1.00 0.56 -0.13 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.39 1.00 0.57 0.05 
5-Aminopentanoic acid 0.75 1.00 0.57 0.06 
Narciclasine 0.00 0.00 0.57 0.14 
Uric acid 0.93 1.00 0.58 -0.10 
PE-NMe2(18:1(9Z)/18:1(9Z)) 0.54 1.00 0.59 -0.11 
PE(22:1(13Z)/15:0) 0.45 1.00 0.59 -0.12 
[FA hydroxy(4:0)] 1,9S,11R,15S-tetrahydroxy-
13E-prostaene 
0.94 1.00 0.59 0.31 
2,3-Butanediol glucoside 0.63 1.00 0.60 -0.20 
Cer(d18:0/20:0) 0.84 1.00 0.60 0.18 
LysoPE(18:0/0:0) 0.20 1.00 0.60 -0.17 
Camelliagenin A 0.82 1.00 0.60 -0.28 
LysoPC(16:0) 0.00 0.38 0.60 -0.14 
FA amino(7:0) aminoheptanoic acid 0.00 0.22 0.61 -0.09 
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0.00 1.00 0.62 -0.14 
PC(18:1(9Z)/20:1(11Z)) 0.36 1.00 0.62 -0.13 
Propanoylagmatine 0.96 1.00 0.63 -0.06 
Lysyl-Tryptophan 0.85 1.00 0.64 -0.17 
hydroxymethyl-dCDP 0.04 1.00 0.65 0.08 
Lactic acid 0.12 1.00 0.65 0.28 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-
dimethyl-quinazolin-2-yl)- guanidine 
0.08 1.00 0.65 -0.09 
Deoxycytidine 0.26 1.00 0.65 0.77 
Glycerophosphocholine 0.05 1.00 0.66 -0.13 
1-Octen-3-yl glucoside 0.61 1.00 0.66 -0.23 
Di-2-propenyl hexasulfide 0.86 1.00 0.66 0.07 
PC(20:3(8Z,11Z,14Z)/20:1(11Z)) 0.88 1.00 0.66 0.19 
PE(20:2(11Z,14Z)/15:0) 0.36 1.00 0.67 -0.13 
N3-fumaramoyl-L-2,3-diaminopropanoate 0.13 1.00 0.67 0.45 
Leucyl-Proline 0.83 1.00 0.68 -0.13 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-
ynylidene)-1,6-dioxaspiro[4.4]non-3-ene 
0.00 0.94 0.68 -0.06 
Lenticin 1.00 1.00 0.68 -0.20 
Tetrahexosylceramide (d18:1/16:0) 0.54 1.00 0.69 0.12 
N-(2-hydroxyhexacosanoyl)-eicosasphinganine-
1-O-[D-mannopyranosyl-alpha1-2-myo-
inositol-1-phosphate] 
0.58 1.00 0.69 -0.05 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.78 1.00 0.69 -0.09 
Acetic acid 0.15 1.00 0.69 -0.06 
[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-eicosatetraenoate) 
0.75 1.00 0.70 0.07 
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Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.01 1.00 0.70 0.08 
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)) 0.70 1.00 0.70 0.09 
PG(16:0/16:0) 0.93 1.00 0.71 0.23 
Dimethylarginine 0.18 1.00 0.71 0.07 
Hordatine B glucoside 0.50 1.00 0.71 0.09 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.12 1.00 0.72 0.19 
PS(35:0) 0.47 1.00 0.72 -0.11 
Glyceric acid 0.07 1.00 0.73 -0.26 
PE(18:3(6Z,9Z,12Z)/22:0) 0.27 1.00 0.74 0.08 
PI(16:1(9Z)/18:1(11Z)) 0.40 1.00 0.74 0.09 
Glycerophosphocholine (52:4) 0.88 1.00 0.75 0.04 
Psidinin C 0.70 1.00 0.75 -0.17 
Methyl 3-hydroxybutyrate 0.97 1.00 0.75 0.12 
Gnidicin 0.14 1.00 0.75 0.30 
Isocitric acid 0.78 1.00 0.75 0.09 
6-Phosphonoglucono-D-lactone 0.03 1.00 0.76 0.20 
2,3-Dimethylbenzofuran 1.00 1.00 0.76 0.24 
Sorbitan stearate 0.86 1.00 0.76 -0.17 
cis-(homo)2aconitate 0.00 0.05 0.76 0.03 
Probenecid 0.71 1.00 0.76 -0.10 
Deoxyuridine triphosphate 0.08 1.00 0.76 0.29 
SM(d18:0/16:1(9Z)) 0.70 1.00 0.77 -0.06 
PC(22:2(13Z,16Z)/16:1(9Z)) 0.59 1.00 0.78 -0.07 
PE(P-18:1(9Z)/14:1(9Z)) 0.78 1.00 0.78 0.03 
5-(4-Acetoxy-1-butynyl)-2,2'-bithiophene 0.52 1.00 0.78 0.09 
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) 0.34 1.00 0.79 -0.09 
Pyruvic acid 0.05 1.00 0.80 -0.15 
Creatinine 0.92 1.00 0.80 -0.04 
(2alpha,3alpha,5alpha,22R,23R)-2,3,22,23-
Tetrahydroxy-25-methylergost-24(28)en-6-one 
0.06 1.00 0.81 -0.11 
PE-NMe(16:0/16:0) 0.81 1.00 0.82 0.08 
Pipecolic acid 0.98 1.00 0.82 0.13 
PG(42:6) 0.56 1.00 0.83 -0.05 
N-(2-hydroxytetracosanoyl)-4,8-sphingadienine 0.96 1.00 0.84 0.08 
Diisopropyl sulfide 0.56 1.00 0.84 0.07 
Lumequoylacetone 0.82 1.00 0.84 -0.13 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.71 1.00 0.84 0.02 
PE(18:3(6Z,9Z,12Z)/20:0) 0.30 1.00 0.86 0.07 
Prenol 30,32-dihydroxy-2b-methyl-
bishomohopane 
0.71 1.00 0.86 -0.10 
2-Hydroxyundecanoate 0.99 1.00 0.86 0.16 
PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) 0.92 1.00 0.86 -0.05 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.37 1.00 0.86 -0.02 
Pyrrolidine 0.14 1.00 0.86 -0.02 
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Cer(d18:1/24:1(15Z)) 0.90 1.00 0.86 -0.11 
1,6-Naphthalenedisulfonic acid 0.09 1.00 0.87 -0.06 
TG(41:0) 0.86 1.00 0.87 -0.04 
CDP-Glycerophospholipid (38:5) 0.12 1.00 0.87 -0.04 
Ganglioside GM3 (d18:1/24:1(15Z)) 0.13 1.00 0.88 0.04 
SM(d18:0/16:0) 0.99 1.00 0.88 0.07 
Luteolin 7,4'-diglucuronide-3'-glucoside 0.37 1.00 0.88 -0.07 
5,8-Dihydro-6-(4-methyl-3-pentenyl)-1,2,3,4-
tetrathiocin 
0.00 0.00 0.89 0.01 
4-Hydroxybutyric acid 0.40 1.00 0.89 -0.11 
PS(P-39:0) 0.25 1.00 0.89 -0.04 
7-methylthioheptanaldoxime 0.38 1.00 0.89 -0.11 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.86 1.00 0.90 0.03 
PI(18:2(9Z,12Z)/20:1(11Z)) 0.57 1.00 0.91 0.05 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z
)) 
0.89 1.00 0.91 -0.06 
UDP-N-acetylmuramoyl-L-Ala-D-gamma-Glu-
6-carboxy-L-Lys-D-Ala 
0.92 1.00 0.91 0.01 
PI (36:0) 0.74 1.00 0.91 -0.04 
Stenopalustroside A 0.48 1.00 0.91 -0.06 
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)) 0.81 1.00 0.91 -0.02 
6-Hydroxyluteolin 6-xyloside 0.44 1.00 0.91 0.05 
Triradylglycerol (61:8) 0.90 1.00 0.92 -0.01 
TG(15:0/20:0/20:0) 0.70 1.00 0.92 -0.02 
Piperidine 0.02 1.00 0.93 -0.01 
Phosphocreatine 0.72 1.00 0.93 -0.04 
5-Hexyltetrahydro-2-furanoctanoic acid 0.94 1.00 0.94 -0.02 
Proline betaine 1.00 1.00 0.94 0.06 
Iodixanol 0.51 1.00 0.94 0.01 
Triradylglycerol (65:6) 0.53 1.00 0.95 -0.01 
3'-O-Methyladenosine 0.36 1.00 0.95 0.01 
Kanzonol R 0.84 1.00 0.95 0.04 
5-(3-Buten-1-ynyl)-2,2'-bithienyl 0.87 1.00 0.96 0.01 
1-Pyrrolinium 0.99 1.00 0.96 0.03 
SM(d18:1/18:1(11Z)) 0.38 1.00 0.96 -0.02 
SM(d33:1) 0.72 1.00 0.96 -0.02 
beta-D-Glucosyl-1,4-N-acetyl-D-
glucosaminyldiphosphoundecaprenol 
0.95 1.00 0.97 0.00 
2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-
benzopyran-7-ol acetate 
0.84 1.00 0.98 0.00 
Imidazoleacetic acid riboside 0.02 1.00 0.99 0.00 
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Table A3 Metabolome changes in the control group at time point 2 hours (after the LPS 
administration) compared to the baseline of this study, - 50 minutes. 1-way ANOVA results 
in the global.p values, and t-tests are the local / pairwise comparisons (local p). 
Metabolite global.p global.p.adj Control 
120/Contro
l -50: 
local.p 
Control 
120/Contro
l -50: ratio 
Propionylcarnitine 0.12 1.00 0.02 -0.62 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)) 0.04 1.00 0.02 -0.78 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.03 1.00 0.83 0.02 
Phosphocreatinine 0.45 1.00 0.21 0.30 
L-Histidine 0.65 1.00 0.15 1.11 
Hymenocardine 0.34 1.00 0.48 0.22 
Chinomethionat 0.49 1.00 0.34 -0.44 
Glycerophosphoinositol (41:6) 0.17 1.00 0.06 -0.94 
N(6)-Trimethyl-L-lysine 0.01 1.00 0.10 -0.32 
5'-Dehydroadenosine 0.02 1.00 0.06 -0.21 
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.36 1.00 0.10 -0.58 
Moracin 0.12 1.00 0.03 -0.97 
N-desmethylclarithromycin 0.38 1.00 0.08 0.21 
Glutamine 0.01 1.00 0.94 -0.01 
CDP-Glycerophospholipid(40:6) 0.11 1.00 0.01 -0.45 
PC(P-18:0/15:0) 0.21 1.00 0.65 0.36 
[FA amino(8:0)] 3-amino-octanoic acid 0.00 0.38 0.07 -0.35 
PI(O-20:0/14:1(9Z)) 0.30 1.00 0.03 -0.60 
Urea 0.11 1.00 0.06 -0.28 
Triradylglycero (60:5) 0.23 1.00 0.47 0.21 
Prolyl-Gamma-glutamate 0.07 1.00 0.05 -0.27 
[PR trimethyl,methyl,methyl(5:0/15:0)] 2,6,14-
trimethyl-6,7-epoxy-10-methylene-9-(3-
methylpent-4-enyl)-pentadec-2-ene 
0.09 1.00 0.10 -0.91 
1-18:2-2-18:3-monogalactosyldiacylglycerol 0.41 1.00 0.40 -0.27 
N(alpha)-t-Butoxycarbonyl-L-leucine 0.24 1.00 0.16 -0.98 
Bruceoside A 0.01 1.00 0.04 -1.04 
Phosphatidyl glycerophosphate (O-42:2) 0.49 1.00 0.29 -0.28 
PS(41:2) 0.11 1.00 0.02 -0.66 
PC(O-16:0/18:2(9Z,12Z)) 0.10 1.00 0.04 -0.41 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.54 1.00 0.12 -0.26 
LysoPC(18:2(9Z,12Z)) 0.00 0.01 0.03 -0.58 
L-Carnitine 0.01 1.00 0.06 -0.19 
PC(o-18:0/20:4(8Z,11Z,14Z,17Z)) 0.35 1.00 0.15 -0.23 
Epimedin K 0.52 1.00 0.67 0.03 
Galactaric acid 0.32 1.00 0.44 -0.70 
Iodipamide 0.73 1.00 0.34 -0.55 
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.27 1.00 0.07 -0.61 
Ranunculin 0.00 0.12 0.05 -2.08 
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Spirolide B 0.60 1.00 0.40 -0.10 
CDP-Glycerophospholipid 
(18:1(9Z)/18:2(9Z,12Z)) 
0.32 1.00 0.05 -0.58 
PS(39:4) 0.75 1.00 0.39 -0.22 
3-Amino-1,2,4-triazole 0.52 1.00 0.76 0.13 
Di-2-thienyl disulfide 0.19 1.00 0.03 -0.57 
[6]-Gingerdiol 3,5-diacetate 0.74 1.00 0.69 -0.23 
PC(o-16:1(9Z)/18:2(9Z,12Z)) 0.24 1.00 0.10 -0.25 
Glycerophosphocholine (40:6) 0.15 1.00 0.03 -0.64 
PI(O-36:2) 0.25 1.00 0.05 -0.75 
CDP-Glycerophospholipid (38:4) 0.25 1.00 0.09 -0.46 
PC(18:1(9Z)/18:1(9Z)) 0.09 1.00 0.07 -0.38 
PE(24:1(15Z)/15:0) 0.17 1.00 0.09 -0.34 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.45 1.00 0.23 -0.17 
Prostaglandin F1a 0.31 1.00 0.09 1.02 
Succinic acid semialdehyde 0.01 1.00 0.62 -0.06 
3-O-Caffeoyl-4-O-methylquinic acid 0.06 1.00 0.45 -0.14 
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) 0.23 1.00 0.14 -0.22 
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) 0.57 1.00 0.62 -0.09 
Glucose 0.00 0.47 0.32 -0.11 
Oxolucidine B 0.00 0.02 0.03 -0.57 
Beta-1,4-D-
Mannosylchitobiosyldiphosphodolichol 
0.19 1.00 0.63 0.06 
PE-NMe(18:1(9Z)/18:1(9Z)) 0.36 1.00 0.04 -0.39 
Artonin K 0.00 0.00 0.20 -0.16 
5-Ethoxy-4,5-dihydro-2(3H)furanone 0.00 0.65 0.57 -0.08 
Didodecyl thiobispropanoate 0.38 1.00 0.47 -0.34 
Erucicoyl-EA 0.75 1.00 0.22 0.75 
PC(16:0/16:0) 0.57 1.00 0.19 -0.36 
Xanthine-8-carboxylate 0.10 1.00 0.02 -0.57 
N-(tetracosanoyl)-sphinganine-1-O-[myo-
inositol-1-phosphoryl-6-D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.56 1.00 0.08 0.20 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.48 1.00 0.23 -0.19 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.25 1.00 0.19 0.79 
Ganglioside GM3 (d18:0/20:0) 0.50 1.00 0.76 0.03 
Epoxymurin B 0.77 1.00 0.08 -0.92 
carboxynorspermidine 0.59 1.00 0.87 -0.05 
PE(15:0/22:0) 0.33 1.00 0.22 -0.22 
Glycerophosphoserine (55:0) 0.39 1.00 0.04 -0.37 
PS(37:2) 0.34 1.00 0.05 -0.64 
DG(43:5) 0.63 1.00 0.08 -0.35 
3S-hydroxyhexacosanoyl-CoA 0.56 1.00 0.11 -0.29 
Trihexosylceramide (d18:1/24:0) 0.84 1.00 0.75 0.04 
PS(21:0/0:0) 0.00 0.27 0.13 -0.57 
PE(P-18:1(9Z)/14:0) 0.32 1.00 0.59 0.06 
Creatine 0.72 1.00 0.41 -0.31 
L-Acetylcarnitine 0.01 1.00 0.13 -0.40 
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PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.63 1.00 0.29 -0.17 
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)) 0.75 1.00 0.26 0.50 
Tartronate semialdehyde 0.37 1.00 0.52 -0.33 
SM(d34:2) 0.65 1.00 0.25 -0.23 
Sedoheptulose 0.69 1.00 0.53 -0.13 
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) 0.88 1.00 0.42 -0.47 
LysoPE(20:0/0:0) 0.04 1.00 0.49 0.36 
Diphenylcarbazide 0.65 1.00 0.86 -0.11 
PC(P-
18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
0.61 1.00 0.11 -0.35 
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z)) 0.14 1.00 0.34 -0.15 
PE-NMe(16:0/18:1(9Z)) 0.54 1.00 0.78 -0.16 
PC(14:1(9Z)/20:2(11Z,14Z)) 0.17 1.00 0.33 -0.19 
L-Cyclo(alanylglycyl) 0.77 1.00 0.41 -0.59 
PG(O-36:1) 0.26 1.00 0.24 -0.23 
CDP-Glycerophospholipid (38:6) 0.67 1.00 0.23 -0.27 
D-Sedoheptulose 7-phosphate 0.87 1.00 0.31 -0.23 
PS(41:4) 0.44 1.00 0.09 -0.38 
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)
) 
0.89 1.00 0.35 0.10 
Dehydrotomatine 0.73 1.00 0.18 -0.36 
Tin chloride (SnCl4) 0.64 1.00 0.63 0.04 
PC(14:1(9Z)/22:2(13Z,16Z)) 0.28 1.00 0.23 -0.20 
PC(o-18:1(11Z)/18:2(9Z,12Z)) 0.62 1.00 0.43 -0.17 
Arginine 0.00 0.60 0.45 -0.15 
Adenosine 0.11 1.00 0.85 -0.05 
6-Deoxodolichosterone 0.81 1.00 0.16 -0.42 
Niclosamide 0.41 1.00 0.29 -0.28 
LysoPC(20:4(8Z,11Z,14Z,17Z)) 0.02 1.00 0.11 -0.47 
1,2,4,8-Tetraacetoxy-7-hydroxy-3-(4-
hydroxyphenyl)dibenzofuran 
0.66 1.00 0.14 -0.84 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic 
acid 
0.04 1.00 0.46 -0.34 
Glycerophosphocholine (38:6) 0.71 1.00 0.18 -0.31 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.39 1.00 0.90 0.01 
5-Aminopentanoic acid 0.75 1.00 0.46 0.09 
Narciclasine 0.00 0.00 0.02 -0.56 
Uric acid 0.93 1.00 0.38 -0.11 
PE-NMe2(18:1(9Z)/18:1(9Z)) 0.54 1.00 0.36 -0.18 
PE(22:1(13Z)/15:0) 0.45 1.00 0.32 -0.20 
[FA hydroxy(4:0)] 1,9S,11R,15S-tetrahydroxy-
13E-prostaene 
0.94 1.00 1.00 0.00 
2,3-Butanediol glucoside 0.63 1.00 0.35 -0.33 
Cer(d18:0/20:0) 0.84 1.00 0.71 -0.11 
LysoPE(18:0/0:0) 0.20 1.00 0.21 -0.36 
Camelliagenin A 0.82 1.00 0.31 -0.52 
LysoPC(16:0) 0.00 0.38 0.11 -0.38 
FA amino(7:0) aminoheptanoic acid 0.00 0.22 0.08 -0.34 
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LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0.00 1.00 0.08 -0.61 
PC(18:1(9Z)/20:1(11Z)) 0.36 1.00 0.17 -0.35 
Propanoylagmatine 0.96 1.00 0.84 0.03 
Lysyl-Tryptophan 0.85 1.00 0.70 -0.13 
hydroxymethyl-dCDP 0.04 1.00 0.84 -0.03 
Lactic acid 0.12 1.00 0.39 0.30 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-
dimethyl-quinazolin-2-yl)- guanidine 
0.08 1.00 0.97 -0.01 
Deoxycytidine 0.26 1.00 0.68 0.48 
Glycerophosphocholine 0.05 1.00 0.17 -0.36 
1-Octen-3-yl glucoside 0.61 1.00 0.26 -0.55 
Di-2-propenyl hexasulfide 0.86 1.00 0.07 0.16 
PC(20:3(8Z,11Z,14Z)/20:1(11Z)) 0.88 1.00 0.74 -0.12 
PE(20:2(11Z,14Z)/15:0) 0.36 1.00 0.48 -0.21 
N3-fumaramoyl-L-2,3-diaminopropanoate 0.13 1.00 0.43 0.49 
Leucyl-Proline 0.83 1.00 0.27 -0.36 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-
ynylidene)-1,6-dioxaspiro[4.4]non-3-ene 
0.00 0.94 0.59 -0.08 
Lenticin 1.00 1.00 0.64 -0.21 
Tetrahexosylceramide (d18:1/16:0) 0.54 1.00 0.43 -0.17 
N-(2-hydroxyhexacosanoyl)-
eicosasphinganine-1-O-[D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.58 1.00 0.60 0.08 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.78 1.00 0.62 -0.10 
Acetic acid 0.15 1.00 0.41 -0.13 
[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-
eicosatetraenoate) 
0.75 1.00 0.81 -0.04 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.01 1.00 0.12 -0.25 
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)) 0.70 1.00 0.60 -0.10 
PG(16:0/16:0) 0.93 1.00 0.63 0.27 
Dimethylarginine 0.18 1.00 0.35 -0.18 
Hordatine B glucoside 0.50 1.00 0.40 0.15 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.12 1.00 0.44 0.24 
PS(35:0) 0.47 1.00 0.07 -0.51 
Glyceric acid 0.07 1.00 0.27 -1.02 
PE(18:3(6Z,9Z,12Z)/22:0) 0.27 1.00 0.31 -0.26 
PI(16:1(9Z)/18:1(11Z)) 0.40 1.00 0.86 -0.05 
Glycerophosphocholine (52:4) 0.88 1.00 0.52 0.07 
Psidinin C 0.70 1.00 0.51 -0.34 
Methyl 3-hydroxybutyrate 0.97 1.00 0.88 -0.04 
Gnidicin 0.14 1.00 0.41 0.59 
Isocitric acid 0.78 1.00 0.44 -0.23 
6-Phosphonoglucono-D-lactone 0.03 1.00 0.22 0.52 
2,3-Dimethylbenzofuran 1.00 1.00 1.00 0.00 
Sorbitan stearate 0.86 1.00 0.22 -0.61 
cis-(homo)2aconitate 0.00 0.05 0.72 -0.03 
Probenecid 0.71 1.00 0.20 -0.36 
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Deoxyuridine triphosphate 0.08 1.00 0.59 0.39 
SM(d18:0/16:1(9Z)) 0.70 1.00 0.27 -0.17 
PC(22:2(13Z,16Z)/16:1(9Z)) 0.59 1.00 0.42 -0.23 
PE(P-18:1(9Z)/14:1(9Z)) 0.78 1.00 0.74 0.04 
5-(4-Acetoxy-1-butynyl)-2,2'-bithiophene 0.52 1.00 0.66 -0.11 
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) 0.34 1.00 0.16 -0.46 
Pyruvic acid 0.05 1.00 0.87 -0.07 
Creatinine 0.92 1.00 0.53 -0.09 
(2alpha,3alpha,5alpha,22R,23R)-2,3,22,23-
Tetrahydroxy-25-methylergost-24(28)en-6-one 
0.06 1.00 0.24 -0.40 
PE-NMe(16:0/16:0) 0.81 1.00 1.00 0.00 
Pipecolic acid 0.98 1.00 0.89 0.08 
PG(42:6) 0.56 1.00 0.33 -0.19 
N-(2-hydroxytetracosanoyl)-4,8-
sphingadienine 
0.96 1.00 0.77 -0.11 
Diisopropyl sulfide 0.56 1.00 0.46 -0.28 
Lumequoylacetone 0.82 1.00 0.49 -0.37 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.71 1.00 0.51 0.05 
PE(18:3(6Z,9Z,12Z)/20:0) 0.30 1.00 0.16 -0.47 
Prenol 30,32-dihydroxy-2b-methyl-
bishomohopane 
0.71 1.00 0.15 -0.86 
2-Hydroxyundecanoate 0.99 1.00 0.74 -0.32 
PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) 0.92 1.00 0.74 -0.07 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.37 1.00 0.13 -0.17 
Pyrrolidine 0.14 1.00 0.31 -0.12 
Cer(d18:1/24:1(15Z)) 0.90 1.00 0.80 0.15 
1,6-Naphthalenedisulfonic acid 0.09 1.00 0.42 0.20 
TG(41:0) 0.86 1.00 0.38 -0.17 
CDP-Glycerophospholipid (38:5) 0.12 1.00 0.03 -0.59 
Ganglioside GM3 (d18:1/24:1(15Z)) 0.13 1.00 0.31 -0.22 
SM(d18:0/16:0) 0.99 1.00 0.91 -0.06 
Luteolin 7,4'-diglucuronide-3'-glucoside 0.37 1.00 0.18 -0.88 
5,8-Dihydro-6-(4-methyl-3-pentenyl)-1,2,3,4-
tetrathiocin 
0.00 0.00 0.92 -0.01 
4-Hydroxybutyric acid 0.40 1.00 0.85 -0.16 
PS(P-39:0) 0.25 1.00 0.20 -0.29 
7-methylthioheptanaldoxime 0.38 1.00 0.88 -0.13 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.86 1.00 0.66 -0.09 
PI(18:2(9Z,12Z)/20:1(11Z)) 0.57 1.00 0.48 -0.27 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17
Z)) 
0.89 1.00 0.44 0.35 
UDP-N-acetylmuramoyl-L-Ala-D-gamma-
Glu-6-carboxy-L-Lys-D-Ala 
0.92 1.00 0.96 0.00 
PI (36:0) 0.74 1.00 0.30 -0.38 
Stenopalustroside A 0.48 1.00 0.16 -0.80 
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)) 0.81 1.00 0.70 -0.07 
6-Hydroxyluteolin 6-xyloside 0.44 1.00 0.29 -0.50 
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Triradylglycerol (61:8) 0.90 1.00 0.61 -0.06 
TG(15:0/20:0/20:0) 0.70 1.00 0.32 0.15 
Piperidine 0.02 1.00 0.34 -0.11 
Phosphocreatine 0.72 1.00 0.23 -0.51 
5-Hexyltetrahydro-2-furanoctanoic acid 0.94 1.00 0.51 -0.19 
Proline betaine 1.00 1.00 0.83 -0.16 
Iodixanol 0.51 1.00 0.51 -0.10 
Triradylglycerol (65:6) 0.53 1.00 0.52 -0.06 
3'-O-Methyladenosine 0.36 1.00 0.13 -0.23 
Kanzonol R 0.84 1.00 0.17 -0.95 
5-(3-Buten-1-ynyl)-2,2'-bithienyl 0.87 1.00 0.37 0.11 
1-Pyrrolinium 0.99 1.00 0.64 -0.23 
SM(d18:1/18:1(11Z)) 0.38 1.00 0.23 -0.38 
SM(d33:1) 0.72 1.00 0.49 -0.22 
beta-D-Glucosyl-1,4-N-acetyl-D-
glucosaminyldiphosphoundecaprenol 
0.95 1.00 0.59 0.04 
2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-
benzopyran-7-ol acetate 
0.84 1.00 0.62 -0.07 
Imidazoleacetic acid riboside 0.02 1.00 0.84 -0.02 
 
 
Table A 4 Metabolome changes in the control group at time point 4 hours (after the LPS 
administration) compared to the baseline of this study, - 50 minutes. 1-way ANOVA results 
in the global p values, and t-tests are the local / pairwise comparisons (local p). 
Metabolite global.
p 
global.p.ad
j 
Control 
240/Control 
-50: local.p 
Control 
240/Contr
ol -50: 
ratio 
Propionylcarnitine 0.12 1.00 0.06 -0.54 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)) 0.04 1.00 0.01 -0.70 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.03 1.00 0.80 -0.02 
Phosphocreatinine 0.45 1.00 0.63 0.13 
L-Histidine 0.65 1.00 0.52 0.46 
Hymenocardine 0.34 1.00 0.08 0.46 
Chinomethionat 0.49 1.00 0.22 -0.55 
Glycerophosphoinositol (41:6) 0.17 1.00 0.08 -0.93 
N(6)-Trimethyl-L-lysine 0.01 1.00 0.10 -0.32 
5'-Dehydroadenosine 0.02 1.00 0.13 0.29 
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.36 1.00 0.18 -0.42 
Moracin 0.12 1.00 0.03 -0.82 
N-desmethylclarithromycin 0.38 1.00 0.38 0.10 
Glutamine 0.01 1.00 0.00 -0.47 
CDP-Glycerophospholipid(40:6) 0.11 1.00 0.17 -0.27 
PC(P-18:0/15:0) 0.21 1.00 0.09 1.13 
[FA amino(8:0)] 3-amino-octanoic acid 0.00 0.38 0.01 -0.61 
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PI(O-20:0/14:1(9Z)) 0.30 1.00 0.45 -0.23 
Urea 0.11 1.00 0.06 -0.29 
Triradylglycero (60:5) 0.23 1.00 0.68 0.11 
Prolyl-Gamma-glutamate 0.07 1.00 0.39 0.17 
[PR trimethyl,methyl,methyl(5:0/15:0)] 
2,6,14-trimethyl-6,7-epoxy-10-methylene-9-
(3-methylpent-4-enyl)-pentadec-2-ene 
0.09 1.00 0.77 -0.10 
1-18:2-2-18:3-monogalactosyldiacylglycerol 0.41 1.00 0.07 -0.69 
N(alpha)-t-Butoxycarbonyl-L-leucine 0.24 1.00 0.19 -0.91 
Bruceoside A 0.01 1.00 0.00 -1.92 
Phosphatidyl glycerophosphate (O-42:2) 0.49 1.00 0.04 -0.57 
PS(41:2) 0.11 1.00 0.41 -0.26 
PC(O-16:0/18:2(9Z,12Z)) 0.10 1.00 0.03 -0.38 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.54 1.00 0.15 -0.22 
LysoPC(18:2(9Z,12Z)) 0.00 0.01 0.00 -1.15 
L-Carnitine 0.01 1.00 0.00 -0.42 
PC(o-18:0/20:4(8Z,11Z,14Z,17Z)) 0.35 1.00 0.03 -0.29 
Epimedin K 0.52 1.00 0.21 0.10 
Galactaric acid 0.32 1.00 0.13 -1.79 
Iodipamide 0.73 1.00 0.81 -0.16 
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.27 1.00 0.77 -0.10 
Ranunculin 0.00 0.12 0.47 -0.62 
Spirolide B 0.60 1.00 0.86 -0.02 
CDP-Glycerophospholipid 
(18:1(9Z)/18:2(9Z,12Z)) 
0.32 1.00 0.54 -0.19 
PS(39:4) 0.75 1.00 0.51 -0.17 
3-Amino-1,2,4-triazole 0.52 1.00 0.68 -0.17 
Di-2-thienyl disulfide 0.19 1.00 0.11 -0.40 
[6]-Gingerdiol 3,5-diacetate 0.74 1.00 0.94 -0.04 
PC(o-16:1(9Z)/18:2(9Z,12Z)) 0.24 1.00 0.06 -0.30 
Glycerophosphocholine (40:6) 0.15 1.00 0.57 -0.20 
PI(O-36:2) 0.25 1.00 0.36 -0.34 
CDP-Glycerophospholipid (38:4) 0.25 1.00 0.48 -0.23 
PC(18:1(9Z)/18:1(9Z)) 0.09 1.00 0.03 -0.41 
PE(24:1(15Z)/15:0) 0.17 1.00 0.03 -0.39 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.45 1.00 0.07 -0.23 
Prostaglandin F1a 0.31 1.00 0.22 0.83 
Succinic acid semialdehyde 0.01 1.00 0.00 -0.62 
3-O-Caffeoyl-4-O-methylquinic acid 0.06 1.00 0.08 0.46 
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) 0.23 1.00 0.04 -0.30 
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) 0.57 1.00 0.17 -0.20 
Glucose 0.00 0.47 0.02 0.36 
Oxolucidine B 0.00 0.02 0.00 -1.04 
Beta-1,4-D-
Mannosylchitobiosyldiphosphodolichol 
0.19 1.00 0.30 0.12 
PE-NMe(18:1(9Z)/18:1(9Z)) 0.36 1.00 0.58 -0.15 
Artonin K 0.00 0.00 0.01 0.53 
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5-Ethoxy-4,5-dihydro-2(3H)furanone 0.00 0.65 0.42 0.10 
Didodecyl thiobispropanoate 0.38 1.00 0.13 -0.84 
Erucicoyl-EA 0.75 1.00 0.98 -0.01 
PC(16:0/16:0) 0.57 1.00 0.07 -0.42 
Xanthine-8-carboxylate 0.10 1.00 0.17 -0.38 
N-(tetracosanoyl)-sphinganine-1-O-[myo-
inositol-1-phosphoryl-6-D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.56 1.00 0.91 0.01 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.48 1.00 0.10 -0.25 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.25 1.00 0.02 1.41 
Ganglioside GM3 (d18:0/20:0) 0.50 1.00 0.81 -0.02 
Epoxymurin B 0.77 1.00 0.73 -0.22 
carboxynorspermidine 0.59 1.00 0.65 -0.15 
PE(15:0/22:0) 0.33 1.00 0.10 -0.25 
Glycerophosphoserine (55:0) 0.39 1.00 0.35 -0.14 
PS(37:2) 0.34 1.00 0.59 -0.23 
DG(43:5) 0.63 1.00 0.78 -0.08 
3S-hydroxyhexacosanoyl-CoA 0.56 1.00 0.43 -0.14 
Trihexosylceramide (d18:1/24:0) 0.84 1.00 0.18 0.16 
PS(21:0/0:0) 0.00 0.27 0.01 -1.43 
PE(P-18:1(9Z)/14:0) 0.32 1.00 0.17 -0.20 
Creatine 0.72 1.00 0.85 0.06 
L-Acetylcarnitine 0.01 1.00 0.01 -0.73 
PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.63 1.00 0.13 -0.22 
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)) 0.75 1.00 0.24 0.50 
Tartronate semialdehyde 0.37 1.00 0.40 -0.45 
SM(d34:2) 0.65 1.00 0.13 -0.25 
Sedoheptulose 0.69 1.00 0.08 -0.30 
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) 0.88 1.00 0.88 -0.09 
LysoPE(20:0/0:0) 0.04 1.00 0.05 -1.51 
Diphenylcarbazide 0.65 1.00 0.91 0.07 
PC(P-
18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
0.61 1.00 0.93 -0.03 
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z)) 0.14 1.00 0.05 -0.30 
PE-NMe(16:0/18:1(9Z)) 0.54 1.00 0.28 -0.63 
PC(14:1(9Z)/20:2(11Z,14Z)) 0.17 1.00 0.11 -0.31 
L-Cyclo(alanylglycyl) 0.77 1.00 0.37 -0.65 
PG(O-36:1) 0.26 1.00 0.07 -0.30 
CDP-Glycerophospholipid (38:6) 0.67 1.00 0.83 -0.05 
D-Sedoheptulose 7-phosphate 0.87 1.00 0.47 -0.16 
PS(41:4) 0.44 1.00 0.76 -0.08 
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z
)) 
0.89 1.00 0.57 0.07 
Dehydrotomatine 0.73 1.00 0.65 -0.12 
Tin chloride (SnCl4) 0.64 1.00 0.48 -0.05 
PC(14:1(9Z)/22:2(13Z,16Z)) 0.28 1.00 0.03 -0.33 
PC(o-18:1(11Z)/18:2(9Z,12Z)) 0.62 1.00 0.25 -0.27 
Arginine 0.00 0.60 0.02 -0.48 
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Adenosine 0.11 1.00 0.45 0.23 
6-Deoxodolichosterone 0.81 1.00 0.42 -0.25 
Niclosamide 0.41 1.00 0.14 -0.45 
LysoPC(20:4(8Z,11Z,14Z,17Z)) 0.02 1.00 0.00 -1.20 
1,2,4,8-Tetraacetoxy-7-hydroxy-3-(4-
hydroxyphenyl)dibenzofuran 
0.66 1.00 0.99 0.01 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic 
acid 
0.04 1.00 0.16 0.78 
Glycerophosphocholine (38:6) 0.71 1.00 0.69 -0.10 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.39 1.00 0.14 0.11 
5-Aminopentanoic acid 0.75 1.00 0.70 0.05 
Narciclasine 0.00 0.00 0.00 -0.90 
Uric acid 0.93 1.00 0.74 -0.04 
PE-NMe2(18:1(9Z)/18:1(9Z)) 0.54 1.00 0.09 -0.27 
PE(22:1(13Z)/15:0) 0.45 1.00 0.22 -0.21 
[FA hydroxy(4:0)] 1,9S,11R,15S-
tetrahydroxy-13E-prostaene 
0.94 1.00 0.76 0.21 
2,3-Butanediol glucoside 0.63 1.00 0.56 -0.20 
Cer(d18:0/20:0) 0.84 1.00 0.91 -0.03 
LysoPE(18:0/0:0) 0.20 1.00 0.05 -0.52 
Camelliagenin A 0.82 1.00 0.26 -0.82 
LysoPC(16:0) 0.00 0.38 0.00 -0.76 
FA amino(7:0) aminoheptanoic acid 0.00 0.22 0.00 -0.71 
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0.00 1.00 0.04 -0.71 
PC(18:1(9Z)/20:1(11Z)) 0.36 1.00 0.06 -0.43 
Propanoylagmatine 0.96 1.00 0.87 0.02 
Lysyl-Tryptophan 0.85 1.00 0.95 0.02 
hydroxymethyl-dCDP 0.04 1.00 0.00 -0.53 
Lactic acid 0.12 1.00 0.05 1.00 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-
dimethyl-quinazolin-2-yl)- guanidine 
0.08 1.00 0.04 0.54 
Deoxycytidine 0.26 1.00 0.12 2.04 
Glycerophosphocholine 0.05 1.00 0.02 -0.68 
1-Octen-3-yl glucoside 0.61 1.00 0.39 -0.47 
Di-2-propenyl hexasulfide 0.86 1.00 0.21 0.10 
PC(20:3(8Z,11Z,14Z)/20:1(11Z)) 0.88 1.00 0.66 -0.14 
PE(20:2(11Z,14Z)/15:0) 0.36 1.00 0.13 -0.46 
N3-fumaramoyl-L-2,3-diaminopropanoate 0.13 1.00 0.07 1.46 
Leucyl-Proline 0.83 1.00 0.35 -0.30 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-
ynylidene)-1,6-dioxaspiro[4.4]non-3-ene 
0.00 0.94 0.05 0.45 
Lenticin 1.00 1.00 0.71 -0.17 
Tetrahexosylceramide (d18:1/16:0) 0.54 1.00 0.14 -0.31 
N-(2-hydroxyhexacosanoyl)-
eicosasphinganine-1-O-[D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.58 1.00 0.66 0.06 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.78 1.00 0.22 -0.20 
Acetic acid 0.15 1.00 0.13 0.30 
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[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-
eicosatetraenoate) 
0.75 1.00 0.22 -0.17 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.01 1.00 0.04 0.39 
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)) 0.70 1.00 0.28 -0.17 
PG(16:0/16:0) 0.93 1.00 0.83 0.14 
Dimethylarginine 0.18 1.00 0.11 -0.28 
Hordatine B glucoside 0.50 1.00 0.94 -0.01 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.12 1.00 0.08 0.81 
PS(35:0) 0.47 1.00 0.64 -0.15 
Glyceric acid 0.07 1.00 0.02 1.29 
PE(18:3(6Z,9Z,12Z)/22:0) 0.27 1.00 0.08 -0.45 
PI(16:1(9Z)/18:1(11Z)) 0.40 1.00 0.43 0.25 
Glycerophosphocholine (52:4) 0.88 1.00 0.39 0.09 
Psidinin C 0.70 1.00 0.52 -0.33 
Methyl 3-hydroxybutyrate 0.97 1.00 0.81 0.07 
Gnidicin 0.14 1.00 0.06 1.38 
Isocitric acid 0.78 1.00 0.64 -0.14 
6-Phosphonoglucono-D-lactone 0.03 1.00 0.02 1.09 
2,3-Dimethylbenzofuran 1.00 1.00 0.95 -0.05 
Sorbitan stearate 0.86 1.00 0.58 -0.34 
cis-(homo)2aconitate 0.00 0.05 0.01 0.31 
Probenecid 0.71 1.00 0.49 -0.17 
Deoxyuridine triphosphate 0.08 1.00 0.06 1.62 
SM(d18:0/16:1(9Z)) 0.70 1.00 0.08 -0.23 
PC(22:2(13Z,16Z)/16:1(9Z)) 0.59 1.00 0.24 -0.30 
PE(P-18:1(9Z)/14:1(9Z)) 0.78 1.00 0.44 -0.09 
5-(4-Acetoxy-1-butynyl)-2,2'-bithiophene 0.52 1.00 0.11 -0.49 
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) 0.34 1.00 0.72 -0.13 
Pyruvic acid 0.05 1.00 0.12 0.89 
Creatinine 0.92 1.00 0.51 -0.09 
(2alpha,3alpha,5alpha,22R,23R)-2,3,22,23-
Tetrahydroxy-25-methylergost-24(28)en-6-
one 
0.06 1.00 0.01 -1.03 
PE-NMe(16:0/16:0) 0.81 1.00 0.29 -0.37 
Pipecolic acid 0.98 1.00 0.95 -0.03 
PG(42:6) 0.56 1.00 0.91 0.03 
N-(2-hydroxytetracosanoyl)-4,8-
sphingadienine 
0.96 1.00 0.69 0.14 
Diisopropyl sulfide 0.56 1.00 0.27 -0.46 
Lumequoylacetone 0.82 1.00 0.81 0.18 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.71 1.00 0.59 -0.05 
PE(18:3(6Z,9Z,12Z)/20:0) 0.30 1.00 0.43 -0.22 
Prenol 30,32-dihydroxy-2b-methyl-
bishomohopane 
0.71 1.00 0.83 -0.13 
2-Hydroxyundecanoate 0.99 1.00 0.77 -0.26 
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PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) 0.92 1.00 0.59 -0.09 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.37 1.00 0.37 0.12 
Pyrrolidine 0.14 1.00 0.70 -0.06 
Cer(d18:1/24:1(15Z)) 0.90 1.00 0.53 -0.33 
1,6-Naphthalenedisulfonic acid 0.09 1.00 0.07 0.52 
TG(41:0) 0.86 1.00 0.19 -0.23 
CDP-Glycerophospholipid (38:5) 0.12 1.00 0.74 -0.09 
Ganglioside GM3 (d18:1/24:1(15Z)) 0.13 1.00 0.70 -0.08 
SM(d18:0/16:0) 0.99 1.00 0.76 0.12 
Luteolin 7,4'-diglucuronide-3'-glucoside 0.37 1.00 0.86 -0.11 
5,8-Dihydro-6-(4-methyl-3-pentenyl)-1,2,3,4-
tetrathiocin 
0.00 0.00 0.00 0.31 
4-Hydroxybutyric acid 0.40 1.00 0.20 1.12 
PS(P-39:0) 0.25 1.00 0.14 -0.31 
7-methylthioheptanaldoxime 0.38 1.00 0.34 -0.81 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.86 1.00 0.27 -0.19 
PI(18:2(9Z,12Z)/20:1(11Z)) 0.57 1.00 0.85 -0.08 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17
Z)) 
0.89 1.00 0.63 0.21 
UDP-N-acetylmuramoyl-L-Ala-D-gamma-
Glu-6-carboxy-L-Lys-D-Ala 
0.92 1.00 0.73 0.03 
PI (36:0) 0.74 1.00 1.00 0.00 
Stenopalustroside A 0.48 1.00 0.70 -0.23 
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)) 0.81 1.00 0.28 -0.16 
6-Hydroxyluteolin 6-xyloside 0.44 1.00 0.47 -0.36 
Triradylglycerol (61:8) 0.90 1.00 0.49 0.09 
TG(15:0/20:0/20:0) 0.70 1.00 0.76 0.04 
Piperidine 0.02 1.00 0.65 0.07 
Phosphocreatine 0.72 1.00 0.49 -0.23 
5-Hexyltetrahydro-2-furanoctanoic acid 0.94 1.00 0.78 -0.09 
Proline betaine 1.00 1.00 0.74 -0.24 
Iodixanol 0.51 1.00 0.60 -0.07 
Triradylglycerol (65:6) 0.53 1.00 0.28 0.11 
3'-O-Methyladenosine 0.36 1.00 0.70 -0.05 
Kanzonol R 0.84 1.00 0.92 -0.07 
5-(3-Buten-1-ynyl)-2,2'-bithienyl 0.87 1.00 0.98 0.00 
1-Pyrrolinium 0.99 1.00 0.66 -0.21 
SM(d18:1/18:1(11Z)) 0.38 1.00 0.24 -0.35 
SM(d33:1) 0.72 1.00 0.11 -0.41 
beta-D-Glucosyl-1,4-N-acetyl-D-
glucosaminyldiphosphoundecaprenol 
0.95 1.00 0.71 0.03 
2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-
benzopyran-7-ol acetate 
0.84 1.00 0.22 -0.21 
Imidazoleacetic acid riboside 0.02 1.00 0.01 0.40 
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Table A 5 Metabolome changes in the control group at time point 8 hours (after the LPS 
administration) compared to the baseline of this study, - 50 minutes. 1-way ANOVA results 
in the global.p values, and t-tests are the local / pairwise comparisons (local p). 
Metabolite global.
p 
global.p.ad
j 
Control 
480/Contro
l -50: 
local.p 
Control 
480/Contr
ol -50: 
ratio 
Propionylcarnitine 0.12 1.00 0.13 -0.52 
PC(14:1(9Z)/22:4(7Z,10Z,13Z,16Z)) 0.04 1.00 0.01 -0.84 
Kaempferol 3-rhamnosyl-(1->2)-[glucosyl-(1-
>3)-(4'''-p-coumaroylrhamnosyl)-(1->6)-
galactoside] 
0.03 1.00 0.15 0.13 
Phosphocreatinine 0.45 1.00 0.46 0.17 
L-Histidine 0.65 1.00 0.22 1.05 
Hymenocardine 0.34 1.00 0.87 0.05 
Chinomethionat 0.49 1.00 0.21 -0.58 
Glycerophosphoinositol (41:6) 0.17 1.00 0.03 -1.19 
N(6)-Trimethyl-L-lysine 0.01 1.00 0.02 -0.54 
5'-Dehydroadenosine 0.02 1.00 0.50 0.11 
PE(P-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.36 1.00 0.04 -0.72 
Moracin 0.12 1.00 0.03 -0.76 
N-desmethylclarithromycin 0.38 1.00 0.53 0.07 
Glutamine 0.01 1.00 0.73 -0.05 
CDP-Glycerophospholipid(40:6) 0.11 1.00 0.00 -0.60 
PC(P-18:0/15:0) 0.21 1.00 0.45 0.58 
[FA amino(8:0)] 3-amino-octanoic acid 0.00 0.38 0.00 -0.63 
PI(O-20:0/14:1(9Z)) 0.30 1.00 0.04 -0.50 
Urea 0.11 1.00 0.04 -0.31 
Triradylglycero (60:5) 0.23 1.00 0.51 0.20 
Prolyl-Gamma-glutamate 0.07 1.00 0.80 0.04 
[PR trimethyl,methyl,methyl(5:0/15:0)] 2,6,14-
trimethyl-6,7-epoxy-10-methylene-9-(3-
methylpent-4-enyl)-pentadec-2-ene 
0.09 1.00 0.83 0.09 
1-18:2-2-18:3-monogalactosyldiacylglycerol 0.41 1.00 0.09 -0.53 
N(alpha)-t-Butoxycarbonyl-L-leucine 0.24 1.00 0.17 -0.93 
Bruceoside A 0.01 1.00 0.01 -1.63 
Phosphatidyl glycerophosphate (O-42:2) 0.49 1.00 0.10 -0.45 
PS(41:2) 0.11 1.00 0.01 -0.71 
PC(O-16:0/18:2(9Z,12Z)) 0.10 1.00 0.01 -0.50 
N-(2-hydroxy-tetracosanoyl)-1-beta-glucosyl-
4E,6E-hexadecasphingadienine 
0.54 1.00 0.09 -0.25 
LysoPC(18:2(9Z,12Z)) 0.00 0.01 0.00 -1.05 
L-Carnitine 0.01 1.00 0.02 -0.23 
PC(o-18:0/20:4(8Z,11Z,14Z,17Z)) 0.35 1.00 0.02 -0.34 
Epimedin K 0.52 1.00 0.76 0.03 
Galactaric acid 0.32 1.00 0.28 -1.06 
Iodipamide 0.73 1.00 0.13 -0.88 
PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) 0.27 1.00 0.05 -0.62 
Ranunculin 0.00 0.12 0.07 1.30 
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Spirolide B 0.60 1.00 0.46 -0.09 
CDP-Glycerophospholipid 
(18:1(9Z)/18:2(9Z,12Z)) 
0.32 1.00 0.04 -0.59 
PS(39:4) 0.75 1.00 0.03 -0.46 
3-Amino-1,2,4-triazole 0.52 1.00 0.96 0.02 
Di-2-thienyl disulfide 0.19 1.00 0.09 -0.38 
[6]-Gingerdiol 3,5-diacetate 0.74 1.00 0.76 0.17 
PC(o-16:1(9Z)/18:2(9Z,12Z)) 0.24 1.00 0.01 -0.42 
Glycerophosphocholine (40:6) 0.15 1.00 0.01 -0.79 
PI(O-36:2) 0.25 1.00 0.02 -0.84 
CDP-Glycerophospholipid (38:4) 0.25 1.00 0.01 -0.68 
PC(18:1(9Z)/18:1(9Z)) 0.09 1.00 0.01 -0.51 
PE(24:1(15Z)/15:0) 0.17 1.00 0.02 -0.47 
PC(o-18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.45 1.00 0.03 -0.29 
Prostaglandin F1a 0.31 1.00 0.54 0.39 
Succinic acid semialdehyde 0.01 1.00 0.08 -0.28 
3-O-Caffeoyl-4-O-methylquinic acid 0.06 1.00 0.32 0.26 
PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) 0.23 1.00 0.01 -0.40 
PC(P-18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) 0.57 1.00 0.04 -0.38 
Glucose 0.00 0.47 0.37 0.11 
Oxolucidine B 0.00 0.02 0.00 -1.08 
Beta-1,4-D-
Mannosylchitobiosyldiphosphodolichol 
0.19 1.00 0.23 0.14 
PE-NMe(18:1(9Z)/18:1(9Z)) 0.36 1.00 0.00 -0.51 
Artonin K 0.00 0.00 0.13 0.24 
5-Ethoxy-4,5-dihydro-2(3H)furanone 0.00 0.65 0.02 -0.44 
Didodecyl thiobispropanoate 0.38 1.00 0.07 -1.13 
Erucicoyl-EA 0.75 1.00 0.73 0.26 
PC(16:0/16:0) 0.57 1.00 0.17 -0.33 
Xanthine-8-carboxylate 0.10 1.00 0.81 -0.06 
N-(tetracosanoyl)-sphinganine-1-O-[myo-
inositol-1-phosphoryl-6-D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.56 1.00 0.18 0.12 
PC(o-16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) 0.48 1.00 0.03 -0.35 
hexane-6-keto-1,3,4,6-tetracarboxylate 0.25 1.00 0.09 0.95 
Ganglioside GM3 (d18:0/20:0) 0.50 1.00 0.70 -0.05 
Epoxymurin B 0.77 1.00 0.10 -0.74 
carboxynorspermidine 0.59 1.00 0.38 0.28 
PE(15:0/22:0) 0.33 1.00 0.03 -0.36 
Glycerophosphoserine (55:0) 0.39 1.00 0.28 -0.15 
PS(37:2) 0.34 1.00 0.01 -0.83 
DG(43:5) 0.63 1.00 0.02 -0.35 
3S-hydroxyhexacosanoyl-CoA 0.56 1.00 0.02 -0.33 
Trihexosylceramide (d18:1/24:0) 0.84 1.00 0.87 0.02 
PS(21:0/0:0) 0.00 0.27 0.01 -1.10 
PE(P-18:1(9Z)/14:0) 0.32 1.00 0.61 0.05 
Creatine 0.72 1.00 0.76 -0.10 
L-Acetylcarnitine 0.01 1.00 0.00 -1.00 
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PC(o-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 0.63 1.00 0.07 -0.29 
PE(18:4(6Z,9Z,12Z,15Z)/20:2(11Z,14Z)) 0.75 1.00 0.89 -0.07 
Tartronate semialdehyde 0.37 1.00 0.18 -0.81 
SM(d34:2) 0.65 1.00 0.22 -0.21 
Sedoheptulose 0.69 1.00 0.16 -0.28 
PE(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) 0.88 1.00 0.19 -0.62 
LysoPE(20:0/0:0) 0.04 1.00 0.03 -1.98 
Diphenylcarbazide 0.65 1.00 0.49 -0.47 
PC(P-
18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 
0.61 1.00 0.02 -0.38 
CDP-DG(16:0/20:4(5Z,8Z,11Z,14Z)) 0.14 1.00 0.04 -0.36 
PE-NMe(16:0/18:1(9Z)) 0.54 1.00 0.18 -0.85 
PC(14:1(9Z)/20:2(11Z,14Z)) 0.17 1.00 0.02 -0.52 
L-Cyclo(alanylglycyl) 0.77 1.00 0.38 -0.63 
PG(O-36:1) 0.26 1.00 0.02 -0.44 
CDP-Glycerophospholipid (38:6) 0.67 1.00 0.05 -0.39 
D-Sedoheptulose 7-phosphate 0.87 1.00 0.38 -0.20 
PS(41:4) 0.44 1.00 0.01 -0.49 
PE(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)
) 
0.89 1.00 0.56 0.06 
Dehydrotomatine 0.73 1.00 0.09 -0.38 
Tin chloride (SnCl4) 0.64 1.00 0.49 -0.05 
PC(14:1(9Z)/22:2(13Z,16Z)) 0.28 1.00 0.02 -0.40 
PC(o-18:1(11Z)/18:2(9Z,12Z)) 0.62 1.00 0.14 -0.36 
Arginine 0.00 0.60 0.01 -0.60 
Adenosine 0.11 1.00 0.06 -0.73 
6-Deoxodolichosterone 0.81 1.00 0.06 -0.53 
Niclosamide 0.41 1.00 0.17 -0.35 
LysoPC(20:4(8Z,11Z,14Z,17Z)) 0.02 1.00 0.02 -0.79 
1,2,4,8-Tetraacetoxy-7-hydroxy-3-(4-
hydroxyphenyl)dibenzofuran 
0.66 1.00 0.01 -1.59 
3-Deoxy-D-glycero-D-galacto-2-nonulosonic 
acid 
0.04 1.00 0.74 0.14 
Glycerophosphocholine (38:6) 0.71 1.00 0.08 -0.34 
N-(2-formyl-3-chlorophenyl)anthranilic acid 0.39 1.00 0.89 -0.01 
5-Aminopentanoic acid 0.75 1.00 0.49 -0.10 
Narciclasine 0.00 0.00 0.00 -1.00 
Uric acid 0.93 1.00 0.33 -0.14 
PE-NMe2(18:1(9Z)/18:1(9Z)) 0.54 1.00 0.04 -0.37 
PE(22:1(13Z)/15:0) 0.45 1.00 0.06 -0.37 
[FA hydroxy(4:0)] 1,9S,11R,15S-tetrahydroxy-
13E-prostaene 
0.94 1.00 0.68 -0.24 
2,3-Butanediol glucoside 0.63 1.00 0.14 -0.60 
Cer(d18:0/20:0) 0.84 1.00 0.98 0.01 
LysoPE(18:0/0:0) 0.20 1.00 0.01 -0.76 
Camelliagenin A 0.82 1.00 0.18 -0.73 
LysoPC(16:0) 0.00 0.38 0.00 -1.24 
FA amino(7:0) aminoheptanoic acid 0.00 0.22 0.03 -0.44 
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LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) 0.00 1.00 0.01 -1.02 
PC(18:1(9Z)/20:1(11Z)) 0.36 1.00 0.17 -0.36 
Propanoylagmatine 0.96 1.00 0.68 -0.05 
Lysyl-Tryptophan 0.85 1.00 0.21 -0.44 
hydroxymethyl-dCDP 0.04 1.00 0.92 -0.01 
Lactic acid 0.12 1.00 0.12 0.57 
N-[2-(4-Chloro-phenyl)-acetyl]-N'-(4,7-
dimethyl-quinazolin-2-yl)- guanidine 
0.08 1.00 0.21 0.33 
Deoxycytidine 0.26 1.00 0.29 0.99 
Glycerophosphocholine 0.05 1.00 0.01 -0.77 
1-Octen-3-yl glucoside 0.61 1.00 0.06 -0.88 
Di-2-propenyl hexasulfide 0.86 1.00 0.44 0.09 
PC(20:3(8Z,11Z,14Z)/20:1(11Z)) 0.88 1.00 0.59 -0.21 
PE(20:2(11Z,14Z)/15:0) 0.36 1.00 0.04 -0.66 
N3-fumaramoyl-L-2,3-diaminopropanoate 0.13 1.00 0.16 0.83 
Leucyl-Proline 0.83 1.00 0.18 -0.41 
(2Z,4'Z)-2-(5-Methylthio-4-penten-2-
ynylidene)-1,6-dioxaspiro[4.4]non-3-ene 
0.00 0.94 0.10 0.30 
Lenticin 1.00 1.00 0.68 -0.18 
Tetrahexosylceramide (d18:1/16:0) 0.54 1.00 0.33 -0.21 
N-(2-hydroxyhexacosanoyl)-
eicosasphinganine-1-O-[D-mannopyranosyl-
alpha1-2-myo-inositol-1-phosphate] 
0.58 1.00 0.86 -0.03 
PC(18:2(9Z,12Z)/18:2(9Z,12Z)) 0.78 1.00 0.10 -0.29 
Acetic acid 0.15 1.00 0.62 0.08 
[ST (20:4)] cholest-5-en-3beta-yl (15S-
hydroperoxy-5Z,8Z,12E,14Z-
eicosatetraenoate) 
0.75 1.00 0.30 -0.14 
Trihydroxy-3,6,7,4'-tetramethoxyflavone 0.01 1.00 0.35 0.14 
PC(20:3(8Z,11Z,14Z)/20:2(11Z,14Z)) 0.70 1.00 0.31 -0.20 
PG(16:0/16:0) 0.93 1.00 0.62 0.35 
Dimethylarginine 0.18 1.00 0.13 -0.28 
Hordatine B glucoside 0.50 1.00 0.80 0.04 
N3-(4-methoxyfumaroyl)-L-2,3-
diaminopropanoate 
0.12 1.00 0.14 0.46 
PS(35:0) 0.47 1.00 0.04 -0.60 
Glyceric acid 0.07 1.00 0.52 0.67 
PE(18:3(6Z,9Z,12Z)/22:0) 0.27 1.00 0.18 -0.35 
PI(16:1(9Z)/18:1(11Z)) 0.40 1.00 0.13 -0.40 
Glycerophosphocholine (52:4) 0.88 1.00 0.18 0.12 
Psidinin C 0.70 1.00 0.84 -0.11 
Methyl 3-hydroxybutyrate 0.97 1.00 0.98 0.01 
Gnidicin 0.14 1.00 0.35 0.60 
Isocitric acid 0.78 1.00 0.56 -0.17 
6-Phosphonoglucono-D-lactone 0.03 1.00 0.06 0.80 
2,3-Dimethylbenzofuran 1.00 1.00 0.92 0.08 
Sorbitan stearate 0.86 1.00 0.18 -0.66 
cis-(homo)2aconitate 0.00 0.05 0.12 0.14 
Probenecid 0.71 1.00 0.39 -0.32 
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Deoxyuridine triphosphate 0.08 1.00 0.29 0.72 
SM(d18:0/16:1(9Z)) 0.70 1.00 0.08 -0.24 
PC(22:2(13Z,16Z)/16:1(9Z)) 0.59 1.00 0.33 -0.28 
PE(P-18:1(9Z)/14:1(9Z)) 0.78 1.00 0.42 -0.09 
5-(4-Acetoxy-1-butynyl)-2,2'-bithiophene 0.52 1.00 0.50 -0.19 
PE(P-18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) 0.34 1.00 0.02 -0.73 
Pyruvic acid 0.05 1.00 0.34 0.40 
Creatinine 0.92 1.00 0.43 -0.11 
(2alpha,3alpha,5alpha,22R,23R)-2,3,22,23-
Tetrahydroxy-25-methylergost-24(28)en-6-one 
0.06 1.00 0.00 -1.42 
PE-NMe(16:0/16:0) 0.81 1.00 0.52 -0.23 
Pipecolic acid 0.98 1.00 0.57 0.36 
PG(42:6) 0.56 1.00 0.06 -0.35 
N-(2-hydroxytetracosanoyl)-4,8-
sphingadienine 
0.96 1.00 0.95 -0.02 
Diisopropyl sulfide 0.56 1.00 0.59 -0.19 
Lumequoylacetone 0.82 1.00 0.12 -0.86 
N-(2-hydroxyhexacosanoyl)-4R-
hydroxyeicosasphinganine-1-O-[D-
mannopyranosyl-alpha1-2-myo-inositol-1-
phosphate] 
0.71 1.00 0.41 -0.06 
PE(18:3(6Z,9Z,12Z)/20:0) 0.30 1.00 0.05 -0.81 
Prenol 30,32-dihydroxy-2b-methyl-
bishomohopane 
0.71 1.00 0.26 -0.68 
2-Hydroxyundecanoate 0.99 1.00 0.97 0.03 
PC(18:3(6Z,9Z,12Z)/20:3(8Z,11Z,14Z)) 0.92 1.00 0.17 -0.27 
4'-Methoxy-2',3,7-trihydroxyisoflavanone 0.37 1.00 0.52 -0.08 
Pyrrolidine 0.14 1.00 0.02 -0.35 
Cer(d18:1/24:1(15Z)) 0.90 1.00 0.66 -0.25 
1,6-Naphthalenedisulfonic acid 0.09 1.00 0.26 0.28 
TG(41:0) 0.86 1.00 0.31 -0.20 
CDP-Glycerophospholipid (38:5) 0.12 1.00 0.01 -0.61 
Ganglioside GM3 (d18:1/24:1(15Z)) 0.13 1.00 0.02 -0.64 
SM(d18:0/16:0) 0.99 1.00 0.61 -0.20 
Luteolin 7,4'-diglucuronide-3'-glucoside 0.37 1.00 0.21 -0.77 
5,8-Dihydro-6-(4-methyl-3-pentenyl)-1,2,3,4-
tetrathiocin 
0.00 0.00 0.08 0.18 
4-Hydroxybutyric acid 0.40 1.00 0.91 0.09 
PS(P-39:0) 0.25 1.00 0.03 -0.51 
7-methylthioheptanaldoxime 0.38 1.00 0.38 0.64 
PC(18:2(9Z,12Z)/20:2(11Z,14Z)) 0.86 1.00 0.36 -0.18 
PI(18:2(9Z,12Z)/20:1(11Z)) 0.57 1.00 0.07 -0.71 
PC(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17
Z)) 
0.89 1.00 0.79 -0.12 
UDP-N-acetylmuramoyl-L-Ala-D-gamma-
Glu-6-carboxy-L-Lys-D-Ala 
0.92 1.00 0.25 0.08 
PI (36:0) 0.74 1.00 0.27 -0.35 
Stenopalustroside A 0.48 1.00 0.03 -1.35 
PC(20:3(8Z,11Z,14Z)/18:2(9Z,12Z)) 0.81 1.00 0.12 -0.25 
6-Hydroxyluteolin 6-xyloside 0.44 1.00 0.07 -0.92 
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Triradylglycerol (61:8) 0.90 1.00 0.58 0.06 
TG(15:0/20:0/20:0) 0.70 1.00 0.32 0.19 
Piperidine 0.02 1.00 0.01 -0.42 
Phosphocreatine 0.72 1.00 0.23 -0.43 
5-Hexyltetrahydro-2-furanoctanoic acid 0.94 1.00 0.29 -0.34 
Proline betaine 1.00 1.00 0.93 -0.07 
Iodixanol 0.51 1.00 0.28 -0.15 
Triradylglycerol (65:6) 0.53 1.00 0.44 -0.08 
3'-O-Methyladenosine 0.36 1.00 0.44 -0.11 
Kanzonol R 0.84 1.00 0.80 -0.17 
5-(3-Buten-1-ynyl)-2,2'-bithienyl 0.87 1.00 0.88 0.02 
1-Pyrrolinium 0.99 1.00 0.87 -0.08 
SM(d18:1/18:1(11Z)) 0.38 1.00 0.87 0.05 
SM(d33:1) 0.72 1.00 0.14 -0.41 
beta-D-Glucosyl-1,4-N-acetyl-D-
glucosaminyldiphosphoundecaprenol 
0.95 1.00 0.65 0.04 
2,2,4-Trimethyl-3-(4-fluorophenyl)-2H-1-
benzopyran-7-ol acetate 
0.84 1.00 1.00 0.00 
Imidazoleacetic acid riboside 0.02 1.00 0.17 0.25 
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